var title_f27_2_27680="Approach psychosis child";
var content_f27_2_27680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Approach to acute onset psychosis in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 576px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SLE: systemic lupus erythematosus.",
"     <br>",
"      * Attempt verbal deescalation. Progress to physical restraints, as needed. Check rapid blood glucose, provide empiric oxygen therapy. Administer chemical restraint as needed (see text).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Other laboratory studies should be obtained if a diagnosis has not been made at this point and may include a complete blood count, liver enzymes (eg, aspartate aminotransferase [AST], alanine aminotransferase [ALT], lactate dehydrogenase [LDH], alkaline phosphatase), liver function tests (total protein, albumin, total and direct bilirubin, prothrombin time, and activated thromboplastin time) ammonia, serum electrolytes, serum&nbsp;blood urea nitrogen&nbsp;and creatinine, and thyroid function tests. Additional testing for inborn errors of metabolism, or SLE is indicated in selected patients with specific physical findings (see text).",
"       <br>",
"        &Delta; Implicated medications include corticosteroids, amoxicillin, clarithromycin, erythromycin, isoniazid, topiramate, and phenytoin.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27680=[""].join("\n");
var outline_f27_2_27680=null;
var title_f27_2_27681="Estradiol: Patient drug information";
var content_f27_2_27681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Estradiol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?37/58/38824?source=see_link\">",
"       Estradiol (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/34/40485?source=see_link\">",
"       Estradiol (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11724 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27681=[""].join("\n");
var outline_f27_2_27681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/58/38824?source=related_link\">",
"      Estradiol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/34/40485?source=related_link\">",
"      Estradiol (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27682="Red marrow normal adult";
var content_f27_2_27682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of bone marrow in a normal adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AR0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5qt1BgTjqBUkbdOCecYxUNuo8lDk846VOeox1PA4oAl6MegbvzT8AkfKc9OlRIcrggZ+tTDPl5z34zQAq5Odq9DmpB16jd0Ge31qHjP4djTwAWIA3ADPFADjkc5HJ5xSHqGx0/nTnbcwMihSAAMDtimAsCOe31oAeu4gBFJJ7Hk00F1c5GD24oxtHUBe23mmrsG4Kd2PXigB2CXHI247U/cpA4b1BPpUe4Z6EnFGQXOeaAJDgrjk49e9BLZHXGP8AIoBC4zgmo5WVFZj0yM8dOaAMPUv+P2T8P5V7r8I1ARQSOUHP5V4VqX/H7L+H8q92+EyF4l4xiMc/gKcdzKofRXhZfltGJH3sV2UwAinAIxjtXFeFlBjtQpI+fGa7SVWUXKqedvFbEIIQskNtgqMDApbWNF1C4AHYAkGkgXEFsR2GDmnW2f7QuQODxjNJjHXcSm0UAjAZf51bChmUHHQ/zqpPvNiNo53D+dWk+Zt3PORxSGhLZFElzjjc/P5Ulyi7YQV3DzF/lTrZT5lxkDl/6CqGv30dhawySOFXzkUn60uo3oizC6mzR2KqAD+AzWbcazZWzXMTSKrF3zyOuBXhPi34rS20M9rZyAsfMiyBx9/ivJdR8XahexzrPcNuM7uHyRnIHFJyRnzX2Ps6bXLFrvyDICyOV+h8vNadlcx3FnbTo3DqhzXwu3irULeVJUuZDIJDj5s/w4/lXqPw8+Kcmm29rbak+75ovm6jbyKakmNSPp+1RfICKOMk/rUd2oEbSEfMqkZ9twrI8F63DrOkwzxty4Zvf7xrZnJEZXr8rHn6ijqX0JZU/eD0Ktn9Keyjy+g4FI/3gfQGnnlDipKK7xqLuI45O7+Qp7ICGyOAePypH5uYuvBYfpT24LE+vH5UCFdQWHA5Byao6XEsd5qKrjJkUn/vkVebqnoATVHTgP7T1Igk5ZDz/u0dB9T804gfs8ZJGwDpn2p4IHcgds0W+028Zx2HU0+MktlcYBz14qSx4K4IzjmnxttBDBSPT2oycEnGSTwKUZ6HHOD1oABnO459s0pJBPOO4xSHG7uOMdalKEoGyCpyMA8j60ANYZB+YnB/yKA2Vyvf0pqgAY5HoM9qSVmIARRweee1ACsELE7uCO3akbGdvbsDSEYGCMD1o+62MkH60AICM4JpUfJyOMHlf60ijnHTHvTiNpzg5PBoAeGwOvzEfnSKV2srqDkHgnj60idDx09aAxI4Bz60AYV4CLlwzbjxz+Fe7/CGU+XhiPuDH5V4XqQxeyD0x/Kvb/hFIAhyOsY/lTjuZ1D6Q8KnaloD8oL12MxA+0MemK4fwqfktGJx82cDmu0lYPFcnOODWxmTIw+z22BnIHAos3P2+6H90CmQN+4s8nqP6U6zONQu84xgUmMLh2GnKx3ZLrnH1rRBxKo7YNZdwp/s9GZyQWHHbrWpkeeo77TSY0R2rgy3WOobp+FeI/HjxS9nbQWUT/u5Gik3A+hOa9neeO1ivpmAG1iT6n5a+X/2gbtbi/sGVh80UZx6cmpeiJm9Ejya6vXld8g5yxBx3zmsq5klkE5YAjzGyAParW4zl12O+Axb25qjbz+W118vG4jaTk9KyJJSxjSIjBDN1HOeKuWciQNDkhyVVsZ96zzJvlt1zgZyV6DpU8LIJQSBvXaeO3NAz3z9njxHJFdfYp5SYnOxAT0+avpOTEgCkHBjPP418c/Bm6FtrUTEZXzhg+nzV9iWh3xREnJMbfzrZPRFRLcvcjspp/8ACPpTZQce2DTv4R9Kg1ISP36Hnhmz+VLJvLoI9mN/z7vTb2984pQMS9f4j/KnNyy/X+lMQ4jj6CqNgrLqOoE/dJjx/wB81ebpVe3yLu5yeCVx+VJbD6n5oQ48iIcngc/hSgdjg0W7KLaMHgbB+dOU8g5pFCgfLgggDNOwPQkAdPSnbhjJIAFSYBkAXJBGc++KAIvTnPFSHaqndnnNLjCZUDAI71MASPMk+UlWyuOP/rUARbsEFVPOVx6cU3KEEk4f0qwvMirgsFPbsNvWoQqDcANwG0g+nrQBCAMZIOCODQeByD1/OpZFG0AEHOckH36ComIDLtXgcnBoAQkAkKc5A7e1O3YGCDhfboabnJ+UAsD3pxDKNy5IPHPegBVZcjg/jTSeMrn0+tLnkDjPfntSA5GOfloAxtQ/4/JM9eP5V7d8KG2xjHXyx/KvEdRObyQ4x0/lXtnwmiLqD1HljIH0FNbmdQ+h/CbMtvavwMvjJ9K7aUFvtXTgcVxXhVP9GtV6Df0Y12jrmS4PJwueK2MwV28myyMjvipbZgL+7A4+UGo41ItbPcOfY1Jbox1K5IxgoKABjjSVJIwGHP41ok5ukxn7prMlR/7OZcHkgYz71fSNkuV4HCnBBzzSY0V7xAYb/eu4E8gf7tfLPxitJFe2k2ZhCR/MeSOTX1b5e/7aGOQce38NfO/xk0tYrWCUIxDeUCN3fJ5qJbEyPAELxSgpkcMD+dRC1iEd2eWbzCfcDGa3nhja4aFFJZBJn8xUM9vHG98sWMbjwfTbWdhGS0EP7sIWDM4xk/wkUyziV3Q85YAcHjrWlPZrm28t9xBRTntleafaWXyRPxgKpY+nzUWGdP8ADC3ne7Hk5BWYcAd9wr7J0FGj0+0353CJs/nXzj8EdLW5W5ZiQqykqR3G4V9NW0ZWONeyqw/WtUrIqJbfoc+hpeoH0pr+nqD/ACpw+4M9cVBqNPD/AI/0o+8VIPGcj8qD9/8AH+lDE5Uc53YP5UxDm6VWt2Bu7kdxtz+VWW7VVtzm9uRjOAn8qFsPqfmdExMES9TgHpTi3zZbFV0OIkO45wOppVJPJPvmpKLitgEkcZqVAWQL/Hn14qqG43FuuatAbZGLH5cdfwoAsTqluoThmOGDc/yqwTN9nbaUEaq5y3Vhxn61QjOExnPT3rReaSLTkaHHlTCRCSOoDDI/lQAkcTPIiLAXc/d2k9l/yariP906I6s+UI7Hnt6V0lxpdzcyQ5cJAHVGuV5UYiBx+QrA4ktZSrJvzHweG78/oKAIp1iUybJGdNoHzJglu+ME8A96rMSHI/pQ7s0SoxIVG+X2yafKfNkbd74x3NADVdl4JGB0xUe4dcnA9e9PBEmSCM9MChl+bAyec4J60ANPK/3WPGAKFOEJP5UrAhsDP0zSNhVwDk/nQBjX/N0+cZ46fSvb/hBnacfe8sAD8K8Qv+buTnPP9K9u+D7gOBjd+7FOO5nUPofwyCLa2zyPM/Gu1nVkkucLkbfyrjvDLv8AZLbjkydM12twW8u42gEheRnrWxmRQlvstkevTOKltBjVbsBv+Wa8elRWLStY2ZcKnPHPap7Y7tXuu/7sDgfWgZDdMU0sktlQ/OfrWrvxdoinPBJyKzrrc2kncB1x9Oa0iSLmIeqnNSwRHbMzXN6DjAYD6cV5X8YtKkl0ATPhY4zCMgYP3zXqdq4+13wA6bTn14rlviNHHc+F44pSCGlhzn/epWCWx8lXsZttQnjZC53SgEcE1kM5c32/KEyZG7/dru/Flutt4mv4oxiMSTFRnOBgVx4EU39pynO3eMccA7TWZmilJL5k9sT86syZbGOdvTFXNLYzzxQRx8KVUjPJ+eopVlkFiJlVSWi27O4wea3fC4V9XjjKodygKQOc7+tNFHs3wO08raXkqKQgmYAH03ivdc4mjUdw39K4P4RWMdp4UZguWM8mSf8AfrupTm8hweArg/pVvsaRJ3PX2B/lTh9wfSmyfcb6H+VJCcwRk/3R/Ko6FC/xn6/0pWI3L0GW/pTVP7x/TcP5UkvDxY/vj+RpgSP2/wA9qq2/N5ccfwoc/gasycr+FUlYi6k5GNif1oQ+p+ZMZAjXnt0qQH5W44IH4DNRRchFHB4xUqsF3lhliABn61JRKp2hg2COelWpFd7sh8E7QfkwQOKhj/dLKVbHysvI68Vf0+ErqUMIRPnTOWzgZXP50AM8l44yXPOEbHqCa3rGOE6ZceYrfLDcSk4OVOUA9sVlW11G5Kk4UiHdkZyVbn+ddva6KZfCd1rURJhIvonJjOzCiPG30+9QBueLI7a81fTrvzpLexmiSL/R3yTi2GCV9c9a4AKlzBdKZI/MuDbFcJjPJyQe3Sva77wlpFtP4auLCe9kF3D5FwhUYOLPIIXqO/Nea3+mWxuZTGRbgQ6eViBJEofqc9uKAOEkEiwMu0crknOcYbtTLmNopGB2jA42nIq89uqacZfO2CVXVVP8QWQcitSLQ7rxD4js9O0K1e5lugfJRBjJ9W7ADGSegFAHOxxNIHIA652g9BSAhnAwOuM9sV7Z8T/C3hDwJ4Ll0zU3W98e3pjmLWjlUtMdsdAuM8Hlic8DGPGri1a0lijmU7ZkSQEeh70AUiSeR70n3cZ7jPHOKlZcOwyDgkZFQt/PrgUAZN8MXTj6fyr2/wCEG0EDGMxjOK8PvRi5cYx0/lXuPwgiSZ0SR9oMY7+1NbmdQ+i/C4P2K23YYeYDmu4lQE3IHdMmuK8MRILGJeSPMHNdz5W1p9rFgU71qZlKzYnTrE42ktkA1PbDGs3I9YhmoIlhg060fd91/wBa5rU/FFpa+JLhHlVClucc9eaAbOquCi6K5zhRk89uanubqKO/twzjlSR+VeQ6v47iHhidUbO7epG4561nS+Md2r2LQygxeUVw7ZB+WloLmPU5fEVpb3WtEuP3SRtn1yDXnnjzxK0/hi18oqeYScnH8dcY+sC41TWHLtEPIizz169Kx/EeoCXwjbqCWRkj3MTzw9K4m7jdab7T4nue+TP3zzisNdOjgt9X2AFo2Qqp6coa1poWk1txFli4mIz3+XtUFnYTyXOuzQjG1Iy6uf8AYNQJGBd6czrpeQVZ3g5VuNpB4FbGgWsFrr6ecJDHCoB7ceZTdTs8afYTY273ttqg5PU9KsrDKmpmIKx/dMQpPJxL3p7MZ7n8PfEtvD4ZuY23KqXkqKfUbx/jXokmowPq1tCj5JEoOOmQAa+ZdOlaDT9dmWQqkd2/yt0B+WukutVuLbVbIfaWWY3E5zk42mIHFVe41Kx9CmZGjkIbgD/2XNFnIslpbuOjICPyrxG38aXUWImKqomVH5J6wmtfwt41nj0XRPtRR3eJumeynH8qLItTPWkOZZRj7pH8qSQ48nGPvj+RrD8OaympzXLo4KbYiB3BK5NbUpPlwlcY3Jj6UrWLTuTPna2PSsxLctcvJn70UY59s1qN7daqxedhSVGdi55+tEdB9T8xh5JC+Xv6LktjOcc/hnNWbJk2yR5T94oTLHp8w59qpxhcKWIHTmpU4jcOpzgbe3frUFGwNImDXKxyRXHlJKxVG6BcZb6c1r3Ih1W5tpXLiZtiCOOPaSiRdevXI61R02OO30+S4tZUS4KTxSCcfKU2joe7HPStDTNOe78QQyW8RkYYUoASo/dZPP50AUFsfJVRsUPPFbyqnXIZ8YFe022m36eAdZsYInjtbQapL9ml5C48rr6nk/SvNFQRaJP5kf8AxMPLsCkrHHlDzCMfyr1zTrHVrPwVc7Zbi91OZdZ85clYwuxAxBOO2DjvmgDr9ea4LeFxcxz291cXozNagFEUWGPLz13EZ4+teY+L7aG31pms7FI0+x6PcIs8m3cc9cdwRkV7i3h/7E/h+aa4/ewXYLqDldw09hwOxyK830Hw3/wsLxraR6vbqq2unaY8rwn5QieYSvPZgAv40AZMHwN13WvAemalbSWz312plNlN+78lJJdwKvnn5CCQenbJ4rotd1Pw58EtPk0Tw2Y5/Fl+jeZfSAOLReMD26ghe55bsK+gdZ1fTdCsHu9WvLeytYwTulYKMDsB3PsK+Mfjy2i6r8TLm88PpJCHiL3KyoEWWcHkqOvzAr1A5ye9AHKa2bq/Grz6lK11qX20tJM5+dvkPJz26VgyI4ubR5yFyIxyTnBrW1y4H2jUW1Cya2vWn5VD8qjZjZ/WszUIFiks42lWZpI4pDJn7uf4T9KAK99A8F5NDKNsisQST+P8qrNjIOM/jUpCxzzAESYJA7jvzVXdxwRgdQaAM2+yLp8+38q91+DRBmiDKD+6zn0rwm8/4+X69a9w+DTB7iIENkRcU47mdQ+kPCqFraPdt2iQcenNd4UK3E2D8vl9K4XwsQLNEZtwaQbR6V290whaWUsfljPy+tamaOC8e62tj4VgaAhJVmGD+NeCaprjXPiWV52y7xEZB711PxK1NLmwijjlaPM5znoOa8qvismsgZ+YR/KR3NZyZG5dnu5Bo11G8paMM20d6kupHSbTWsonIIHG7vtrBcSR6bcNJ8ylmHXoa1LOWdpdOgSXCEjHPQ7aSYGtpTvPql8HDF2t4857c1BNbzyeGFM7EqpAXn+DzP51oaBE8+vzlFcSraou09Dya14rHPg+RZnG94gBx93971p2Au29kkOswzRqzqjzR+W3X/V5zUGmRxyaxrSlWWYxxEjOABsNas8Jh8QxWdqRIUlmJd+Mjy/Ws6zuPtWtaqIU8xHtoN4PQnY1MDLu4Wk0DS5HCRIHtRgdSNx5raWzVNW67mFvOm4dRiUc1nyp5fhXTonGyUraMp6/8tSM1uTW9ydZIYplLWcs44yBIM8UwZzt8k8On+IWi+djdOD6YCqafK0lxqlmt48gLSysCoxj90OntW9qdkqab4ne3mDqLiQCIjuY15rn9SimivdNgkkWK8W5fcG7KYc1IIr/AG5oJZbWVg6lo5CwHfyjU2m6qbXw/oLLI8iuCM4+7lWHFUWmzqBLBY4yYQXx38tgBVbSjMPD2jRQ7ZHLkqT/AAjDZFAz03wTrr2eqzO1wVY/Zx5fYgoRk17lpt0t7pFhOPl3+Ua+ToLlotTEiS7o/Lt/MHfcA1fQnw01OW88MWKyhUdPIwCeoLEZq1qXFnoufmYY7VXiJVVBbPyj+tT5+c/hVHLqVDKv3B0+pqYo16n5jRnIUduOassx8rLnqgVcemaghz8oUZPB/GpIyDHIp5Jwoz161BRtwK40mJoCzxv5xZH+5wByPet7w1dxQxGDN1HcfaVczQyYYL5R4x7msmC2lkWSG0tc3Kxzlo26ooUZbB9s1rql0ni7ytLhRhuVkKqMH9z/AIZoAW5eWKfSpF8t4xFZMyA7jJiRsEnsc19B6cuqz/269gr4mXWz5Mx27XZYcAfnXznp8K6dDGt7GqMzWkqxhtxkUyHkfh2r6LGoTQ25m0m1kmVYtccpOxRlX91ls98UAeh3Si9FtEt2RNFqCq7quPnGnnI5+teRaZ4mv/h9pE9vBBFBrFxHpURuJG84GB96ghOxGGPJOdw4459imsjNfS3fmOA16JkXOFz/AGeR+ua8c8WyJ/Y8c6W8a31tD4fYPI24yjMuMD34zQB5Xq+reItWnuL29v5NTu2gnjl81i5iiFwoyOy84wBWVrt19s8Vah9pnlh2tMC84y2f7pPY5GPard9eXjpKlhawI/kzrNIrfM6tc5LHPTBwB7Cpddsvs11fNqNpNJelbppHfGCwZQrD6EmgDB115ba+vbS4JFwbgOwLeZkFOPm79ax7wOkkfnKG3IjfKegI4rqfH13Hd+JrqQWcViqSKhEYDHIhUfr1/GuWlhlhG90wFC5BPXIzQBV3Lu+RT/Wot20EYGeDUswAl+QALt4qIH5QDx7igCjdZE7A9RXt/wAGjsmhL5VSnB/KvD7nJmbPWva/g/JvlhXazALxuPFOO5nUPpfwyspstygOnmg7h6d66PxPdeTHKY3B/dHPFcz4XuGj04oqNgyAVd8eXnkW8gG7eYjyvbitTJ7Hzb4rv3msyrt0nJ2tz3rlJGb+1w0gCjYfpWzrLhrEtIpDGY8nkmspYhPqaAocLETzzWLJRAGZrC8+UNEN20+hqSyDmTTwqjfuU89+KjafyLe5VFJ3bhz9Kk0yLF1ZP5jEnbhD9KEB2/hJmbxJKu4rut4928+/aujl3L4QkUJGQEIXYc5/e9/Sud8PeXLr0jyMQsdtGSxGMHdW6LyKHwrJ5Zby2ibcQvU+bVoDb1HaZVnjCvL9tlVlY4OPKrO0SVRrN7FbxMA0FtuIGOdrdavy4W/5G5Dcyvg8EfuaxbS7Fzqrvbsd629qrbflzw2eKYGczEaZp8cybc/ZSAcnjzjXVujreyMiLIxhu1552gSDNcxKQ+iWkc8iK3l2xDf9tz0NdPAbexmnfzpcol3nIySS60AXLwQzWfiQRqBGZXYtwCWES8Yrk/EqF5rRrmHbK05YH+Ir5HArrbt4r7+3fIQbTO4Zxx/yxXtXOeLQjW6xG6+dLsKDj5seR60mB54kqho4t8zLLLA7knI+43FamkyhNH0guA6REAbO5IesKxdo30/cwMbPBneOhw36VveH9OV9JtZIJGUblJ3dFOH6UhkVkfs9/A3zP5n2Yvk5A+9Xsnwj1ASxQh1KhTCq7u/7xuleQ3oj/wCJeIiVkMdoTj+LlutelfDiVbaSON3UxgW5DHgqTKe1VHca3PoXILbuecYrMvp/JnVQn8AOfxNXrZibaFmbcTgZ9a5Txjdz2+oQeRIVRohxg9dxojvY27H522yliu3npxnGfagA5GOo5/WnRMPswj8tAxZW83J3AAdOuMc56Z4pySMquikbXABOPQ5rMs3bJ5N81/cmSfz4Z0DA4OQoGf1rf8Mo1hqkl3bR3fkrKIRNKw2jdCeGHc+hrlRO8Fq3zryJE2r7gZ/Cuj0OK/vdWRopEMDTBdsknyFhEefrgUAQakA17pZWaVxHBZrGQPuZc8Y9fSvpJ7aawutaubm8n+yR6brIj83iXcxjzkDjjivmu7DWTxL5yiR1tJMBcYwxOB6kV9F2epXzeEtUuXEEqfZ9ZZnl+bcMw8Z9aAPTrGdmtZdyzktcAIp+Xn+zxxjt0P414z4zntLK90+5kuZo7yGHQQymPzFi5ckkeoFe53Upj/eyCNpLi5LQgn+L7Cf8D+BrwvxCVtri9ScBGYeHZG6kbvm7nov+FAHkviaC5sQlxF5iw3sNwTMwA3qLo9AOgziptV1JdajEN1PMDCLphlcclk5J79OlM1O5v57S4l8qGUSwyRNJK/8AC13nKeh3YH0rT8eG+sdcvIZI4pJpUuopIFC7IwTHnbjv70AYfiea2uvGOoz286h/tDIPOQ7dgiAyc98jFctfwuyBxuWEOiFj0zt6Z9a6W7ia31q8hgiVriO8dis4LFVEXQn05/SuYv2fzY4H5XCsVV9wJK8HPrQBWmkaR90hBIG3gdgKhY9euO1WbuVZCGAAwFUADHAHtVcfRce1AGdc585s9a9t+Cx23cGXXaEzhhXid0CJ2Br2j4MEm5iBQY2d+9NbmdQ+lNAYm0YrJx5i4x0qT4izA/IGGTESdvFV/D6yixb92APMFZ3xSujFdLtTIMXXOMVq9jF7Hz/qZL2jIz5HnnGaWzgc6/bjzRjyuQe4zRNN5mnsDGrET1raLbiXxFEBHg+Qfl655rISOY8QRFTfGMBY97AADocVn6ZM6rbeX+8ud64cemOldX4phligvY2hwvmNg/hXNWUsUd1pzwhiAy5GOpwaXUEd74aM39uYTymjNpH5itxn5q2L2RE8H3SqoIWJwvpnzeKyvDrINblaeIMRbR/KP9+napfqvhi4jVOD5g2+n7wVfQGbElxLFMZZkVpxdOGYNnrD0pmkj7P4ncTRL5RtLQybe33qzVvYZtYHybd1wcso/wCmVX9HFvd+IJm/eeaILXAY44Oc00CKepEvolv5axyFEgKYPQeecZrfljnBllYYlZbsuCeGO5elcvqZSLQLSKJioUQ+YQMcfaD3rq4VhgurhPnJK3uA5yACVoA1I5FdvEAlgUQ+czKyevkDrXLeIo7h4IWjgjkuHvlZF6AjyK6KJbZ01/ZJKUWcnI7/ALgVjeIFW7GmCESIguFG4dR+4pAedqGhn08eWGOYD8wyQcNxXW+ArcTeHYXkiZD5i7AT8v8AGMmuUu7hUm0yQsXKxRZUHno9dv8ADOAP4YtJ5Z38oyKoU8jPz0IoyNTWOOS2DLkeRZglBjje3NdR4QuFtXMkkAfy1twm05J/fGuc1O3SW6jYM/yQWYHb+Nq1tHeARxlHyxkh3Y4yfPNNbgfS9k4m0yzkCcMynB7c1zvi5y11bbfl/d9x/tGtbwzch9Mt1d9zccf8Cb/CszxVJ5bWmxyAUboue9UtGa3PzojOF/Ad6eeehzwP50W7AL83Qj1py4yD7dBxnmsTQ0Bck6ctrLbqPKEzBwPnJOOp9sVqaBJcQ6xbtbzmOSJt67xwSIz+vUVjjEglYkrtDMFzwOldF4ait7nUoo7i0aRppeD5hDqPKPA9jxQBFeSvqk9rPLHsfZaKGQbV+8Rk/wCe1e36LPDH4b12w1GZnEVrrZTyxuBfMfLY+nWvEIYYYIxFqNxJhxaNEFXBCl/mH4DNez+Gbq30eTXQqmeCTTtZSPywGYjKfexz070Ae2SakP8AiT3Ow+TPdHaGGWUf2aSMfrmvK/G2qA63vitH3GDQplQgg/fk4I7jn9K9OsFjvk0Z0DRmzn2sg6ZOm9P1H5V5zrpafxSkM4SA3FpoSCQ8FBvck89O4oA8Vu7iK30IzTuGe8t5CkaqcIwu85z06Z5qz46kRfFbuiyQlklZbgt/rXLKck/lmqnip4rPSLP7PciRZbW4RkAztIuz8vtwM1N4qkWfUop5FSVGgmMKHhY2ymDz0NAGfr1xd23ivXUE9zInnSmaaP8Ai+Tn+fPtXMXkMMKw+TN5ly2wkqflAI6fXNdbez3WoXWs20yGWeS6eVo9+3OITk59OK5mUlpo7uN4WCNGiqo6kDPT0oAz3f8Aevu+U42kYx2qup4UdeOBUzZkmcsuSSS3tTMA4JPOOcDpQBn3PMzV7T8GpFSeHnBK9QK8WuM+c2a9t+DZAeDHXaOQKa3M6h9G6E4GmSlm4DCuW+Js6SagmZCw8nuMAda6nS0K6TN90AEHPrXAfESZpdSTyzhTDggnrWj2MWeXxFJbQrvPNxwe3Wu08KQxS+JoQxIfyscDr0rnNKtN+mB9oY+fzivU/AuliXxNaNIoRfJyp/EVMUCOZ8baSi6ZfSNkOJGPA/2a8v09Ea605CQsW5SWA5zg19FfE/Rmi0i/dRkMzcj/AHa8E02CMtYOI8sJFBBPPQ0mtRLc67Skjt9cmZHMmbNG57fPWBq06t4buFZnVh5pUZ7eYK15b+Cz1do5WRHksFRSO/z1yWozuujTMR5ibZkBUdPnFDA2tImeLUoxIVY+e3J53fuu9dDoBlh8QTmVgWaytiFH1OK5azWdJkaRNkRuBjGM/wCq/lXSaNFDD4hEkcg3/wBnwNgnOCSaaAguEt5fCkJMv7xYomdj6/aK34LkRahdF5FMnl3jFF5HVa5m9gVPCBeRcSGFMH/t49Kl1INb6jcywAsDFdjcvQ8LzRcGdHdauiR+IPLaJd0w5JwcGAVW1a+TFiA6qq3EZZycZ/cGuKieJzrMb73DEEq/XPletMmuN0FnHdOZQ1zEQOgwYjSuAajE91f2Mdog8tltyPf71eofCnTRP4I08xofluhu9Dy9eUQEme1WJ5EUmAKqHI43d/X2r6G+BunInw+0/wAteRdFj6nlv8aqJcTgdbsRDdROR/y72mM9v3rcVnabCmxSwAbETfLwMi4IxXa+LtIjXUkBJYiytiATxnz2ririDy4dshZHVF6dABc0E9T3zwVcbrVFQAqoUZPXJds1N4mhjLWvmBiQrYx9axvBbBFjiVuA6Hjv+8at7W4leO2JBbG8Zz/tVXU0T0Pzhh52cE9KVG5PUnGB+feo492z5eOnNSoVUMCAzMoOem05rE2Lu4x2+1shsvngYzxWkjSFzPZO8WJVCbfv52c49qzYrYzQlvNVcpIwDHrjHT39q1dL8w6lELYszhgwAP8A0zOaAGiJ5NSsUmLxuTbjcyjCqWxu9xXvNvBFb6Pr2nrma4L60EntxsZ1CxY3DHC9eK8Ct1druzYGWVA0AbJ3c7+Bj09q9wstNv30i6M3nbTFrcjGNxHJn93nIPUe1AHs1vcRWD2J+WRbjVhG5iGAjHTeMdj0ryvXo4x4ja4vWMriLQmg84YyhZ8hgP516IdVZNVsLBoPIsbW4PmTE/eP9ncYH1I5ry/x5c2lnr+jWVurTRS2uiswU7zsVnyc96API9dMraXaKBDIFNzt2gZXNzxn/PQ1p69/aDeJDb3MVpLOgnfZGM7WOzJP0wMU1raxUXbQSrIiWN043Lg5W64/HbzUepasl14l1DUssnmR3MkaQj503YA3Z7e4oAk8bvZS+KdckvPMgvTeOX8kbUC+T0A/3q5e/jhdbYW+Y3EURKR9T8p3H9Kv67ILjWb6SYTziSQtmQjcSYx1PrWcrxtp6yRq5lV403noMKc/nQBmzO08krkYf73HAxUaozRZ3BVHHP51PcEGZ8jHAOV6Diq3OBn7vc0AULvPntnGeOn0r2j4MkedAGyRjoOK8Wuf9c1e1fBVSbiA9eO9NbmdQ+ibQqmkTEZXnBzXnfjNw+rJ02+VzmuwnuDFo9xj5WyMjrXCazL9p1GP5dx8vGBVswZR0K283SiyoSTP6+9e4+DdPA1S1Z4wGWDPH1FeaeDbUzaSqbeTPjp0r3HQrTyLmAkknyMZP1FNaIqK1ML4j2qv4c1Bo1BkBY9f9k18k73hezjORl1ZcnGetfWvxOnjg8P3pBwxJH/jpr5F1EgwWvl7ZHLJyOx5qZEvcmM8l1q6ySH/AFduACT0G7tVIXLPpV3A0ZXYZcMT97LCoICRqgZ85EGQPfdTzJt025/dK7v5pYk9Bkc1AG/oqyedGJZXVTdhC3UL+76Vv6NAV15EGdwt7YYHOV3HmsTRZsvFGDtgNyHGOxEddB4VnH9rp55SOMWkDZU9fnOKtDG6rMR4VQjEm6MKG7KftFQatLLBdvE7n/l8B2+mB1qW4gV/DbyRnMJhMmCef+PjtVLVHnknuZYjvAN1/wCgjINJkmLYTwCXU3Z8FsA5H/TKrLQrNY2JSTNz9oiPTAx5ZpTGttHfBtgLlG6Z6wmm3W4WFnG0ZjYSwcoef9WaQxNMEi3unyy/KqeTiMfxHcwzX098FDu8BWLKoRjKxYD/AHjmvlmwebz7PPP/AB74Oe25q+pPgjOJvBcCLtDRzMpCnP8AEeauOxcdyPxzZtHftLAoDLb26AnsPPPH615drVuwjuTIwZslAfpcj/GvfPENssqyzvjaI4u3ORJmvJ/FNt5cF2pAeRhI6gDGB9oFMUlZnR+BZ3E8MTspA2ksPaUiuq1+d4IrQIq/NvJyf9qvPvD92dLv4jI6+SSq7T1BM/Su71799b2bSFd37z2/ipofQ/OmMnZtB6gU7sADz3qJQuVzn1xTshjkAqPasToLQJMe1yU2bsEnv6VseH7lodUjkiCoQTgNz1QisVAjW4O/c/zZB/h6c1PbO0t8NmIwRzyQOF/rQBek3xXFoVXycpAyBW5b5uG+tfQWgx5sdTlvbwSLFba4kazEhnYpHlmJ6nJ/lXzzNdvPfWU+AkkKQIhUYxg8cd697sbyfxDo2u6te6hG8r2uslEiQBn+WPqvQZ9fagD1ayRrk2ca+aVtboK+QGVydMJznr1rw/xKRpVzHMWIube20Zodyk5Ultyg+nXivZvDl7fT2klvqtjJbsJ1eSWM8On9mcLnqSBXlfjj/Sob7UIovIis7LQY7eOQ53glsHP5j6UAeUa1dGGINCc/aYZ4GBGMfvyTj9KgvZZ7GSWBtuI/NiO9eqnbkZ7mn6l9pltpfORRF5Ukq8cAGfnB7nNVdWDWurXtvh5FTd5au2dpIHOaANCxU6trTwIPsiTSPIIs7toERPU/Ssm7mt5oo3ixAAI0aMkklgvLfQ1ZuNNv5L2+mgV2eF8PtGDyueB+PatbwhbvYRrq14Vg8kgo00auCuwqflYEHO7rjPpzWc6sYJts7cNl+IxMoxhHR63eist3fsupxwzvOX4JyPyqMSfKRxj0xWl4gv4L/UGktoBFCihB23YzyaykBLDJOQPwqottXasc9enGnUlCEuZLqupTuP8AWtXsnwa8wXMBB/hxz2rxu4/1zV7J8IF/e2zjPA6Zq1uc1Q9a8R3LR6XNtbk43YNc1Bcvc3ilFwNnLd60PF84WwnQjBO0bR/WsvQlb7aqsTgoenSq6mB6H8OrcyaSm4Bj9oOPWvYYh5d7CvXERwMV5T8OAYtKQ/Kw+08+1ert82o25z/yyPSr6Fo83+LE08ug3ix8HzDyP9018txBkktgy/KGX5j0r6t+JFrK+k3xQfMWPA/3TzXy7PA/l2qGMtuZOc/Ws5bkdTMdpTqJEjJ8sOM46jd2qZvKGiyMG2OFlzkdfmFQTxH+0z5kgO23yOOfvdKls5lk0u+B6rHKQCOvI5qQOg8PXKpMjLFjE65PUcx8DFdFpcQfUljmVQz2du528Yw54rmPDk0aoDceYJjdIflXgjZwK6PTufEEUN0fLZ7K3ILDGR5hq0Mj1F3j8NNGgKq9vsP+yfPAFVL2NoTcwx7i6NdBuep2rzir+uIp8PXXyhVWI4weWb7RVe/t1t726E0jiUvcZ/GNSBSYjIebz9UuQ4whSNdwHfyulNnZMQBAJA00K4zhgQh6U6KNobm8WYl4lkj2sOv+qNS30SRpA8LhpGeAEgfdOw96QyhbQMfsE0asCPJABOCw3kV9Efs+3ajQZIGG0/aD8vp8xrwLTZUmk0oRhw8TRLnscuf61798CLNhosssrHzDOcjrjEhq4lR3PUdQ2vaMrsFXamT/AMDrzbxjB+/nfBINvKp2jkHz1r0m6Qvbuj4A8tG/EPXC/EJAttevCDuEMhyO375aY5HD3N4ouXCZb98B64xOMiuu8R6irWWnFbxYFzMAGPJ+euIvpFiC5cGQzspTHJ/fLzUviOaSWx09iqYD3CjcfSShEdD4+U/dPXjvTuvGc8U+yt3up0hiCb26BnCgn6nim42k5wc8Y/GsjqJYxHiRn4G1toxnntV+MpDKGtyZYjtDB1GSSnI/PNUT9+YHaQFPT1rZ8PwRzavb2pUsTJu28EYCE96AK8e8SxREqyO0BwuPXp9ea9qUppVr4hszpKGeKLV45HVtoTKxEEfQdq8htI4cxYJ88ta+WT2y/J/lXu9xpkrWGpCR5DKi6880hPzSDbHjce4oA7d42vk07ULdxFZXVyhCbiSv/ErIY49vSvO/FSx32t6bp9sga3ax0PzEkO1W+YqMgf71ekeHrnTbGDTtKW485nuowQUyFY6YcAHt7/WvNtOsnbxHFLPIuVTQ0i2pnbGz4GB35HU0AeXa359tYG3zDhY7mMBSOFFzz+Zx+Aql4hhWF4fNRBOBIJNpJyfl2kn6HtXVeK9DZLS4n0+3afMFy07BeYyt5t3t6ZyBSavoV3puuW9nqMO97GCa5kIIPm42scZ64z+lKTsrmlGmqlSMG7Jvd9PM0LC1FpEy7zI7sXdz1Y//AKgB+Fc747I8m2zcAL5g3Q5HPX5sdaTV/EV3bahcW6RLGsfyDep3Ele/oRXHzrMVjknZ2L7W3NySD3J/CuGjhp8/tZvU+vzXPcI8J9QwkW42Svtt+L+diS+8m5vC0aJEjADy17EL/Ws4jAGDVmfaZptjbju4wMZFVwQeSTyc47V3nxhSuP8AXNXsfwfcRy27Meg7jIrxy4/1rV7B8ID++gzjGKa3M6h6F4vY+VNu45HfrT9EXZdowUKvl/XPFReJvmjnB2kDHP41Z0Lc08QC/wAH9Ko50d94FWT+y8qnH2jr+VeqIw+3Ww7+W3T8K81+HkZfRnZm+b7Qfp2r0TfjVrbB6RHPFX0NEZ3ie3WXTr0vjbhuv+7XyP4jhaOG1khJCgpjHBzk19X+Nbry9Evtp3ZZlPbHymvlDU2Bt7V2c70ZCqk54yaiRD3MWeGSbUUXyw3+i7sg9Pmp0MKnTbjAJ+SbC454IpsKzf20kwY/NbsT7DdUhjZNNvj1MhmXn0yKgDZ05Nt1E8TgAXEfzMOv7utayKPrIZ2SbFjb9Ov+sPAqhpsG4RW0igM88LGReQvydMVf0WEL4kt3RCA1lF8g5/5acmqQxLhftXh+aSRdqpAePpOKm1UibVbh5UBjmNwAuTuGI1wai13dB4enySRLHIqj0/fj8q0b9JtrrAqCRTOdxXj/AFQoEc/iKXUNQRNpAWMlSSMEQnpSQbUtbQOyeZ59qWZTnHyN1qzaYTWNQhztXyom3KOP9SazriMixsnX7hntcjHOdpoGTafF5V5pyoDhmiO4/wDXVs19DfAxok8NyeWSytcv8x9d54r56mCpc6Vsk+bZHuHfPmkjFev/AAAv5DptxG+cG8K7c4531Uew47ntl2GWJ+MkIox/wKuM8W/vIr4ZPl+TIrYPfzlxXYzNumcjODEv/oVcf48RhbXoQ4LQSkAd/wB6maaKkeceKkK3USCIGRXd+nOBKnNY+uTk2VmY3cqZbg8cj/WV1HjGPcqzkE7GdWIPT94lchczLDZpv2fNc3BGRn+P2qSD5cQ5UZHYd6ULgrn06CiJtu3AweMZoUn72fu9PzqDqNC1hSYzq7iFlidjnjOBwv1rVa3jNxDLE42OUT9wcsD5eTxwevWsqNUnnlkuHKoyOwPJyccD861/D0T3uoRLbwZlz97ooAjOf5UAEaI7W1wYHSKFLXcoOSV38t+NfRehJBeabrF40kzDydfVVYfM6skRwwPcc8/SvDdHj0tbSBLa4a4uHXT2cuMCNzP8yAdx0r6BuBBFr/iGdExciLX42VV2KQEhIODxmgDZhiXTJ9MgntI1tP7Rjw6gYDNphxz1J4rkb62+y+JNOWwjnCfY9CYiJgzN8zcn1Ndld6jDqcOjWMaqx+1xSK0i/eI0xmDH3yBXnOj6ndS6jpc9zEReGPQUiUvgsBI+Dkdu1AGZDHNbeH9QgkuJUdrC92snzLOpv0G1gemD1Nanxy00/wBpaYgukglVb4yyxnnjyzg47c4rA8UXxuI55o4Wg2WN9mM/cLi/BO0/xZrV+OF3Z2GstcxRXAlv4LxXRmG0bljwQOwznNAHkXiC0u7fV9SRpFmWO4OZOCS3l5zj6VnXMMhsreQOjKvlIEU5zkE8nt9K3tetZv8AhIr02ZaxyETd1XaYMnJ98dPeuTu49pjZVaJSiEKO+R1oAW4YtNMSqqWI6HoPSqg4AGR9c1avmRrg+SGCkL94d8c1TAAOc9MHNAFO4/1pxXr/AMIW/f24HpXkFx/rm4xXrnwgkK3Vv1/xprczqHoviSJmE6j7oxz071c0FJIdQjGVIMfAAp+vICtwccEDk1a0mFY9RttpJzHiqMEeifD6MtoMrABP9IIxW/rN81vqtsCc/unqj4HjRPC0x4yJjz1qHxXMx1KyUkKdjfyqynscB4t8WMuj3sDtufzWOM9tteFT3f2m1tw245ZADjnqa9N8VJERfgSFWBORjg/L1ry1I1OjwPkhldduD71m3qSiSBHfUkAyubRgMnoA1Ph8z+yLpGVdo88h889qZZTSjWYOFQC2cAN0PzVOkRe0uVWIu5M5IX+HgVIHQ6GW/wBFklxhpogH99h61ctElTXLXJ+zl7CInHUfvTzVa0tPKEEu4bzJbgKD8hJQ/rWvpqLJrlsJCNzabGWPp+96CrQyndQvN4XmBkV1WKZi5PT9+OlalxcM1zuyybnmzk8f6kDFZk8scPh6/iUqytHcbARj/lsK2ZokG8sq7t0uUHOf3I5pCKkdlBJe6jGkZRmhhcg9f9Sa52/mFzp1iJojCBJaDI4BwprqdOujLcXxiUM4jg3DqeYj0rndQm26daRRlDGj2jDccnJ3D8qYzJgudrwGZt6hE5xyCJjgCvQ/hHqRtXHlSEIb/lWHIzJjmvOBcqggljwQmxXQjB3CY9K7L4dzqtu7rEEVL/k55P70daIvUFufUyyJKo2DDmPIz6bq5/xfCslhdF1HEM/I7DevFT+F79dStopV/igI9+JCKt+KIUk027h6F7eVvyKmq2NHqjyrxRw75LCP94cDkH94mK5HW9lsqpHEj5uJySOn3hXonjGFLe2kkkGceYDj3aPiuI1+BWjQqcD7TPyO/K1LMm7HySOdvXoPenAYGPUURgEADjpzTlXIGDzUHWPdnwwII4rc8PX76bdwxh5TH5olIi4J+Qj8uaxHAVmVScHP5Vb0qWZL+KWNwJEbALcjoaANNmhghURwYLRWrAk4LHeSWBHTNd9LrtnbLqCS3M8kg/tSNY97MU8yNAOT1yR1NeXybjNbhG80usZx6NnpXV+JVFpd3s06sl9NNdxzWsZB8rATBJ9M5/KgDpNL8XXsEtiLm7FtZWt1ATGchz/opTzM9cAfzrnz4hvJNNnnaV1uYI9PSFwMFfLZsEfnmsoW0jqGeCb7QQijf/d8nJP5cispZl3worOY3EZkB9QT09qAOsn8QyzeGbW1mcusdjcW8Te73SuzfXrW94olQa3exLi98lbklpCcNGY04H0rzyS5gW02qWLlJFClsbCXyCPwHNaWu3BiEHlTTNIPM3M5w2CF7dvxoAl8VXix69qItUMMUkiny2cnA8sCufkAkaLL4UqilsZ/Sr9/eDUdXuLi6RMSHewU8ZCYHP4Vl7tqKQOFxkZ70AJK0juzS7mY9W9cVAUDEbiQPerMziV84IyOgqPA7du1AGbOMSt3r1v4PY+1QZzj2NeTXX+vbNet/B1lS7tsgZJxzTW5nUPZdXiMlpckR8cZp+jRbtStQQC4QjGenFGqN/o12dxACjgc1jaVriR6tbMxB/d4yTir6mB7l4TRIfC8q4wDIeKw/GIB1azIPOxsD14rV8IXSXHg92XkiQ/nmqGu28k+t2GV+Uhhk9OlUUzxDxRITcajFgFc5znpwa4XzoRo1qxC5QoQD35Nep+PtFa3vL4iMmPgkjqflPFeRiAz6RDJ5YBV1QAH3NZMlFWSXdrduGbgQv2zjLVqksdIuTbsQA0+Xz94YFZETxJq4XJDNbyKf9k5qa1liXSbsFiznzsIeg4HNIDpINSnW1tYmXzP31uflbBHyntU9tqZttbtmn8tQLFVJz0/e/qa5yzuZLiyieNv34e3xtIJPBqJncalH5gd3NkCAx6MJM5qrjOlvNQik8NyKE+YLcBWbr/rlNa39oQG+eGYMxVpmLq3rCMCuCluZW024jkBYqk0jKOinzBmtRJXutQ+1Qhiru4weOkQpXEdBZXjW2oXoEW7dDboXzjBMZxWLJH5WlWp3o6mS03E9VOWpbBm/tC6gBZ98UL7gc5whqhd3kcmk27Sy7JFa1BUY5GW5p3GOuJbdjGE+faE6dv33P1NdB4VlCi42B0i+3b0PQN+9FceisksMhBEW0H5f4v3vWur0r/kDzsj5ZL0rsb7x/er0pJ6gfR3gO5VYISx4W2bd+M3Su11eHzLS46ZMMgH44ry74bztI3lTZLPauVbPZZuhH4161dDdDKD02t/StH0NI7HnPji0E0UsbEjCy9B/FmM5rzzWLZkZwHDr9qmwf8AvmvVPiEgtoXl2kq4kJ+vyV59r9kJXZIW27LmbIHvtNSzKWh8axZBQjH0pccnBFES/ICeBjOacoBHIGD3H1qDrHDdtbA4IIb36VreGbxbTV4GuIop4w25kcZDHaev51ltjOFVRgY47+/1pYZArgMPlzkjHU0AHmN5sbFjlCu32GeK6LUg0izXd0WkmmmuVcE852qcn8/0rCRY2t3Yn94u0KPXk5qxExkYs5kClZW+XrnHf26UAaOl395ELdnk326zKCsnK58sqM/hWPDhpolZiGOwK/Yc1bguppLEWAKiIzCcBh3CEdapFsvCVHO1ck8c5oAnliOCAEKjf8w9m6mtL7TDJfSs8izF4pE+cYI+UYPH0rJATYS52llbnk4O6o2ym0nIbBByOKAJZ5C87suVzj5e44pLkr8uwMBtUnPr3/Clugou2EW6ReMMRtJ4quWLKNx+YY7dRQA92JbJbsOtNAGOW9/SgggY+nOOtNzkc85446UAU7k5mavVPhE5+2W49/SvK7n/AFzV6l8Iji9tzkfeprczqbHu13EBZXQBO7aMkCsW08OrPq1gY/4VLHPeukEbyWl0QQw2+tQafceXfWrGQhvL71ZgemeD7eKLwzIhXbiU5FaV4I21awVk+XaxB9K5DStcx4cucOuRMRweamn8SINS05pXT7jdT7VRVzG+KEcCwahLy0gIwQP9k185y3Mclhbqq4AZN2P9417N451lNQj1ErL8pYAj32n9a8SvFddMtSirhtpDDt8xrORPUznCLrTEkgCN8YHU7u9acqJFo01wHOHkmQgDsVFZ0wVtWgI6tDJvHpzVtRv0u6iUmSMPLhj1PyjmoAh0W4VLCJoExMJYArZ+uaS3khg1mBrpSwa328HOG8zrSrF9jRYwAfmt3yOgPtSxRQyavC9wfLUwgnHQ/vaYx2qeW2mM0BIYi4VscHHmDr+dWY2kgMULsExI4yvTmLrVe8iMmm6hGjZRDcFCB1G5etSafKy2yRxMHZZyctz/AMsuRQAuiySR6hdF33y+TGqnPyn5TVfVIEhsrdxIHRo7Vs47liDTrcyrqjRxARr5UTDHOTtNOkEk+jWhkH3DbICOmCzcGgYwzPJAj4ZVjAX/AMjVv6XcK8V9JlkP23JAPA/eJ3rmI0OxY3yd+4bicZImFaWjiVzqCwIyxvcEgHpxKnFC3Ee4fDa/SC7LszDyYZlxuzn98OK96L+dG2DwVkHH1FfKem6mLKS4kb7v2edVweM+cOa+ivCN813pk5J3vmYg+vK1otUXBifEaIzaVKB1SGUgev3a8xvnEEtyxmOJLqQ4Pb5Ur0/xvNm1nRVBwkobJx/Cv+NeV6y8ULSC5OCbqXbx1GEqXsRU6nx6mRGCCcEAc0o4Jx1+lNj+4ufSnHrzjrzUnUPwPXg5xSkqGy3POcD6VF67vrx0pV6/zoAcAcLzjIzzUoaSLAOdwDDnngjmojgEc9qUsW6dgTmgCUyZO/o3HHTtimA7WDZyBjrSB1MZAUBs53Z5oXJGewwTQAvZgxI4IH5005I4OTzSE5JOR055oBwOCOnNAEzk/aVKZHGCCfaogTu+bnGOKe2fMwxBPfnvTWGTngHpQAYYHkn8KavDYHAxTmJ/iA57g+1RnHfnjigCrOMSsK9S+EJX+0LXIGd3WvLZv9a2K9L+FDFb6DBx83WhbmdQ+l9OhBsrptmRtwBjGax7u28q9t/LXLFOQwxgVuaEu7TbkFh06sM81Xmsw13b7pAT5fP0rUxMfR5x/ZN6m3gT5+lY/j25iivdOwxibdjIPUY6Vr2Vqz2V+kcm1fO4IrjfiNaXLapp8EZYuHHTkgVL2EV79mEF4EIZN2ffOK4O5lV9JtimSy7c+3zGu61a2lsYrtHIYZBz6/Ka80MxFnEGbbjHy54PzVLAfHEJ9TjDl0/dSFWz1OatQ7oILoFCxDzAc8/d9Kph5I9RikVQxaJ8DsPm61pW7M6XRYdpvmPU/KKkCvNM9xcQDBbAgTPsBTQsdzNDiRkZLYgL3J82rOlxGby0kwjM0HOMVB5Dx6lbLF8geEDPX/lp1/CmMhvLlhpzoy9FuFODj+Mc1o28PlRxOFAHnEEA8j911+lQTWCmK+V2LHbcFSO+HFa1tYzPBKiRk7bgjaB6Q880IDKsFdNUiVld2MUXfn7pqS3jk/sxVlcrEDbNyePvHqKtW58nW7f5DCzwwDd3GVPIpLxYhpcKxIS4W1Db/Xc1MZk3kccdlBPEzZYMfYHzu1ayzfZ4r4q+V+0MQqcYPmL1+tZl66voFqVT5gJFyBwuJhWK188bXxDnDSHkeu4dqluwjoH15l89ZGzlJl4PC5kBr6O+DfiAXVtGDKdrRXRHvhl5r5Os7J76WIbZNkm456jlxX1b4O8JSeGbYrtcj7JcqhA+7nYauFxrQ6P4kX2yG9McxVMTDK+oSOuJ8RMrOPlE4MznduxyVTNdT4ks2utI1KSVWEcbTY46fJGc1wniSby7p1AXb5z4OMZG1KJEyPlNM7AQf4aX5snqabHnA6dKUfd9Kk6x3QkAnGO9HJyR0o6jHH4Up4wT39KAE6nPf6UrMWzkdf1pMZIx1pT3wR06GgABBTgYOacMknqeKaAe+BjmncY/zzQAnTHHIoGfbFIRtJ5zS5wOD17A0AOUjd8wP1pHfPJyelCncx4/LtSOwPFAD41MhC5wDjkngdsmi5i8meWIPHJsYrvjOVbB6g+lNYqeQAF9BTRywGaAKs4xK1elfCsH7TCQDnd6fSvNZ/8AWtXpnwnf/S4VJ43dBQtzOpsfTPhgH7PcxvGSQvep7qOSO7tcR5JXbk03wthYrj5wMgZBNdBqcKq9jIuMY6kVsYnKWtmxstQynBkB+tQ6no8c97YXCwFpCp4PYAV01kkclhfHIb5+xqDVJQv2ONWAKq3AGOMGkB4p40mjGrXUTFgSoIGOOhry25UPbRKy5ACnd6fNXpHi9sapcgMFJxjJyTxXm8soNkAQQMqDge9ZMSLNnGr30Wwk7YXyc/7QrUkiB+2rG+whpcA+m0Vn2EjNewKBgGFwMDGee9bUYCC+O0b8TZyc/wAIoBlWyhXYgZzjfbgkc4FWZ7bz7uwESScW4wcYyfNpunxNKitGGGWgyp6Zx1rpdDtzPqmmhnUhbZVAz1Pm1SQyCx0d2sNUV428xIbr58f7a/8A16W7H2NZ0iV1K3OCD1OYO9e2aHoKy6HqTsiBpLa7HqfviuC8d6FJY3N3LGA6GcZQjgZt+tDVgPPvs/mapE5C4Edsob/gBqnPtFhCEJYt9lGe4wzZroorfdqkIcBVENsVUdD8prEcR/Zo5BFgN9lBHp8zdqAM0xD+wtrucHeFIHDfvh1rLt7GBL++S5Dl1mIwo4++vT8K25lEWkw5lVsb8Bf+u4qJopJZ9QyoHkXDF8dRmRRxUh1Og8P6bbrPb+QQYdsnJHpMtfWUqpOrKOvkzqAR2+Wvk7QXdo4Y4dwUiU5J6/vlr6fS88lWKj5xDcEjvgbea0jsUih4qdIdD1eNGUb2lU+gG1K8l8ZJLHeFX3N++kIPTjCV6jrZa8W6wuUmmfkdOiAirniTwrHdOh8vGJHxjjghaUkRJaXPz4T7o78VICSTk/nUan5QMc4zSqSxINQdZIeR2+tOJOAOuPWmg9QT+VISMk9DQA5emeQT1pcjd1z9aaAR0znpTkViu4IxReGIGcHnGaAFDc/jzmherDkihSNuO1AJ/iyRjmgAIwB6etNOO3TNO+XJ6+vWkA4YNgZ7Z4oAASsmVOD7dqTAK5xgZpdvzDI5x60nRyCOfzoAcykjJIH49KbnB5FO28dPwzQdxYdMj26UAVLg5lYivSPhMFOowZXcQ2a82mx5hxXpvwlRDcxsX2uHHHqPUULczqbH074fVWinwpUBR+Fdvc2Sy21sCnIXvXE+GlzHP8xP+1+PSvQxH5hthk5K1sjJHLaTbC2srtDHkeZkAVR8UwiC6tJVypYMOPpXViz/ANFuiDkGTPrWJ4xiR0tCoxjJIA9qGDPnfxoqm/uWCgDjB75wa81dgtuhdtwyOf7vNeo+JYAbq53k8nqT7HivNLqEJGgxkEqfrzWLJRf0ZQNQQ9vJf73f5uorc8gMl6zfKxMuQemNo4rJ0geZeHkki3fYAcbea27DmK7Mpy2Jt3udo5oBlrT7c+WQyjdm3Hy9xit3wpZFNesgeFMCcf8AbXtWXaws0iqXaOMtbjaV9jzXaeFbTfrtmISSv2VCCfXzatIZ7LodqE0S4bbkmK4HXr89cr8RbVJVul2nH2kBgB/0wPNd7p1usWhzZPzFJske7Vynj6Ha8zlhs8/JUDk/uKpjlseHC1QarAiSE/u7cZB5+6a57UoDLZLKjKm0WqCPPX5m5rr7u2f+2k8goD5dsQcf7DVz2pW/k2UEqlSubUEEYydzc/SpYjDvIohoNuB/rfmOc9CJxUNo6Lf6nJIxYGZsj+8PMWtAKJNHjjnEajEhUgY6zCsuOKRbm9T5fLEzBsn/AKaLUdQ6nTeG0Y7IznYfNUBj90eauK+n49MaRWYMSvkXCbgOOdv+FfOvhy2LxqGYb/KkKEd/3or6p0yPNiMgA7XBB/CtFsVFXM+DR0k0maNjmUSMwOOQfl/wq1raEmP52GWY/otaoQLHKo4BJ/pVHVwrGPeAcFu30pN3HNe6fmIJCBjANKJGGMdRUdFQbkvnN6LSGVj2H5VHRQBN57egpftD84wM9cVBRQBN57ei0ouWHQKKgooAmE7DHAo89vRahooAmFww6Kv5UpuXIAwvHtUFFAE4uG9F/Kj7S/otQUUAOdizEnqa9L+FGPtsWefm6V5lXpfwqO2+hKnndyKFuZ1Nj6k8LxgW0v8AEG4NejWiKogYMSCnQd6818LM/kTDhlAxXpVryLcFdp2dK2RmhtvEn2e5IJGZOlYXjOIEW24YGTz3zit2yybW5wCG8ys/xOhItCwyxyCMexoYPY+dfF9q0RmLMAGY9fpXlLgNDHHuGCRnPQc17X47tw7ToAPvNkn6V4xsbyY/uAA8AjrzWLIRf0kBL5B95TC4yD2zXTWECKlyzA/8tgR6/KK5vTj5OqI+BkxMOO3PpXUWO6S2viSHyJsY6j5RQgZf02BsoituiLwe/ODXovgDThL4gtFJ2utsp46f6w9a4bQoWuGjKbSC8GPTgV7L8PNPMeoxuygMbVTnH+2a1iUkd6sAi0+VD90JKDj3auY8b2y+RM+wvvlboef9Sa665yLSYY42v0+tY3iy0M9hJ5a5bzCR/wB+zSKktDwaW026xbhmO4RW/A6fcbH41y2pW2beJtzAkWoIJ/2m7V2F5Fs1og7hiK3YBuTjaeK5HV2eOxRvmPFufw3mkyDIusJosa43bd7ZB5/14qgIWGo3vlt8jXJDBx23rV66jR9IVuA+HB7AfvhTdOhM0tyJHIAuXyVbJ++tT1A7TwvZNJGA0rLgSgdsjzVr6csARGpzxh8/XIr5v8MB8WqopfIlOD2HmivpSAFLfLDkIxPGB2q+hcC0+RHJznris/WVZjFsbby2f0rQ3homK8j2qjqJDMoPZiOfwqSp7H5fUUUVJqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFem/Cdwl9DlSfm7V5lXpvwoyL6LOCu7oaFuZ1Nj6e8KMPJmIBJznAr0m3Ic27fMPk4H9a818KgLFLt2g4HvXpUON8K8DCdjWyM0MspN1pchFYfvDy3fmmauQGtQVYtz0+lSwAm2uNxx8/U0+6i3TW+GBXB7+1AHh/xFt2hupU2nBBPyjnmvCruIvbwmMFVUjdkf7XWvpT4i2226uWUgtsHf1Br56vURLNEJ2KSCST1+as2iFuMsHj/ALVgyCVaFxu/Gup06MLbXkqB1JMq7Bz/AAjmuasUb+0YgmNixvtzx3rsdLiaOO9YBWdfN6nI+6KSBm34XjN01thdqkwAkDHODXvXhiFILi3Xnd9kAxj/AGq8o8B2PmvGykJ+8h6/SvbtOhKSxNgf6kDgf7VaLYuKJ53C2czMCFAfIHPeo9TUSWx2kjJbB/4AamcH7NKOuQ/86dKm9DkEYJP/AI7SL3PB9atwPEflqQJhBblWK4PQ5rhNXVP7JQzMBg22D6jea9b8XWuzXxKQCfIgUZ4ycNXk2tfutOhUDcrrASMZwQ56UMyOevCTAwI/duHKrj/psKfpUEZ+3FT832og4GMfMtMmR5NNgZMgIspwe/70Ve0aLI1GPbuX7QTnr/GvWo6iPTPBunIL63ErLuKzkA/9dBXu7/LE+4/IEbOa8v8AB2m7nhaRSGiWb5s5zl1r1N1BV1IJDBuKvZGkVoORFihKwgKDk8VHMsZZs4J3H+QqYD5SB2zVLUDsYYB5Yk/kKkqT0Py9oooqTUKKKKACiiigAooooAKKKKACiiigAooooAK9L+FOTew5PG6vNK9J+FWft8PPG/pR1M6mx9PeFI94kK5J969KiPzQHaAdteb+F/N8qQrx7n0r0ZHO2DBXO3g1sjNCwAmxuQzcl+DjpU2xhc239wA8fhVa3lc204Y7jv78VPucXVszMQDnimBwPxPtlf7S6jacKMY9jXzXqcAa1iUgkggZPpmvpf4sSMdMuyAVIK8jvwa+YWuSwTcxcgj+dZSI6lzTYl+3wAkgCJ+D0YZrsNIiX/SkiG0Seb74+UVyVjMf7UtwFCjy3HX1Ndvo9vh7gZOwGXDAf7I4pID0n4c6cphiypLb4iCf92vWbRWE0PIKiLH61wPw9iKWiE5LBoh9OK9Bgys8aHHEf9a0exqhSNscm3HIc/rUjoCpPU5J/wDHabKCI3I4wr08klJOB3H6VIzzjxjahtQDODtEUJyOTn5q8Z1C3dYHUAFgkBBJ6ZkOK9y8UttvhuAP7qEY9fvcV4zrLqluRGuw7Ycf9/DTZm9zjb+OOLT4y2SU8xGGe/mjpXQaHaNPLqJmLJ/pH3QcfxLWBrEwazHlLucvJ82Oh80HP0rpfDV8ZNRvopG+bzicEc5ytStyUe8+CYSdOWTawG6bOT/tCu0f5ZAATlgxx+Vc74PRodFQbgW3St+bV0Tk+euBxtbJ9OlUzaIsm4IT7E1X1BGcpggdev4VZl+aBx1OD0+lV798bPkJ69s+lSglsflzRRRUmoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV6R8LD/p8PGRuxivN69G+GAH22E5530dTOpsfUnhWQfZ5gykDA/KvRbc8W2VG3bn9K838JHEUwY8bQenv616VASfIHbb1rZGaGWcim0nYJ1k71Jw97aA5VgDwaZCpNpdBjxv49qkA/0q0PU898dqYHnfxhlaPT7wDIDbRlfoa+WUkK4G0Fsjnv1r6r+K8fm2d2JCAg2++ODXy5Pa/uVYcDdwfxrKW5PUvWp33UblR/q2PT3rvvDF95qXSkEBhIMY9hXnlmJF1K3RGOCrdfrXovg+PEtwXbcv7wDjpwKSEe7fDyMR2ClEO1ih/8drsVw96COnl/+zVh+FLcwaTCMcnYePTFbkX/AB9R8f8ALL+taM1Q+Zv3EnHZqlUY3k9zn9Khk/1Mmf7r/wA6mH3eP88VLKRwvjNSL4tyqgQEn0GW4rwzxRdp5IG07sQ5z2/eGvf/ABfCZHlGeqRcD1y1fOXiiMmAt5oyqQlieCf3hpsyluYbzxf2O2C2/dJgHj/loOlP0C+8vV7hyGXdOwIx15XFUNRZDaKFL/MXY46Z8wVteGrFZtYuSpXAudw3fVahbiR9R+FJBJosDLkEpIf1FdNIRgjvtNc94Tg8vSLcBQABIDx7it6T7/IGSG/pVs1Q9OEkz6n+VU9QzvGMnk8enSrcn+obtwahvCARkdz3+lSEtj8uKKKKk1CiiigAooooAKKKKACiiigAooooAKKKKACvQ/hkSb+FR3bPFeeV6P8AC1tt/GQBndR1M6mx9N+Fi0cUowSu0fzr0yMuEhKKFbb9a8v8JSL5dwOd2OtemRTENbKf7vatkZIdZFmtbkyLnD9TSzMwv7NQCTg/hUMUjCzueQQH6VK7k3tkRhTg5z9KYzkviegTTr1toY/KSB1PBr5jljlFkrnkFhgf8Cr6g+IO2SxvFAJPy9e/Br5jlMnkLuIwrgBcf7VZy3I6jYYS2q26r12MeDz1r0/wlbhYrnI3cvwOewrz6wUvrsQiAUhH3Z5716d4SlijSfaC0gaUccfw0oge4eH1cafCWyOIxj8K0kb/AImQUA7fJ/8AZqzNCufMsrcueSEwPwrTiJ+3qQAAYv61ozVD7hmW0nI6gPip0+7k9/8ACoGbdBKBzkPwfY1Nu+UZHt+lSNHL+JDvuZ484wkWPzNfO3iu2ZbRcYDfulyeeshwK+hfEtyEuZ1YDaYoufQ5NeJ+Jo1udOUqMvthYZHX96aHsZy3OIaxke3jZxvP7wNjjB3iux8B2nnavebYydlywO4deVrAZjDE3nbcEuSoOMnzBziu9+Gsu3X9RyB5IuG6DqSVpRWolue5WgEUKRorKpEnb3FXZjhWJ7Bv5UxNq4Ixxvx+dSynOQfRh19qbNRQd0ZPqP6VSvd7SHb5ZAJ+8uew96uk4iOOOP6VDOyxscrnJz09hSCWx+W9FFFQahRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXo/wALSi38W4Z+avOK9H+Fyg38Lbud2MUdTOpsfTfhJovLnzGFOO3evSY3BjgymTs/GvNPCMSvDPvcjPHSvS4Y1YQFmA+XvWyMkRWjqbK5yvAk6mppWQahZttyMEdagtoSlrcBnUgP2ORVl41+12hR9z88DnjFMZy3xEdRY3mAMkDBzyODXzPKU8hFKEnf+fzGvpP4hwbrS6CyBScH9K+cb+EQQwtkjLD5iP8AarOW5HUs6bJFHrkZaM4aNwO56ivQdAe3ihnXbtYvISxPX5a88sYh/bMDFwwKPwD7iu20aNZ47oBlV0aTDNxn5aSA9y8Jzxz2ELDO0eWAPwrpI2T7Yh7mM4+ma4rwI5fT7ffgH93nj2rs4l2Xyc5/dH8Oa0ZqiRwq282P9s/41L8pAJ7f4VDPHuhkKtg7XFPk+WMZI56n/gNSM4HxTdp/bDwEZWWCE9cd2rzLXPsq6KCspAVYQcjkfvTXc+IiW1coGVz9nhOT9T3rzvWow2msA4ZBHCXUHjPmmmzJnO3CRTRvLkFT5qqT0z5gr0X4a+W2qXkRBRvPJI6/3e9ecXEOIJEfYNvmNj6yCvT/AIbWpg1G9LlSfPYAj/gNTHcFue2Dapx2O408gfMSOeetQQxEqfm7uPzNTyqdwI7Bv5UGxFCJDExnZScnG3oBiku3VWG71P8ASpmGYWHXI/pUV1FvIyoJ/wD1UhS2Py3oooqTUKKKKACiiigAooooAKKKKACiiigAooooAK9E+Fwb+0Yigyd1ed16J8MCRqEWDg7uMUdUZ1Nj6d8JxsYZsrhuv616VEjH7MWXgJ+teaeE5CIpQWYsehr0m3mG22JHO3I9q2RkiOAP9kuQgAxJ16mpgjRX1qyDqMc1BaOwtbgg8eZ1qzI26+tPQZ4NMZzfjiBmt7zcmWwOn418361HKbWEMn7sHkDn+KvqHxPGWtbtyBncMflXzT4gV47NGkbADZC/8CrORD3KGlxumtQ4iyWifGT05rs9LjZUuAQ3mB3yfbbXG6YWOtwsGBHlvjt3rutNJMdwQQXLvk4/2aSA9U+HsktxYQNIu0fu+MV3yDF+m1cAxHof9quJ8AE/YICRsTMeQeucV2o3fbVEbY/dHHGf4q0Zoh8gIt5vXEh4p12d0A4PT/2U0PloJcY3HfT5QCqhsAL/APE1IzyHXZvK1doyjY+zQZPfqRiuA1sCHSzJ5T9Id3uPMNejeJSU8QuyYA+zwnHrgmvP/EMjSaVEYWAykLSDOefNNDMzm74b4LjCkNukwOuPnHFepfDBpGkvlERT/SGy2en3eK80uZPMldUlCsGkIHr84r2T4YROG1QEcG4Ykkd/lpR3CJ6bCCo6HOX/AJ1LKchiM9G/lQ2Q4xjgN/SpHPyseMgH+VFzYQ58g8c4/pSMQSflJwefyFP/AIR6YqGSREdgzKpz3I9BSB7H5a0UUVJoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFei/DIYvYWyOGzXnVeifDEKb+Ld/eo6mdQ+nPB+1oJi4O4DqOtejwFnW3HGNnYV5t4TXbC+eAeBnrXpdrh44MDHy9Qa2RkiKA7bS4U5LGSrMu1ZrWRmwBngHrxUFuQba6Xr8+TViby1uLQtxyf5UDI76P7RFcqcAHnp7V83eKbMR2+0jcQxyT/vV9NmJT54xhfTt0r598f2B+yhozhVbChe53HmpkSzjdKjVdcjBwAqOVB78ivQvD9o8huMYUlnLYH+yK4XS4UbW4izBXKSDGeTzXp/hiz8vzwRxlz6n7tShHo3g638ixhxgnEYJI7YrqQFW7QkneYz+WaydChH2WLacjbGT+Vaq4W8UHqYz/OtGaofkeVJgY+/Tz83THB/pUZG1JCc8BzUij06f/WqRnm3i61SPXElPP7iIbfXlq831S1B047gqny4yCP8ArrXrniqBHvx181Y4sd+MmvL9chA0+UOWUrFGOvX94abM2cfIqO4xHtmLyhSOmd4r374dWhih1ESEFzO2cf8AAa8H0+1mlTO47fOkAHcfvBX0p4PtFhtblgdzNKxY+/FStAgjfdQMnA70pAOfx/lTD91vU7sU853e3ekbCEDZgdcHBqK4C5G7FTnlDiq15Grld+DjP9KCZbH5b0UUVJqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeh/DIsL+Lb/e6155XpHwuP8Ap0Wefmo6mdTY+l/C3mSRys3zcDFejRptNtk87M4Fec+E5GIlwuR0wa9HRiPs+Dj5eK2RkiG3Zjb3IHUPT3dmu7TggKSDxwaLcZt7k8/f5xU0oP2mzXHHNAy383mTFjz0xj2rxTxvbv8A2cOjI24dOQc5H4V7UhZZ5ypHTArzbxzaF/DYkA2GNg5I9MmlLYTPG9L8v+3oQF+Yq+CeqnNexeFotyzu+WfL9D7V5VpkOdeiZScsrnPTvXsHg0tsuSABnfwfoKmIkei6Om21jwcDahx+FW0/4/ImH/PNhgjrzVW0J+zRlf7qcVbjYtepkjAi7DvmrZoOuP8AVSk5zsfipYx+7OOn/wBaoXYeVOOhw9Sg7ccY5/pUgctr0Rk1NCpAKxR9fqa8t8Wt5enTuw2fu4+OCQfNNexamN17ISBnykx+Zrx3xcRHpzKMHcImz6DzDTexEjC8Oxm68sAlN0rkgn/bFfR2hoI47lRniZufXgV4f4RtEaddhBHmMxOPVxXvFiTtuMjH71h/Kp6FQJGyFb33Gny+3of5VG5JkUH0b+lSyYweecGg0EH+obHpx+VV7tgG+Y9/T2FWT/qyB3FV7mJJmIYE7T2OOwpEy2Py3oooqTUKKKKACiiigAooooAKKKKACiiigAooooAK9D+GJA1GHI43dq88r0D4aKf7TgOcfNR1M6mx9O+FRvhkYK3vnvzXpEfzfZ+OFTI96818KHEUgJyTjvwa9KgGY7fauRs78VqjJEdiQbS6LYYb6mbI1GyA+6M1WsikdleBh/y16Cp5hnULIZ456Uxl/AE05CnHH8q4zxRGP+EUl3KWBXqO3zV2RJMlwFxgf4VyniHy18IyEcZXoT1+ah7CZ4nYqU12PMgA2vhfUZr1nwUNkNy0S5yZB+gryGQoPE8O5cDa/Ga9b8AyCazumTaBmTjPtUxEj0qzT/QoQc52x1NFzfJntEf/AEKqtiy/YLcAEErH3qaMqdVi/veS2D/wKqZoSuT5E7D/AGxU54RM9T6f7tQXGBbTbRxhyamH+qTHX/61SBk3YQ3chY4Aij5/OvG/Fjqmn/IgcusfXt+9NesamCNSk+bBWCPj15NeMeK5QLJQDhNqHHt5ppsiRveBYVeQBGy4Lk5H+2Oa9styVW4Lf89D/SvJPhvDm3UjlvnCn0G8V63AuBOPWQnH5UnsVAceG74+ansRk98g/wAqY4+cc/3qWQkZx0IP8qRY84Ef4VBcLlvTn0+lT4/d+vH9KrXSSM/ytgZ/oKSFLY/LiiiipNQooooAKKKKACiiigAooooAKKKKACiiigAr0T4acahAQMndXndei/DIkajCBx83rR1M6h9K+EtxWbdzwK9NVjvtgnyjb39K838KDCy7lznBHNemw7f9HZ1J+XgZrZGSKUBZrG82/e83I4q1PIqXNgG5YnsM9qhgZTZ3gVSvz46U6Q4vtPwMdeevamMuW5LXN1np15rivGc4j8HgAkdc/wDfVdfNcJDLdOwOcYz+FeWeOtbhbwvBGrbi3HBz/FSewmzyy9vHj8TR4G5Sr4yK9S+GN08cF0pbBHmcduleN3UqHXoipYnDjHeuq8KasbSC5VN28uwP/fNZpko+mLCXzLG228tsj5IxVuMAapGP+mLcY/2hXHeGdcS7sLAbvlKxDPoa6+GQPrMe08eS/wD6EK0ZqmSNuNrcE4+UScdamz+6j4x0/wDQaikIW0uT0P7ynNNhYM8A4ySf9k1IHM+Jbgw3E+MFjbx4/M14X4huxLaK0zD7keCP+unSvUvEGuI95eqrZH2eLH5mvCfEMyCwt2Uk7ihOR/00NDM27s9v+F8qSWk3lnKkuf8Ax8V6vEf9d3+f+grxL4X3sVujh2wCrnGf9sV7NY3Czx3Lp8wEpXjvwKHsaQJWO2QF+248elOkGcknkA4/KmyHbcxqOjK5P6U6bAR+ecH+VIodz5HGOlRzPHGx39z3+gqQf6kZ7j+lV3w8jhudrcfkKSFLY/LiiiipNQooooAKKKKACiiigAooooAKKKKACiiigAr0X4ZLnUYegG7mvOq9G+GZIvoj/tUdTOofS/hRQ0U3OABjJr0mEK8lsAcEJ1xXm/g7dsmyR0zyK9Jjbm3YHC7e/FbIyQyMAWV1k5O+nTBY7qz8wgKOg9OKrPcolpdBWGC/fsa43xp4jFjJbZkHfpyelFwuO8feJ47WO+jt5V3rjB/CvBdV1k3OlxL5jEqenbO6ptY1mS+urjLHDMOorJsrEzWmHGSSCDnjG6s27k7iwq11rULyOScORiun8N2xLXYJIUO+GP8Au0yGxihuYXbG8RyfifShL6SGGcKhUF2IBGf4aQHo/g/UkhtrOFWDENEDu4zmvWdCnE2qREMMLDIDg/7Qr5p0q7uDHBPFkrGIgSF969k+GF5dPfq86vtkifHy9fnrRO5S3PRlRjBcNuGD5uCfSs3XrgRLboH5JA/8cNW9UmNrptyTg7hMfpxmvNNW8R/atVjRGBijVGJJx/yzNA2zltVmeW/kXcWZ7aLPHUZNeeXUP2iwAC4Plpkk9P3nWu4S+iudVSQkKDbRIBj/AGjWZJpivY7l2CMxRkc9/NNSyCjp2oS2SOqycqH244JAcV7x4E8Q2w0+9VmCEXBwnTGQo4rwjU9NdLcTbCzHzl9gAwq/puo3NncXqscKLjIx6fLQnYaZ9SIVklDBvulx/KpJMMGHXqP0rz/wt4qinkeOSQDaZjz1/hrvY23qxBHzZI/IU7dTVSuSEYh29Tt6/hUMsbCRmDAbjnp7Cp25T6D+lQ3JcEbSBz3/AAqQlsfltRRRUmoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV6H8OG23kROQu7qK88r0j4ajddR56A0dTOofRvh67EMMhPUCtzVNaNrHayKTwuOnb0rkdIguJUkWE7QV6/wD16173Rr+4NqueCuM9616GJy+o+K7sQXaKx5bqe1cL4i1m81C6i3H5R6V6SPBVxILrzSd2fSiD4cGQWkkxJJbJHpUtNiseXafZyy3bHyC7Z9M9q7Xwt4Sn1HTnZkKFWXj1Ga9V0fwXZ2+r71BGE/XFdNpunwWVi0cahScHp701EpI4CXwGC1kJI8BQ5Zs9elCfDpW1i6eNS0HPysc/w16rw3lswyAGGKsR4818KVySOPTFVZBZHnHhbwXHb2H2KSH77Rs7HsB/9eu+sNLisp4FjxtiRgCo9WFSwHE0nXpHUoZtiHIyAc59N3SixSItRtGuLWdPVZgPxGK891LwCZNK8uEfv/PUlif4Qhr01Wl3nOzHznvnHFCYzNjHD5x/wGkFkz57uvAV4niHToYzIAbeMu3vk1b07wpf3FpMPL/eRxoAM8f6w817u0MZlt5WA34UU23tUR5FKjaVXgD/AGjRoHKeJ6poF7Z+HVkkUspWbK+h3isDXrYpdakVQxuOile2Fr6Ba2jk0eVGAI3OOeerVl6/4SttRuL2cLh5Y2UfXApNEuJ85WerXGnSyM74YSSryOmdte0aL45U2tuJOS5lDYGMYUVw2ufD+5i0N5V3GVJ5twUduKv2Hhq+sdbMSRs0fkyH5hnPyLSV0FrHrGj+JLe+spWDZKhu2OgFWdb1AW7xDON2TyPYV5nodveWWmTuUkGZ3Ur7YFbvj3UZI7i0RYnOFPI47LTfcJPQ/PmiiiszpCiiigAooooAKKKKACiiigAooooAKKKKACvSfhrJtvYRjILDIooo6mdTofSfht8I2ANhA4H1r0jyY9ls23GFzz3oorZGSGWTLLBcfuxy2ORT96JLbIQDj2oopjLrDy5y+Op6D6U61CPDuVeoHf3oooGSLKnmojA8Bvw5q64Cy7gB/Fn8qKKTAht9heUgnonX6UQbWSMMctj/ANmoopgWZPknBOANr/0oQAxTnjkn/wBBooqOgxIireSDyQF/kadvUXMqdgq/zNFFPqMqcf2Ox5++enf560lwztnnBNFFJjRkzCOS2kR8lXZweOpzVqS3hXUI3KjPluPw4oopskrTWEA0+5VV4Mhb8eKzPGOnw3EtszBsgMOPwooqWKfwn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These photos illustrate the distribution of erythropoietic (red) marrow in the normal adult, as outlined by uptake of transferrin-bound radioactive iron three hours after injection (scintigram on the left). The patient's body outline is shown in the photo on the right for localization purposes. Erythropoietic marrow is most prominent in the spine (white arrow) and pelvis (red arrow), with lesser amounts in the ribs. There is no uptake of iron in skull, arms, or in the long bones of the legs below the upper portion of the femur.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Supplied by Stephen A. Landaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27682=[""].join("\n");
var outline_f27_2_27682=null;
var title_f27_2_27683="Ocular cicatricial pemphigoid DIF";
var content_f27_2_27683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence study in ocular cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photo shows the presence of linear deposits of IgG at the epithelial basement membrane, an abnormal finding and one that is supportive of the diagnosis of OCP. IgG is also present on the surface epithelium, typical of conjunctivitis from any cause. IgG is also normally found in the substantia propria (connective tissue layer) of human conjunctiva, and is shown to be present in this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27683=[""].join("\n");
var outline_f27_2_27683=null;
var title_f27_2_27684="Rifapentine: Patient drug information";
var content_f27_2_27684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rifapentine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=see_link\">",
"     see \"Rifapentine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Priftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Priftin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rifapentine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A long-lasting change in color of contact lenses. Do not wear contacts while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most often taken with at least 2 other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11423 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-053DC9DE2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27684=[""].join("\n");
var outline_f27_2_27684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218455\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028218\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028220\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028219\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028224\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028225\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028227\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028222\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028223\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028228\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028229\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/51/15160?source=related_link\">",
"      Rifapentine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27685="Physiology of the normal menstrual cycle";
var content_f27_2_27685=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of the normal menstrual cycle",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27685/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27685/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/2/27685/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal menstrual cycle is a tightly coordinated cycle of stimulatory and inhibitory effects that results in the release of a",
"    <strong>",
"     single mature oocyte",
"    </strong>",
"    from a pool of hundreds of thousands of primordial oocytes. A variety of factors contribute to the regulation of this process including hormones and paracrine and autocrine factors that are still being identified. The cyclic changes in the major pituitary and gonadal hormones are illustrated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"UTD.htm?14/16/14601\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The physiology of the normal menstrual cycle will be discussed here. Detection of ovulation and ultrasound evaluation of the menstrual cycle are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=see_link\">",
"     \"Ultrasound evaluation of the normal menstrual cycle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHASES AND DURATION OF THE MENSTRUAL CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;By convention, the first day of menses represents the first day of the cycle (day 1). The cycle is then divided into two phases: follicular and luteal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The follicular phase begins with the onset of menses and ends on the day of the luteinizing hormone (LH) surge.",
"     </li>",
"     <li>",
"      The luteal phase begins on the day of the LH surge and ends at the onset of the next menses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The average adult menstrual cycle lasts 28 to 35 days, with approximately 14 to 21 days in the follicular phase and 14 days in the luteal phase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. There is relatively little cycle variability among women between the ages of 20 and 40 years. In comparison, there is significantly more cycle variability for the first five to seven years after menarche and for the last 10 years before cessation of menses (",
"    <a class=\"graphic graphic_figure graphicRef79925 \" href=\"UTD.htm?0/27/446\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, menstrual-cycle length peaks at about age 25 to 30 years and then gradually declines so that women in their forties have slightly shorter cycles. Changes in intermenstrual interval are primarily due to changes in the follicular phase; in comparison, the luteal phase remains relatively constant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The remainder of this topic will review the hormonal, ovarian, and endometrial changes that occur during the different phases of the menstrual cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY FOLLICULAR PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early follicular phase in humans is the time when the ovary is the least hormonally active, resulting in low serum estradiol and progesterone concentrations (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ). Release from the negative feedback effects of estradiol, progesterone, and probably luteal phase inhibin A results in a late",
"    <span class=\"nowrap\">",
"     luteal/early",
"    </span>",
"    follicular phase increase in gonadotropin-releasing hormone (GnRH) pulse frequency and a subsequent increase in serum follicle-stimulating hormone (FSH) concentrations of approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/4\">",
"     4",
"    </a>",
"    ]. This small increase in FSH secretion appears to be required for the recruitment of the next cohort of developing follicles, one of which will become the dominant and ultimately ovulatory follicle during that cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum inhibin B concentrations, secreted by the recruitable pool of small follicles, are maximal at this time and may play a role in suppressing the FSH rise at this time in the cycle (",
"    <a class=\"graphic graphic_figure graphicRef77945 \" href=\"UTD.htm?30/53/31583\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/8\">",
"     8",
"    </a>",
"    ]. There is also a rapid increase in LH pulse frequency at this time, from one pulse every four hours in the late luteal phase to one pulse every 90 minutes in the early follicular phase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early follicular phase is also associated with a unique neuroendocrine phenomenon: slowing or cessation of LH pulses during sleep that does not occur at other times of the menstrual cycle (",
"    <a class=\"graphic graphic_figure graphicRef75987 \" href=\"UTD.htm?14/50/15150\">",
"     figure 5",
"    </a>",
"    ). How this occurs in not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ovaries and endometrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian ultrasonography has demonstrated that the ovary is quiescent in the early follicular phase except for the occasionally visible resolving corpus luteum from the previous cycle. The endometrium is relatively indistinct during menses and then becomes a thin line once menses is complete. It is normal to see small follicles of 3 to 8 mm in diameter at this time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=see_link\">",
"     \"Ultrasound evaluation of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MID-FOLLICULAR PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modest increase in FSH secretion in the early follicular phase gradually stimulates folliculogenesis and estradiol production, leading to progressive growth of the cohort of follicles selected that cycle. As several follicles initially grow to the antral stage, their granulosa cells hypertrophy and divide, producing increasing serum concentrations of first estradiol via FSH stimulation of aromatase and then inhibin A from the granulosa cells in the ovaries.",
"   </p>",
"   <p>",
"    The increase in estradiol production feeds back negatively on the hypothalamus and pituitary, resulting in suppression of mean serum FSH and LH concentrations as well as the LH pulse amplitude. In comparison, the GnRH pulse generator speeds up slightly to a mean LH pulse frequency of about one per hour (versus one per 90 minutes in the early follicular phase). GnRH stimulation is presumably due to release of negative feedback effects of progesterone from the previous luteal phase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ovarian and endometrial changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within about seven days from the onset of menses, several 9 to 10 mm antral follicles are visible on ovarian ultrasonography. The rising serum estradiol concentrations result in proliferation of the uterine endometrium, which becomes thicker, with an increase in the number of glands and the development of a \"triple stripe\" pattern on ultrasound (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"UTD.htm?14/16/14601\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=see_link\">",
"     \"Ultrasound evaluation of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LATE FOLLICULAR PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum concentrations of estradiol and inhibin A increase daily during the week before ovulation due to release from the growing follicle. Serum FSH and LH concentrations are falling at this time due to negative feedback effects of estradiol and perhaps other hormones released from the ovary (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ). As the dominant follicle is selected, FSH induces LH receptors in the ovary and increases ovarian secretion of intrauterine growth factors such as insulin-like growth factor-I (IGF-I).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ovarian, endometrial, and cervical mucus changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the late follicular phase, a single dominant follicle has been selected, while the rest of the growing cohort of follicles gradually stop developing and undergo atresia. The dominant follicle increases in size by about 2 mm per day until a mature size of 20 to 26 mm is reached. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=see_link\">",
"     \"Ultrasound evaluation of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rising serum estradiol concentrations result in gradual thickening of the uterine endometrium and an increase in the amount and \"stringiness\" (Spinnbarkeit) of the cervical mucus. Many women are able to detect this change in mucus character. Studies of cervical mucus samples during the menstrual cycle demonstrate a late follicular-phase peak in the mucin protein MUC5B that may be important for sperm transit to the uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LUTEAL PHASE: MID-CYCLE SURGE AND OVULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum estradiol concentrations continue to rise until they reach a peak approximately one day before ovulation. Then, a unique neuroendocrine phenomenon occurs: the mid-cycle surge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/12\">",
"     12",
"    </a>",
"    ]. The surge represents a switch from negative feedback control of LH secretion by ovarian hormones (such as estradiol and progesterone) to a sudden positive feedback effect, resulting in a 10-fold increase in serum LH concentrations and a smaller rise in serum FSH concentrations (",
"    <a class=\"graphic graphic_figure graphicRef72415 \" href=\"UTD.htm?34/26/35246\">",
"     figure 1",
"    </a>",
"    ). In addition to estrogen and progesterone, other ovarian factors contribute to the LH surge, because it cannot be recreated simply by administering estrogen and a progestin to women in the early to mid-follicular phase to achieve serum concentrations similar to those at the mid-cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At this time the frequency of LH pulses continues to be approximately one per hour, but the amplitude of the LH pulses increases dramatically. The switch from negative to positive feedback of LH release is poorly understood. An increase in the number of pituitary GnRH receptors may contribute but there is probably no change in GnRH input to the pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ovarian changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LH surge initiates substantial changes in the ovary. The oocyte in the dominant follicle completes its first meiotic division. In addition, the local secretion of plasminogen activator and other cytokines required for the process of ovulation is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The oocyte is released from the follicle at the surface of the ovary approximately 36 hours after the LH surge. It then travels down the fallopian tube to the uterine cavity. There is a close relation of follicular rupture and oocyte release to the LH surge; as a result, measurements of serum or urine LH can be used to estimate the time of ovulation in infertile women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even before the oocyte is released, the granulosa cells surrounding it begin to luteinize and produce progesterone. Progesterone acts rapidly to slow the pulse generator so that LH pulses become less frequent by the termination of the surge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endometrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gradually increasing serum progesterone concentrations have a profound impact on the endometrial lining, leading to cessation of mitoses and \"organization\" of the glands [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/17\">",
"     17",
"    </a>",
"    ]. This change can be detected on ultrasonography relatively soon after ovulation: the \"triple stripe\" image is lost and the endometrium becomes more uniformly bright (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"UTD.htm?14/16/14601\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=see_link\">",
"     \"Ultrasound evaluation of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MIDDLE TO LATE LUTEAL PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone secretion from the corpus luteum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/18\">",
"     18",
"    </a>",
"    ] results in gradually rising progesterone concentrations in the middle to late luteal phase. This leads to progressive slowing of LH pulses down to one pulse every four hours. Pulses of progesterone occur soon after these slow LH pulses. As a result, there can be significant excursions in serum progesterone concentrations during the luteal phase (",
"    <a class=\"graphic graphic_figure graphicRef68311 \" href=\"UTD.htm?5/4/5198\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/19\">",
"     19",
"    </a>",
"    ]. Inhibin A is also produced by the corpus luteum, and serum concentrations of inhibin A peak in the mid-luteal phase. Inhibin B secretion is virtually absent during the luteal phase (",
"    <a class=\"graphic graphic_figure graphicRef77945 \" href=\"UTD.htm?30/53/31583\">",
"     figure 4",
"    </a>",
"    ). Serum leptin concentrations are highest in the luteal phase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the late luteal phase, a gradual decrease in LH secretion results in a gradual fall in progesterone and estradiol production by the corpus luteum in the absence of a fertilized oocyte. If, however, the oocyte becomes fertilized, it implants in the endometrium several days after ovulation. The early embryo begins to make chorionic gonadotropin, which maintains the corpus luteum and progesterone production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endometrial changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decline in estradiol and progesterone release from the resolving corpus luteum results sequentially in the loss of endometrial blood supply, endometrial sloughing, and the onset of menses approximately 14 days after the LH surge. Menses is a relatively imprecise marker of hormonal events in the menstrual cycle, since there is considerable inter-individual variability in the relationship between the onset of endometrial sloughing and the fall in serum hormone concentrations during the luteal phase (",
"    <a class=\"graphic graphic_figure graphicRef62189 \" href=\"UTD.htm?14/16/14601\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27685/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In response to falling corpus luteum steroid production, the hypothalamic-pituitary axis is released from negative feedback and FSH levels rise, thereby beginning the next cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176499083\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;By convention, the first day of menses represents the first day of the cycle (day 1). The cycle is then divided into two phases: follicular and luteal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The follicular phase begins with the onset of menses and ends on the day of the luteinizing hormone (LH) surge.",
"     </li>",
"     <li>",
"      The luteal phase begins on the day of the LH surge and ends at the onset of the next menses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The average adult menstrual cycle lasts 28 to 35 days, with approximately 14 to 21 days in the follicular phase and 14 days in the luteal phase. There is relatively little cycle variability among women between the ages of 20 and 40 years. In comparison, there is significantly more cycle variability for the first five to seven years after menarche and for the last 10 years before cessation of menses (",
"    <a class=\"graphic graphic_figure graphicRef79925 \" href=\"UTD.htm?0/27/446\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, menstrual-cycle length peaks at about age 25 to 30 years and then gradually declines so that women in their forties have slightly shorter cycles. Changes in intermenstrual interval are primarily due to changes in the follicular phase; in comparison, the luteal phase remains relatively constant.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/1\">",
"      Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967; 12:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/2\">",
"      Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975; 55:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/3\">",
"      Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976; 42:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/4\">",
"      Hall JE, Schoenfeld DA, Martin KA, Crowley WF Jr. Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition. J Clin Endocrinol Metab 1992; 74:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/5\">",
"      Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     Gougeon A. Dynamics of human follicular growth: A morphologic perspective. In: The Ovary, Adashi EY, Leung PCK (Eds), Raven Press, New York 1993. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/7\">",
"      Welt CK, Martin KA, Taylor AE, et al. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women. J Clin Endocrinol Metab 1997; 82:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/8\">",
"      Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/9\">",
"      Filicori M, Santoro N, Merriam GR, Crowley WF Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 1986; 62:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/10\">",
"      Fleischer AC, Kalemeris GC, Entman SS. Sonographic depiction of the endometrium during normal cycles. Ultrasound Med Biol 1986; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/11\">",
"      Gipson IK, Moccia R, Spurr-Michaud S, et al. The Amount of MUC5B mucin in cervical mucus peaks at midcycle. J Clin Endocrinol Metab 2001; 86:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/12\">",
"      Adams JM, Taylor AE, Schoenfeld DA, et al. The midcycle gonadotropin surge in normal women occurs in the face of an unchanging gonadotropin-releasing hormone pulse frequency. J Clin Endocrinol Metab 1994; 79:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/13\">",
"      Taylor AE, Whitney H, Hall JE, et al. Midcycle levels of sex steroids are sufficient to recreate the follicle-stimulating hormone but not the luteinizing hormone midcycle surge: evidence for the contribution of other ovarian factors to the surge in normal women. J Clin Endocrinol Metab 1995; 80:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/14\">",
"      Martin KA, Welt CK, Taylor AE, et al. Is GnRH reduced at the midcycle surge in the human? Evidence from a GnRH-deficient model. Neuroendocrinology 1998; 67:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/15\">",
"      Richards JS. Hormonal control of gene expression in the ovary. Endocr Rev 1994; 15:725.",
"     </a>",
"    </li>",
"    <li>",
"     Tsafriri A, Chun SY, Reich R. Follicular rupture and ovulation. In: The Ovary, Adashi EY, Leung PCK (Eds), Raven Press, New York 1993. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/17\">",
"      Noyes, RW, Hertig, AT, Rock, J. Dating the endometrial biopsy. Fertil Steril 1950; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/18\">",
"      Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocr Rev 2007; 28:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/19\">",
"      Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest 1984; 73:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27685/abstract/20\">",
"      Cella F, Giordano G, Cordera R. Serum leptin concentrations during the menstrual cycle in normal-weight women: effects of an oral triphasic estrogen-progestin medication. Eur J Endocrinol 2000; 142:174.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7418 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27685=[""].join("\n");
var outline_f27_2_27685=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H176499083\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHASES AND DURATION OF THE MENSTRUAL CYCLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY FOLLICULAR PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ovaries and endometrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MID-FOLLICULAR PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ovarian and endometrial changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LATE FOLLICULAR PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ovarian, endometrial, and cervical mucus changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LUTEAL PHASE: MID-CYCLE SURGE AND OVULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ovarian changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endometrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MIDDLE TO LATE LUTEAL PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endometrial changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176499083\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7418|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35246\" title=\"figure 1\">",
"      Hormones and menses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/16/14601\" title=\"figure 2\">",
"      Menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/27/446\" title=\"figure 3\">",
"      Menstrual interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/53/31583\" title=\"figure 4\">",
"      Hormone levels reproductive age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/50/15150\" title=\"figure 5\">",
"      LH pulses and sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/4/5198\" title=\"figure 6\">",
"      LH pulses and progesterone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44166?source=related_link\">",
"      Ultrasound evaluation of the normal menstrual cycle",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27686="Ethinyl estradiol and norelgestromin: Patient drug information";
var content_f27_2_27686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norelgestromin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24921?source=see_link\">",
"     see \"Ethinyl estradiol and norelgestromin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ortho Evra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Evra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for birth control, do not smoke. Cigarette smoking raises the chance of unsafe heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will get more estrogen if you use this drug than if you use a typical birth control pill. This may cause more side effects. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702079",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, norelgestromin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you weigh 198 pounds (90 kilograms) or more, this drug may not work as well to stop pregnancy. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If patch has not been put on the right way, and 1 monthly period is missed, take a pregnancy test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on once a week for 3 weeks. Put it on the same day each week. Do not use patch on the 4th week.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the buttock, belly, upper arm, chest, or back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on the breast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use adhesives or wraps to hold the patch in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on more than 1 patch at a time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put the same patch on the same place if it falls off and has been off for less than 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a new patch if the patch being used is no longer sticky or if it is sticking to itself or some other surface.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12450 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27686=[""].join("\n");
var outline_f27_2_27686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168398\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027224\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027226\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027225\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027230\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027231\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027233\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027228\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027229\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027234\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027235\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24921?source=related_link\">",
"      Ethinyl estradiol and norelgestromin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27687="Loxapine: Drug information";
var content_f27_2_27687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loxapine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/26/4517?source=see_link\">",
"    see \"Loxapine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7290568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Loxitane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loxapine&reg;;",
"     </li>",
"     <li>",
"      Dom-Loxapine;",
"     </li>",
"     <li>",
"      Loxapac;",
"     </li>",
"     <li>",
"      Nu-Loxapine;",
"     </li>",
"     <li>",
"      PHL-Loxapine;",
"     </li>",
"     <li>",
"      Xylac&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Psychosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:  Initial: 10 mg twice daily (up to 50 mg/day may be considered in severely disturbed patients), increase dose until psychotic symptoms are controlled; usual maintenance: 60-100 mg/day in divided doses 2-4 times/day; satisfactory response often observed with doses of 20-60 mg/day (maximum: 250 mg/day).Therapy should be maintained at lowest effective dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. (Canadian availability; not available in the U.S.): 12.5-50 mg every 4-6 hours or longer; individualize dose early in therapy; some patients respond satisfactorily to twice-daily dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduced dosing may be indicated due to risks of adverse events associated with high-dose therapy. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13393087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13393088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Canadian labeling does not recommend use in severe hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 5 mg, 10 mg, 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loxitane&reg;: 5 mg, 10 mg, 25 mg [DSC], 50 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13393094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loxapac: 50 mg/mL (1 mL) [contains polysorbate 80, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [strength expressed as base; concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylac&trade;: 25 mg/mL (100 mL) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as succinate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xylac&trade;: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15845938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adasuve&trade; oral inhalation: FDA approved December 2012; anticipated availability is early third quarter of 2013.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adasuve&trade; is approved for the acute treatment of agitation associated with schizophrenia or bipolar I disorder.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13393089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution (Canadian availability; not available in the U.S.): Mix prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection (Canadian availability; not available in the U.S.) is administered by I.M. injection. Do",
"     <b>",
"      not",
"     </b>",
"     administer I.V.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of psychotic disorders",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5685244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F190529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Loxitane&reg; may be confused with Lexapro&reg;, Soriatane&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Loxitane [U.S.] may be confused with Lexotan which is a brand name for bromazepam [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: ECG changes, edema, facial flushing, hyper-/hypotension, orthostatic hypotension, tachycardia, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, altered central temperature regulation, confusion, dizziness, drowsiness, extrapyramidal reactions (akathisia, akinesia, dystonia, pseudoparkinsonism, tardive dyskinesia), faintness, headache, hyperpyrexia, insomnia, lightheadedness, neuroleptic malignant syndrome (NMS), sedation, seizure, slurred speech, tension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, photosensitivity, pruritus, rash, seborrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, impotence, menstrual irregularity, polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Adynamic ileus, constipation, nausea, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Priapism (rare), urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Gait instability, muscle twitching, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, ptosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loxapine or any component of the formulation; severe drug-induced CNS depression; coma",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling): Circulatory collapse",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Avoid use in patients with underlying QT prolongation, in those taking medicines that prolong the QT interval, or cause polymorphic ventricular tachycardia; monitor ECG closely for dose-related QT effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other antipsychotics, loxapine has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Risk of tardive dyskinesia may be increased in elderly patients; antipsychotics may also mask signs/symptoms of tardive dyskinesia. Consider therapy discontinuation with signs/symptoms of tardive dyskinesia. Increased incidence of EPS has been observed with I.M. administration compared to oral administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Use associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): NMS has been associated with use of antipsychotic agents; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability. Discontinue treatment immediately with onset of NMS; recurrence has been reported in patients rechallenged with antipsychotic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Loxapine is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Canadian labeling recommends avoiding use in severe hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults May also be inappropriate in older adults depending on comorbidities (eg, dementia, delirium, etc) due to its potent anticholinergic effects  (Beers Criteria). Increased risk for developing tardive dyskinesia, particularly elderly women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Injection (Canadian availability; not available in U.S.): Reserve injection for patients unable to tolerate oral administration; convert to oral dosage form with symptom control and ability to tolerate oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Loxapine may enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F190496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12585971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F190488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Loxapine Succinate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $99.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $127.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $192.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $257.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Loxitane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $191.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $247.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F190478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, orthostatic blood pressures 3-5 days after initiation of therapy or a dose increase; liver and kidney function, CBC at baseline and then at regular intervals (in patients at risk for blood dyscrasias), lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Desconex (ES);",
"     </li>",
"     <li>",
"      Desconex[gtt./inj.] (ES);",
"     </li>",
"     <li>",
"      Enipaxol (IN);",
"     </li>",
"     <li>",
"      Lopac (TW);",
"     </li>",
"     <li>",
"      Loxapac (BE, DK, ES, FR, GB, GR, IE, IN, LU, NL, NZ, TW);",
"     </li>",
"     <li>",
"      Loxaris (IN);",
"     </li>",
"     <li>",
"      Rosup (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Loxapine is a dibenzoxazepine antipsychotic which blocks postsynaptic mesolimbic D",
"     <sub>",
"      1",
"     </sub>",
"     and D",
"     <sub>",
"      2",
"     </sub>",
"     receptors in the brain, and also possesses serotonin 5-HT",
"     <sub>",
"      2",
"     </sub>",
"     blocking activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral, I.M.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, I.M.: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to glucuronide conjugates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 5 hours; Terminal: 19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (56% to 70%, as metabolites); feces (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peabody CA, Warner MD, Whiteford HA, et al, &ldquo;Neuroleptics and the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1987, 35(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/2880887/pubmed\" id=\"2880887\" target=\"_blank\">",
"        2880887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Risse SC and Barnes R, &ldquo;Pharmacologic Treatment of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(5):368-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/2870097/pubmed\" id=\"2870097\" target=\"_blank\">",
"        2870097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz BL, Woerner MG, Kane JM, et al, &ldquo;Prospective Study of Tardive Dyskinesia Incidence in the Elderly,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(17):2402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/1681122/pubmed\" id=\"1681122\" target=\"_blank\">",
"        1681122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert RD, &ldquo;Therapeutic Drug Monitoring: Psychotropic Drugs,&rdquo;",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 1984, 6:403-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tam CW, Olin BR 3d, and Ruiz AE, &ldquo;Loxapine-Associated Rhabdomyolysis and Acute Renal Failure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1980, 140(7):975-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/2/27687/abstract-text/6770772/pubmed\" id=\"6770772\" target=\"_blank\">",
"        6770772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9576 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27687=[""].join("\n");
var outline_f27_2_27687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290568\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190500\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190501\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190522\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190504\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190505\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393087\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393088\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190480\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393094\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190464\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15845938\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393089\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685244\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190529\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190520\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190468\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299619\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190473\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190496\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12585971\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190508\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190488\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190478\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190489\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190467\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190485\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/26/4517?source=related_link\">",
"      Loxapine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27688="Causes of pulmonary eosinophilia";
var content_f27_2_27688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of pulmonary eosinophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27688/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/2/27688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic lung diseases are a heterogeneous group of disorders that share the feature of abnormally increased numbers of eosinophils within the pulmonary parenchyma. The defining characteristics needed for the diagnosis of pulmonary eosinophilia include either [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral blood eosinophilia with radiographically or tomographically identified pulmonary abnormalities",
"     </li>",
"     <li>",
"      Lung tissue eosinophilia demonstrated in transbronchial or open lung biopsies",
"     </li>",
"     <li>",
"      Increased eosinophils in bronchoalveolar lavage (BAL) fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Peripheral blood eosinophilia is, by no means, uniformly increased in many types of eosinophilic lung diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and routine chest radiographs may fail to detect infiltrates in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of pulmonary eosinophilia will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef76875 \" href=\"UTD.htm?22/37/23132\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64886 \" href=\"UTD.htm?15/50/16171\">",
"     table 2",
"    </a>",
"    ). The differential diagnosis of blood eosinophilia and eosinophilia of other tissues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HELMINTHIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helminthic infections elicit several pathophysiologically distinct forms of pulmonary eosinophilia based upon the characteristic behavior of the organisms in the lung and upon the associated host immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transpulmonary passage of helminth larvae (L&ouml;ffler's syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of helminths, Ascaris lumbricoides, hookworms, and Strongyloides stercoralis, have life cycles in which infecting larvae reach the lungs via the bloodstream, penetrate into alveoli, and ascend the airways before descending the alimentary tract into the small bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The syndrome of transient pulmonary infiltrates and peripheral blood eosinophilia, a subset of the pulmonary eosinophilia syndromes, was originally described by L&ouml;ffler; Ascaris infection acquired from the use of contaminated human nightsoil as fertilizer was determined to be the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/8\">",
"     8",
"    </a>",
"    ]. Subsequent investigations have confirmed that Ascaris is the most common cause of L&ouml;ffler's syndrome worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=see_link\">",
"     \"Pulmonary manifestations of ascariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    .) Hookworm larvae and Strongyloides less commonly elicit symptoms or pulmonary eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=see_link\">",
"     \"Hookworm infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients most often complain of an irritating, nonproductive cough and burning substernal discomfort that is aggravated by coughing or deep breathing. Dyspnea, wheezing, fever, and blood-tinged sputum containing eosinophil-derived Charcot-Leyden crystals may also be present (",
"    <a class=\"graphic graphic_picture graphicRef71997 \" href=\"UTD.htm?9/22/9583\">",
"     picture 1",
"    </a>",
"    ). The chest radiograph may show round or oval infiltrates ranging in size from several millimeters to several centimeters in both lung fields; these lesions are more likely to be present when blood eosinophilia exceeds 10 percent. The infiltrates are migratory and may become confluent in perihilar areas but usually clear spontaneously and completely after several weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary parenchymal invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the parasites mentioned above, several organisms can directly invade the pulmonary parenchyma and produce long-lasting pulmonary manifestations rather than briefly passing through the lungs en route to the gastrointestinal (GI) tract. These include Paragonimus lung flukes and cestodes causing echinococcosis and less commonly Taenia solium causing cysticercosis. As an example, Paragonimus lung flukes may invade the lungs and produce pleural effusions or eosinophil-enriched inflammatory infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/7\">",
"     7",
"    </a>",
"    ]. Recurrent hemoptysis can occur, and chocolate colored sputum may be observed, composed of a mixture of blood, inflammatory cells, and Paragonimus eggs. Blood eosinophilia tends to be prominent in the early stages of disease but minimal with established disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=see_link\">",
"     \"Paragonimiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leakage or rupture of pulmonary cysts in echinococcosis or cysticercosis can also cause pulmonary eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heavy hematogenous seeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disease category describes eosinophilic pulmonary responses provoked by heavy deposition of helminthic larvae or eggs that are carried hematogenously into the lungs. This type of hematogenous spread is not essential for the parasite life cycle, in contrast to the \"normal\" transpulmonary migration noted above. Pulmonary symptoms such as cough, wheezing, and dyspnea may result, and blood eosinophilia is common. The syndrome can arise in several settings, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal numbers of the hookworms or ascarids that cause cutaneous or visceral larva migrans with pulmonary involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=see_link\">",
"       \"Cutaneous larva migrans (creeping eruption)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=see_link\">",
"       \"Toxocariasis: visceral and ocular larva migrans\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal numbers of hematogenous larvae in heavy trichinellosis infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"       \"Trichinellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal spread of schistosomal parasites to the lungs via collateral vessels following anthelminthic therapy. In addition, eosinophilic pneumonia may occur in the early phase (three to six weeks) after infection with schistosomes; patients may experience cough and shortness of breath, chest computed tomographic (CT) scanning may detect multiple small nodules and, less commonly, infiltrates [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"       \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperinfection and dissemination of strongyloidiasis may produce invasion of a number of organs (including the lungs) separate from the transpulmonary passage, which is required for the helminthic life cycle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tropical pulmonary eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This form of eosinophilic pneumonia results from a distinct immune response to the bloodborne microfilarial stages of the lymphatic filariae, Wuchereria bancrofti and, less commonly, Brugia malayi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=see_link\">",
"     \"Tropical filarial pulmonary eosinophilia\"",
"    </a>",
"    .) Pulmonary symptoms and infiltrates in a traveler or immigrant from a filaria-endemic region accompanied by dramatic peripheral eosinophilia, markedly elevated serum IgE, and antifilarial antibody levels are pathognomonic for this diagnosis. An identical but nonfilarial syndrome of tropical pulmonary eosinophilia of uncertain etiology has also been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NONHELMINTHIC INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidal infection can cause eosinophilic pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/15\">",
"     15",
"    </a>",
"    ]. Differentiation from idiopathic eosinophilic pneumonia may be difficult because organisms may be absent from cultures and open lung biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/16\">",
"     16",
"    </a>",
"    ]. Pulmonary eosinophilia rarely complicates pulmonary tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEDICATIONS AND TOXINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary eosinophilia has been reported following the ingestion or inhalation of a variety of medications and toxins. The clinical presentation ranges from asymptomatic pulmonary infiltration with eosinophilia to chronic cough with or without dyspnea and fever to acute eosinophilic pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsteroidal anti-inflammatory drugs (NSAIDs) and antimicrobials (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ) are the most common classes of drugs associated with pulmonary eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/19\">",
"     19",
"    </a>",
"    ]. A number of other agents have been implicated in more than 20 published case reports (eg, anticonvulsants, antidepressants, ACE inhibitors, beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    and other sulfa-containing compounds, radiographic contrast media, L-tryptophan,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ). The Groupes d'Etudes de la Pathologie Pulmonaire Iatrog&egrave;ne maintains a frequently updated website listing drugs that have been associated with pulmonary infiltrates and eosinophilia with literature references (",
"    <a class=\"external\" href=\"file://www.pneumotox.com\">",
"     www.pneumotox.com",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of toxin exposures have also been associated with pulmonary eosinophilia including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/21-29\">",
"     21-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aluminum silicate and particulate metals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sulfite-exposed grape workers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Scorpion stings [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhalation of heroin or crack cocaine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhalation of organic chemicals during rubber manufacture [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhalation of dust [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/26\">",
"       26",
"      </a>",
"      ] or smoke [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/27,28,30\">",
"       27,28,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abuse of 1,1,1-trichloroethane (Scotchguard) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare outbreaks of pulmonary eosinophilia have been described. The largest of these, the \"toxic oil syndrome\", affected &gt;20,000 people in Spain in 1981, and was associated with ingestion of rapeseed oil contaminated with aniline derivatives [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/31\">",
"     31",
"    </a>",
"    ]. A similar outbreak, \"eosinophilia-myalgia syndrome\" occurred in 1989, in association with L-tryptophan ingestion. Although the predominant complaints were neuromuscular, &gt;50 percent of the affected individuals had cough or dyspnea and 17 percent had pulmonary infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of drug and toxin-induced pulmonary eosinophilia cannot be overemphasized as many cases will resolve with withdrawal of the offending agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ACUTE EOSINOPHILIC PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic acute eosinophilic pneumonia (AEP) may be a cause of acute respiratory failure in a previously healthy patient. Most patients present with an acute febrile illness of less than seven days' duration characterized by a nonproductive cough, dyspnea, and a variety of nonspecific radiographic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/33\">",
"     33",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50572 graphicRef71567 \" href=\"UTD.htm?36/1/36886\">",
"     image 1A-B",
"    </a>",
"    ). Peripheral eosinophilia is rare at presentation, but may develop during the course of the disease. Hypoxemic respiratory insufficiency is frequently identified at presentation and often requires mechanical ventilation. Histopathology is notable for diffuse alveolar damage, hyaline membranes, and marked numbers of interstitial and lesser numbers of alveolar eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/34\">",
"     34",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef74556 graphicRef58648 \" href=\"UTD.htm?42/8/43146\">",
"     picture 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"     \"Idiopathic acute eosinophilic pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHRONIC EOSINOPHILIC PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic eosinophilic pneumonia (CEP) is another idiopathic disorder characterized by an abnormal accumulation of eosinophils in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/4\">",
"     4",
"    </a>",
"    ]. The syndrome often presents as a subacute illness with a constellation of symptoms including cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases. Peripheral eosinophilia is common, but may be absent in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. CEP occurs predominantly in women and nonsmokers; cases have been reported following radiation therapy for breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chest radiographic finding of bilateral peripheral or pleural-based infiltrates described as the \"photographic negative\" of pulmonary edema is virtually pathognomonic for the disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86465 \" href=\"UTD.htm?21/20/21831\">",
"     image 2",
"    </a>",
"    ) but found in fewer than one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/4\">",
"     4",
"    </a>",
"    ]. Pleural effusions have been described in a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/37\">",
"     37",
"    </a>",
"    ], and cavitation occurs rarely [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/38\">",
"     38",
"    </a>",
"    ]. Histopathologic findings are characterized by interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells (",
"    <a class=\"graphic graphic_picture graphicRef77554 \" href=\"UTD.htm?6/58/7075\">",
"     picture 3",
"    </a>",
"    ). Fibrosis is minimal, and bronchiolitis obliterans organizing pneumonia (BOOP) is a commonly associated finding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=see_link\">",
"     \"Treatment of chronic eosinophilic pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHURG-STRAUSS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Churg-Strauss syndrome (allergic granulomatosis and angiitis [CSS]) is a vasculitic disorder often characterized by sinusitis, asthma, and prominent peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/39\">",
"     39",
"    </a>",
"    ]. It is the sole form of vasculitis that is associated with both eosinophilia and frequent lung involvement. In addition to the lungs, the skin and the cardiovascular, GI, and nervous (especially mononeuritis multiplex) systems may also be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest x-ray abnormalities in patients with CSS are quite diverse, but most commonly consist of transient and patchy opacities without lobar or segmental distribution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71677 graphicRef59884 graphicRef73909 \" href=\"UTD.htm?9/14/9450\">",
"     image 3A-C",
"    </a>",
"    ). Lung biopsy reveals eosinophilic infiltrates, an eosinophilic vasculitis (especially of the small arteries and veins), interstitial and perivascular necrotizing granulomas, and areas of necrosis (",
"    <a class=\"graphic graphic_picture graphicRef50143 graphicRef57180 graphicRef82366 \" href=\"UTD.htm?42/29/43482\">",
"     picture 4A-C",
"    </a>",
"    ). However, tissues from patients presenting with new onset CSS may not exhibit all of the classic pathologic features of this syndrome, but rather may resemble the eosinophilic infiltration seen in CEP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/40\">",
"     40",
"    </a>",
"    ]. In some patients with CSS, CEP has occurred prior to the onset of the vasculitic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction that occurs when airways become colonized by Aspergillus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/1,41,42\">",
"     1,41,42",
"    </a>",
"    ]. Repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise. Immunologic responses elicited by Aspergillus fumigatus are responsible for this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical picture of ABPA is dominated by asthma (or cystic fibrosis) complicated by recurrent episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucous plugs, peripheral blood eosinophilia, and hemoptysis. Wheezing is not always evident, and some patients present with asymptomatic pulmonary consolidation. Imaging studies show central bronchiectasis, but this finding is neither sensitive nor specific for the disorder (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64077 \" href=\"UTD.htm?3/38/3682\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologic findings in patients with ABPA include asthmatic bronchiolitis, eosinophilic pneumonia, bronchocentric granulomatosis, and mucoid impaction of bronchi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/43\">",
"     43",
"    </a>",
"    ]. On occasion, bronchocentric granulomatosis in the absence of endobronchial fungi occurs with associated pulmonary eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44484?source=see_link\">",
"     \"Bronchocentric granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other conditions are less commonly associated with pulmonary eosinophilia. Examples include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypereosinophilic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypereosinophilic syndromes (HES), some of known and some of idiopathic etiology, are associated with marked peripheral eosinophilia and potential involvement of diverse organs such as the heart, GI tract, lungs, brain, and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other idiopathic lung diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest degrees of BAL eosinophilia may be found in patients with idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, and connective tissue disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/47\">",
"     47",
"    </a>",
"    ]. Less commonly, pulmonary eosinophilia occurs in association with BOOP, rheumatoid arthritis, Sj&ouml;gren's syndrome, postradiation therapy, graft-versus-host disease, and usual interstitial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/1,48,49\">",
"     1,48,49",
"    </a>",
"    ]. Pulmonary eosinophilia may also be associated with lung allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    localized pulmonary eosinophilic infiltration occasionally occurs in conjunction with undifferentiated lung carcinomas or lung metastases of cervical tumors; squamous carcinomas of the vagina, penis, skin, or nasopharynx; adenocarcinomas of the stomach, large bowel or uterine body; or transitional cell bladder carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/51\">",
"     51",
"    </a>",
"    ]. Pulmonary eosinophilia may also occur when lymphoma, acute eosinophilic leukemia, or the S&eacute;zary syndrome involves the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GENERAL DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to patients with these disorders must be dictated by the specific clinical findings and the setting in which they occur. Every patient should undergo a thorough history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention should paid to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medication and chemical exposures, including common NSAIDs and antibiotics, as well as occupational exposures to dust, smoke, or chemicals",
"     </li>",
"     <li>",
"      Travel and immigration histories, including residence in or travel to regions endemic for coccidioidomycosis and varied parasites (more frequently encountered outside of the United States)",
"     </li>",
"     <li>",
"      Respiratory history and findings, including antecedent or concomitant asthma, as found in those with ABPA, CSS, some with CEP and some with the helminthic etiologies. Duration of any antecedent symptoms should be considered. AEP is characteristically abrupt in onset, whereas CEP may develop insidiously over months. Asthma in CSS may begin years before the development of vasculitic lung involvement.",
"     </li>",
"     <li>",
"      Presence of symptoms or signs of extrapulmonary organ involvement, since these may be indicative of systemic diseases, including CSS, HES, and neoplasms",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Blood eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an elevated blood eosinophil count helps to support the diagnosis of a number of the entities discussed above. However, the absence of blood eosinophilia does not exclude these conditions.",
"   </p>",
"   <p>",
"    A bacterial pneumonia is typically associated with an eosinopenic response, in part due to heightened endogenous glucocorticoid production. Thus, even mild or moderate blood eosinophilia in a patient with an acute or subacute pulmonary disease should suggest one of the disorders considered above.",
"   </p>",
"   <p>",
"    However, not all of the conditions that have pulmonary eosinophilia will have blood eosinophilia, especially AEP and some CEP. Any concomitant glucocorticoid therapy will also suppress blood eosinophilia. The magnitude of blood eosinophilia is",
"    <strong>",
"     not",
"    </strong>",
"    a reliable means to distinguish the possible etiologies of pulmonary eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic imaging of the chest, especially by high resolution CT, can provide valuable findings early in the investigation of the patient. The ability of high resolution CT scans to help differentiate among the causes of pulmonary eosinophilia has been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"     52",
"    </a>",
"    ]. The three eosinophilic lung diseases that could be diagnosed with greatest certainty were CEP, ABPA and AEP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic CT findings of CEP include: bilateral airspace consolidation and areas of ground-glass attenuation, involving predominantly the peripheral regions of the middle or upper lung zones [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/35,52-54\">",
"       35,52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Common CT findings of ABPA consist of bronchiectasis, mucous plugging, bronchial wall thickening, atelectasis, airspace consolidation, areas of ground-glass attenuation, and upper and central lung predominance [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"       52",
"      </a>",
"      ]. The first three of these findings are the most indicative of ABPA.",
"     </li>",
"     <li>",
"      CT findings in AEP include ground-glass attenuation, airspace consolidation, poorly defined nodules, interlobular septal thickening and pleural effusions. The triad of interlobular septal thickening, bronchovascular bundle thickening, and pleural effusions are most suggestive of this diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT findings in CSS [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/55\">",
"       55",
"      </a>",
"      ], drug-induced pulmonary eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/56\">",
"       56",
"      </a>",
"      ], HES, and simple pulmonary eosinophilia are varied and diverse. Thus, a radiologic diagnosis of these entities is rarely possible [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With all of the eosinophilic lung diseases, radiographic findings need to be combined with clinical and other features to guide the approach to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Invasive diagnostics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the history and associated findings identify a provocative agent, such as a medication, as a likely cause of an eosinophilic lung disease, BAL should be performed. Fluid should be evaluated for the total and differential leukocyte counts. Since mild to moderate airway eosinophilia can occur in a number of common conditions, including asthma, a cut-off of &ge;25 percent for the diagnosis of AEP and &ge;40 percent for the diagnosis of CEP has been suggested, although the specificities of these criteria have not been evaluated prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there have been appropriate geographic exposures for coccidioidomycosis or clinical and radiographic findings suggestive of ABPA, fungal cultures should be obtained. Bacterial and mycobacterial cultures should also be considered.",
"   </p>",
"   <p>",
"    If the BAL is unrevealing, consideration should be given to obtaining lung tissue via a transbronchial or open lung biopsy approach depending upon the clinical and radiographic findings. Video-assisted thoracoscopic surgery (VATS) can substitute for a thoracotomy to provide tissue. If disease is more parenchymal and peripheral, a transbronchial biopsy is less likely to be revealing, and VATS or a limited thoracotomy should be considered.",
"   </p>",
"   <p>",
"    For any of the potential persisting causes of pulmonary eosinophilia, especially CSS, it is preferable to establish and document the nature of the disease. While those with CSS, CEP, and many with HES will respond to glucocorticoid therapy, establishing a firm pathologic diagnosis upfront is prudent given the side effects of long-term glucocorticoid treatment and the options for second-line therapy in glucocorticoid-refractory disease. Moreover, since CSS has the potential to involve and damage other organs, documenting this vasculitis has important implications for the future management of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Serologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing can be helpful with some etiologies of pulmonary eosinophilia. However, these test results are not usually rapidly available, obviating their utility in the evaluation of an acutely ill patient. Serologies for coccidioidomycosis, ABPA, and the chronic helminth infections (eg, TPE, flukes) can help to support these diagnoses.",
"   </p>",
"   <p>",
"    Enzyme linked immunosorbent assay (ELISA) testing for strongyloidiasis is helpful in excluding unrecognized infections with this parasite. This is important because a patient with undiagnosed strongyloidiasis who is treated with glucocorticoids can develop disseminated bacterial infections, which can be fatal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link&amp;anchor=H9#H9\">",
"     \"Strongyloidiasis\", section on 'Hyperinfection syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EMPIRIC GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of strongyloidiasis, most of the varied etiologies of pulmonary eosinophilia will improve on glucocorticoids. However, it remains a clinical question whether glucocorticoids should be administered empirically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid administration is medically indicated if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A patient is acutely hypoxemic and in respiratory distress",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      If the etiology is either AEP or a medication or toxin-elicited acute pulmonary eosinophilia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted, though, that AEP can resolve spontaneously without requiring glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27688/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For other more chronic or potentially systemic causes of pulmonary eosinophilia, we suggest NOT giving empiric glucocorticoids, at least until a diagnostic biopsy has been performed. Following a biopsy, glucocorticoids may be given as clinically indicated pending biopsy results. In contrast, if glucocorticoids are given before a biopsy or empirically, glucocorticoid therapy typically alters histopathologic features and suppresses tissue eosinophilia, obscuring the chance to obtain a definitive diagnosis.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/1\">",
"      Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/2\">",
"      Bain GA, Flower CD. Pulmonary eosinophilia. Eur J Radiol 1996; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/3\">",
"      Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med 1992; 152:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/4\">",
"      Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore) 1988; 67:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/5\">",
"      Hayakawa H, Sato A, Toyoshima M, et al. A clinical study of idiopathic eosinophilic pneumonia. Chest 1994; 105:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/6\">",
"      Dejaegher P, Derveaux L, Dubois P, Demedts M. Eosinophilic pneumonia without radiographic pulmonary infiltrates. Chest 1983; 84:637.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson, ME, Weller, PF. Eosinophilia. In: Tropical Infectious Diseases: Principles, Pathogens and Practice. 2nd ed. Guerrant, RL, Walker, DH, Weller, PF, eds. Elsevier, Philadelphia, 2006. p. 1478.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/8\">",
"      LOFFLER W. Transient lung infiltrations with blood eosinophilia. Int Arch Allergy Appl Immunol 1956; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/9\">",
"      Roig J, Romeu J, Riera C, et al. Acute eosinophilic pneumonia due to toxocariasis with bronchoalveolar lavage findings. Chest 1992; 102:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/10\">",
"      Inoue K, Inoue Y, Arai T, et al. Chronic eosinophilic pneumonia due to visceral larva migrans. Intern Med 2002; 41:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/11\">",
"      Schwartz E, Rozenman J, Perelman M. Pulmonary manifestations of early schistosome infection among nonimmune travelers. Am J Med 2000; 109:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/12\">",
"      Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clin Infect Dis 2004; 39:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/13\">",
"      Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med 1992; 43:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/14\">",
"      Rocha A, Dreyer G, Poindexter RW, Ottesen EA. Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens. Trans R Soc Trop Med Hyg 1995; 89:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/15\">",
"      Fohlman J, Sj&ouml;lin J, Bennich H, et al. Coccidioidomycosis as imported atypical pneumonia in Sweden. Scand J Infect Dis 2000; 32:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/16\">",
"      Lombard CM, Tazelaar HD, Krasne DL. Pulmonary eosinophilia in coccidioidal infections. Chest 1987; 91:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/17\">",
"      Vijayan VK, Reetha AM, Jawahar MS, et al. Pulmonary eosinophilia in pulmonary tuberculosis. Chest 1992; 101:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/18\">",
"      Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med 2006; 27:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/19\">",
"      Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf 2012; 35:447.",
"     </a>",
"    </li>",
"    <li>",
"     Foucher, P, Camus, P. Pneumotox online: the drug-induced lung diseases. (Available online at: www.pneumotox.com) Accessed: August 22, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/21\">",
"      Schwarz YA, Kivity S, Fischbein A, et al. Eosinophilic lung reaction to aluminium and hard metal. Chest 1994; 105:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/22\">",
"      Marguerie C, Drouet M. [Occupational eosinophilic lung in a grape grower: role of sulfites]. Allerg Immunol (Paris) 1995; 27:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/23\">",
"      Shah PK, Lakhotia M, Chittora M, et al. Pulmonary infiltration with blood eosinophilia after scorpion sting. Chest 1989; 95:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/24\">",
"      Nadeem S, Nasir N, Israel RH. L&ouml;ffler's syndrome secondary to crack cocaine. Chest 1994; 105:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/25\">",
"      Bascom R, Fisher JF, Thomas RJ, et al. Eosinophilia, respiratory symptoms and pulmonary infiltrates in rubber workers. Chest 1988; 93:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/26\">",
"      Rom WN, Weiden M, Garcia R, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med 2002; 166:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/27\">",
"      Hirai K, Yamazaki Y, Okada K, et al. Acute eosinophilic pneumonia associated with smoke from fireworks. Intern Med 2000; 39:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/28\">",
"      Shintani H, Fujimura M, Yasui M, et al. Acute eosinophilic pneumonia caused by cigarette smoking. Intern Med 2000; 39:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/29\">",
"      Kelly KJ, Ruffing R. Acute eosinophilic pneumonia following intentional inhalation of Scotchguard. Ann Allergy 1993; 71:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/30\">",
"      Shorr AF, Scoville SL, Cersovsky SB, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 2004; 292:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/31\">",
"      Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltimore) 1993; 72:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/32\">",
"      Swygert LA, Maes EF, Sewell LE, et al. Eosinophilia-myalgia syndrome. Results of national surveillance. JAMA 1990; 264:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/33\">",
"      Philit F, Etienne-Mastro&iuml;anni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/34\">",
"      Tazelaar HD, Linz LJ, Colby TV, et al. Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med 1997; 155:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/35\">",
"      Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies \"Orphelines\" Pulmonaires (GERM\"O\"P). Medicine (Baltimore) 1998; 77:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/36\">",
"      Cottin V, Frognier R, Monnot H, et al. Chronic eosinophilic pneumonia after radiation therapy for breast cancer. Eur Respir J 2004; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/37\">",
"      Samman YS, Wali SO, Abdelaal MA, et al. Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report. Chest 2001; 119:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/38\">",
"      Laufs U, Schneider C, Wassermann K, Erdmann E. Chronic eosinophilic pneumonia with atypical radiographic presentation. Respiration 1998; 65:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/39\">",
"      Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/40\">",
"      Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/41\">",
"      Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986; 146:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/42\">",
"      Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006; 27:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/43\">",
"      Logan PM, M&uuml;ller NL. High-resolution computed tomography and pathologic findings in pulmonary aspergillosis: a pictorial essay. Can Assoc Radiol J 1996; 47:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/44\">",
"      Katzenstein AL, Liebow AA, Friedman PJ. Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi. Am Rev Respir Dis 1975; 111:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/45\">",
"      Slabbynck H, Impens N, Naegels S, et al. Idiopathic hypereosinophilic syndrome-related pulmonary involvement diagnosed by bronchoalveolar lavage. Chest 1992; 101:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/46\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/47\">",
"      Allen JN, Davis WB, Pacht ER. Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 1990; 142:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/48\">",
"      Yousem SA. Eosinophilic pneumonia-like areas in idiopathic usual interstitial pneumonia. Mod Pathol 2000; 13:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/49\">",
"      Norman D, Piecyk M, Roberts DH. Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis. Chest 2004; 126:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/50\">",
"      Mogayzel PJ Jr, Yang SC, Wise BV, Colombani PM. Eosinophilic infiltrates in a pulmonary allograft: a case and review of the literature. J Heart Lung Transplant 2001; 20:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/51\">",
"      Horie S, Okubo Y, Suzuki J, Isobe M. An emaciated man with eosinophilic pneumonia. Lancet 1996; 348:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/52\">",
"      Johkoh T, M&uuml;ller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology 2000; 216:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/53\">",
"      Mayo JR, M&uuml;ller NL, Road J, et al. Chronic eosinophilic pneumonia: CT findings in six cases. AJR Am J Roentgenol 1989; 153:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/54\">",
"      Ebara H, Ikezoe J, Johkoh T, et al. Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features. J Comput Assist Tomogr 1994; 18:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/55\">",
"      Silva CI, M&uuml;ller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging 2005; 20:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/56\">",
"      Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am 2002; 40:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27688/abstract/57\">",
"      Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005; 60:841.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5715 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-B3AA2FA6DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27688=[""].join("\n");
var outline_f27_2_27688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HELMINTHIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transpulmonary passage of helminth larvae (L&ouml;ffler's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary parenchymal invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heavy hematogenous seeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tropical pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NONHELMINTHIC INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEDICATIONS AND TOXINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACUTE EOSINOPHILIC PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHRONIC EOSINOPHILIC PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHURG-STRAUSS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MISCELLANEOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other idiopathic lung diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GENERAL DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Blood eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Invasive diagnostics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Serologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EMPIRIC GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5715|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/21/33107\" title=\"diagnostic image 1A\">",
"      Acute eosinophilic pneumonia PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/43/26303\" title=\"diagnostic image 1B\">",
"      Acute eosinophilic pneumonia CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/20/21831\" title=\"diagnostic image 2\">",
"      Chronic eosinophilic pneumonia CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/53/40787\" title=\"diagnostic image 3A\">",
"      Churg Strauss PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/44/25281\" title=\"diagnostic image 3B\">",
"      Churg Strauss lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/16/23811\" title=\"diagnostic image 3C\">",
"      Churg Strauss CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/38/3682\" title=\"diagnostic image 4\">",
"      Central bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5715|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/22/9583\" title=\"picture 1\">",
"      Charcot Leyden crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/12/11466\" title=\"picture 2A\">",
"      Acute eosinophilic pneum Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/50/2858\" title=\"picture 2B\">",
"      Acute eosinophilic pneum High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/58/7075\" title=\"picture 3\">",
"      Chronic eosinophilic pneu Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/53/858\" title=\"picture 4A\">",
"      Churg Strauss granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/52/38726\" title=\"picture 4B\">",
"      Small vessel vasculitis Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/4/40006\" title=\"picture 4C\">",
"      Lung biopsy Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/37/23132\" title=\"table 1\">",
"      Causes pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/50/16171\" title=\"table 2\">",
"      ILD associated BAL eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44484?source=related_link\">",
"      Bronchocentric granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28232?source=related_link\">",
"      Clinical manifestations and diagnosis of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36229?source=related_link\">",
"      Cutaneous larva migrans (creeping eruption)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42437?source=related_link\">",
"      Hookworm infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11668?source=related_link\">",
"      Pulmonary manifestations of ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=related_link\">",
"      Toxocariasis: visceral and ocular larva migrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20581?source=related_link\">",
"      Treatment of chronic eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=related_link\">",
"      Tropical filarial pulmonary eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27689="Breast sarcoma: Treatment";
var content_f27_2_27689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast sarcoma: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Rashmi Chugh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Mary Feng, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27689/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/2/27689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19021643\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast sarcomas are rare, histologically heterogeneous nonepithelial malignancies that arise from the connective tissue within the breast. They can develop de novo (primary), after radiation therapy (RT), or in the setting of chronic lymphedema of the arm or breast (therapy related, secondary). Although the clinical features of breast sarcoma mimic those of breast carcinoma in some ways, therapy and prognosis differ dramatically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210078\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of breast sarcomas, there are no prospective randomized trials to guide therapy. Treatment principles have been derived from small retrospective case reviews of breast sarcomas and extrapolated from studies of non-breast soft tissue sarcomas of the extremity and chest wall, since clinical behavior, histology, and prognosis are similar.",
"   </p>",
"   <p>",
"    As with soft tissue sarcomas arising in other areas of the body, a multidisciplinary approach at an experienced center involving surgical, radiation, and medical oncologists is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, the choice of treatment is influenced by stage, histologic grade, and tumor size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210085\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery represents the only potentially curative modality for breast sarcomas. The type and extent of the operation is based upon both the size of the tumor and the size of the breast, as well as histology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An adequate resection margin is the single most important determinant of long-term survival with breast sarcomas [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. For larger tumors (ie, those &gt;5 cm), the overall cosmetic result is often better with a mastectomy and reconstruction than with lumpectomy. Deep seated tumors, which are close to or involve the chest wall, may require en bloc resection of the chest wall [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/3,5,6\">",
"       3,5,6",
"      </a>",
"      ]. With the exception of angiosarcomas, the majority of primary breast sarcomas are not multicentric [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2\">",
"       2",
"      </a>",
"      ] and negative surgical margins are more important than the extent of surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7-9\">",
"       2,7-9",
"      </a>",
"      ]. Breast angiosarcomas (primary or therapy-related) often affect a much larger field of the breast or chest wall than anticipated and mastectomy is the standard treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 100 cases of angiosarcoma treated with breast conserving therapy demonstrated that the majority of patients recurred locally within one year (73 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/12\">",
"       12",
"      </a>",
"      ]. Angiosarcomas often have infiltrative cutaneous disease that extends well beyond the visible tumor and recurrences are often seen at the margins of the prior operation in a shotgun pellet pattern. Accordingly, special attention should be given to ensuring the skin margin is clear and margins of 3 cm have been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/13\">",
"       13",
"      </a>",
"      ]. Hence, the authors prefer a mastectomy rather than breast conservation surgery for this histology. Furthermore, given the high risk of recurrence with this histology, reconstruction should generally be delayed.",
"      <br/>",
"      <br/>",
"      In many cases, the wide excision of skin that is necessary to achieve negative margins precludes closure and requires a skin graft or myocutaneous flap. It is often wise to employ temporary coverage until the margin status on final pathology is known and perform definitive coverage in a delayed fashion. Frozen section analysis of the margins can be inaccurate as angiosarcomas tend to have low grade changes at the margins that can be difficult to differentiate from radiation changes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/14\">",
"       14",
"      </a>",
"      ]. Resection by a surgeon with experience in this disease is advised.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210092\">",
"    <span class=\"h2\">",
"     Management of regional nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast sarcomas tend to spread by direct local invasion or hematogenously; regional lymph node involvement is rare except in the setting of widespread metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. The incidence of lymphatic spread is 5 percent or less overall, and lymphadenectomy does not appear to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/5,17,18\">",
"     5,17,18",
"    </a>",
"    ]. While angiosarcomas in general have a higher rate of lymph node metastases as compared to other sarcoma subtypes, up to 13 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/19\">",
"     19",
"    </a>",
"    ], the incidence is still relatively low and prophylactic lymph node dissection is not indicated for a clinical negative axilla. Even when axillary lymphadenopathy is palpable, pathologic examination often reveals only reactive nodes without disease spread [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/20\">",
"     20",
"    </a>",
"    ]. Despite this, the national surgical patterns of care study in the US and the rare cancer network study in Europe found that approximately 40 percent of patients with primary breast sarcoma have some degree of regional lymphadenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. Changing this practice could reduce unnecessary morbidity of treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the patient with a clinically negative axilla, sentinel lymph node biopsy or axillary lymph node dissection is not routinely indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/7,13,22\">",
"       7,13,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For the patient with clinically suspicious nodes, ultrasound-guided fine needle aspiration of enlarged nodes can accurately document regional metastases. When lymph node metastases are detected in a patient with a breast sarcoma, the pathology should be reevaluated and a diagnosis of metaplastic carcinoma or carcinosarcoma should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathology of breast cancer\", section on 'Metaplastic carcinoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the diagnosis of lymph node involvement in a patient with breast sarcoma is confirmed and there is no evidence of distant disease, lymph node dissection is appropriate. Uncontrolled disease in the axilla can be associated with significant morbidity. Furthermore, nodal metastases do not carry the same poor prognostic implication as distant metastases in soft tissue sarcoma. As a result, regional nodal metastases were reclassified from stage IV to stage III disease in the 2010 modification of the",
"      <span class=\"nowrap\">",
"       AJCC/UICC",
"      </span>",
"      staging system (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210099\">",
"    <span class=\"h1\">",
"     ADJUVANT RT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19021753\">",
"    <span class=\"h2\">",
"     Primary breast sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high rate of local recurrence after surgery alone (up to one-third in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/16,23-25\">",
"     16,23-25",
"    </a>",
"    ]) provides the rationale for postoperative radiation therapy (RT).",
"   </p>",
"   <p>",
"    The benefit of adjuvant RT for the treatment of primary breast sarcomas is controversial. There are no randomized trials that have been conducted in this subgroup, and the available observational series, mostly summarizing the experience of single institutions, provide conflicting data [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/5,7,8,16,21,26-29\">",
"     5,7,8,16,21,26-29",
"    </a>",
"    ]. While some have found no benefit for adjuvant RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/5,16,21,26,29,30\">",
"     5,16,21,26,29,30",
"    </a>",
"    ], others suggest improved outcomes, particularly for large, high-grade breast sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7,15,23,27\">",
"     2,7,15,23,27",
"    </a>",
"    ]. Most of the benefit seems to be in reducing rates of locoregional recurrence; the impact on overall survival remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7,8,26\">",
"     2,7,8,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other data to support benefit for RT in conjunction with surgery for primary breast sarcoma are extrapolated from randomized trials conducted in patients with non-breast soft tissue sarcomas, which uniformly demonstrate improvement in local control but without an impact on survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H4#H4\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Benefit of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A preference for preoperative as compared with postoperative external beam RT in patients with extremity sarcoma is based upon results from a randomized Canadian trial that demonstrated similar efficacy but a lower rate of generally irreversible late complications with preoperative therapy, including grade 3 to 4 fibrosis. None of the patients in this trial had primary breast sarcoma, and whether these benefits can be extrapolated to patients with breast sarcomas is unclear. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H10#H10\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Preoperative versus postoperative RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210106\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant RT for primary (de novo) breast sarcomas has not been proven in randomized trials. However, data extrapolated from randomized trials conducted in patients with extremity sarcomas suggest that RT reduces the rate of local recurrence, especially for high-grade or large tumors, which are associated with a higher rate of local recurrence. Our recommendations for adjuvant RT in patients with breast sarcoma parallel those for extremity sarcomas (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H14#H14\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Summary'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest RT for breast sarcomas &gt;5 cm, especially if high grade and for patients with positive margins in whom reresection is not feasible. However, RT cannot compensate for inadequate surgery, and reexcision to ensure clean margins is strongly encouraged in these cases. For patients with large low-grade sarcomas, the risk to benefit ratio should be weighed carefully given the association of breast RT with long-term complications.",
"     </li>",
"     <li>",
"      Adjuvant RT is also a reasonable option for selected patients with high grade lesions between 2 and 5 cm (particularly aggressive tumors such as angiosarcomas in a previously unirradiated field). However, if wide margins (&gt;1 cm) are achieved with mastectomy, the risk to benefit ratio should be weighed carefully given the association of breast RT with long-term complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=see_link&amp;anchor=H949706110#H949706110\">",
"       \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Sarcoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For large deep tumors where the surgeon expects close or positive margins, preoperative RT may be considered in an attempt to increase resectability. However, if the surgeon feels that adequate margins are likely to be obtained, we prefer surgery initially, reserving the decision regarding RT until after review of the final pathology from the resection specimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210113\">",
"    <span class=\"h2\">",
"     Radiotherapy-related breast sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant RT for radiation-related breast sarcomas is undefined, and in the setting of prior RT to the same area, the potential late effects of a high cumulative RT dose (rib fracture, pneumonitis, soft tissue necrosis) must be carefully considered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/31\">",
"     31",
"    </a>",
"    ]. However, particularly for therapy-related angiosarcomas, the concern for late side effects must be counterbalanced by the high rate of disease recurrence with surgery alone (50 to 73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/12,32\">",
"     12,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reirradiation, often with a hyperfractionated schedule of treatment administration, has been used in the neoadjuvant or adjuvant setting in some patients with favorable results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of three patients who received hyperfractionated RT for a secondary angiosarcoma after breast conserving therapy for breast cancer, two could be resected following RT, and all three patients were described as recurrence-free for 22 to 39 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, the five-year survival rate for 14 patients with an angiosarcoma after breast conserving therapy who were treated with hyperfractionated accelerated RT with or without surgery was 86 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/34\">",
"       34",
"      </a>",
"      ]. Only two patients recurred locoregionally, while three developed metastatic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the available data on patients treated using these techniques are limited. These are challenging patients, and treatment must be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210120\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adjuvant RT, the role of adjuvant chemotherapy for breast sarcoma is undefined. Systemic chemotherapy is a routine component of treatment for several apparently localized soft tissue sarcomas that occur predominantly in children (ie, rhabdomyosarcoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H3#H3\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Pediatric-type sarcomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, despite many randomized trials, the role of adjuvant chemotherapy for the more common adult subtypes of soft tissue sarcoma (such as liposarcoma, synovial sarcoma, leiomyosarcoma, and angiosarcoma), including those that arise within the breast, is uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most recent analysis from the Sarcoma Meta-Analysis Collaboration (SMAC) suggests a significant 11 percent improvement in survival for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      -based adjuvant chemotherapy compared with resection alone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, a pooled analysis of individual patient data from the two largest adjuvant trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      -based chemotherapy (both performed by the EORTC, only one of which was included in the SMAC meta-analysis) was negative for any survival advantage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H12#H12\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Pooled analysis of the EORTC trials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no evidence that adjuvant chemotherapy is more beneficial for the chemotherapy-sensitive subtypes of soft tissue sarcomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H13#H13\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Impact of histology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no trials specifically addressing the benefit of adjuvant chemotherapy for breast sarcomas. While one retrospective analysis suggests improved disease-free survival and a trend toward improved survival for patients who received adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/18\">",
"     18",
"    </a>",
"    ], others report no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, in most studies, chemotherapy responsiveness, as judged by response rates to neoadjuvant chemotherapy, was limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,21,22,24,37\">",
"     2,21,22,24,37",
"    </a>",
"    ]. As a result, it is difficult to conclude from any of these series that adjuvant chemotherapy is definitely beneficial.",
"   </p>",
"   <p>",
"    We generally offer adjuvant chemotherapy to patients with a good functional status and a high-risk localized sarcoma, which we define as stage III as defined by TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"     table 1",
"    </a>",
"    ). This includes patients with a high-grade breast sarcoma that is greater than 5 cm in size or has nodal involvement. Given the relatively poor prognosis of angiosarcomas, in the subset of patients with tumor size from 3 to 5 cm, we also offer adjuvant chemotherapy, but only after extensive discussion of the potential risks and benefits. As in other soft tissue sarcoma settings, if adjuvant chemotherapy is administered, we prefer a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -containing regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"     \"Treatment protocols for soft tissue and bone sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with treatment-related sarcomas, the treatment issues are more complicated, and this necessitates individualized decision-making. Patients who have received prior anthracycline-based chemotherapy may not be candidates for additional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based chemotherapy, even if they have a stage III tumor, because of the excessive risk of cardiotoxicity with higher cumulative doses of anthracycline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H5#H5\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Cumulative dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If these patients have high-risk angiosarcomas (&gt;5 cm), a histology for which taxanes are effective in the setting of advanced disease, an adjuvant taxane-based chemotherapy regimen may be offered, but only after a frank discussion of the risks, benefits, and lack of available data proving efficacy in the adjuvant setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H13#H13\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Taxanes and angiosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another group of patients with treatment-related sarcomas presenting a particular challenge are those who have radiation-associated sarcomas who are not candidates for additional radiation. Depending on the tumor location, sometimes very close or positive margins are achieved and additional resection for wide margins is not possible without significant morbidity. If these patients have high-grade tumors, regardless of size (although typically over at least 3 cm), adjuvant chemotherapy is sometimes offered to improve local control when usual measures are not possible.",
"   </p>",
"   <p>",
"    These general treatment principles are in keeping with consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    and the European Society for Medical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/38\">",
"     38",
"    </a>",
"    ], which suggest that the appropriateness of adjuvant chemotherapy be addressed on a case by case basis, taking into consideration the patient's performance status, comorbid factors (including age), disease location, tumor size, and histologic subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H18#H18\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26983248\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy cannot be recommended routinely after resection of a breast sarcoma. The appropriateness of adjuvant chemotherapy must be addressed on a case by case basis, taking into consideration the patient's performance status, comorbid factors (including age), disease location, tumor size, and histologic subtype. We offer adjuvant chemotherapy to patients with high-risk primary (stage III as defined by TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"     table 1",
"    </a>",
"    )) or recurrent sarcomas, and because of their worse outcome, for angiosarcomas between 3 and 5 cm in size.",
"   </p>",
"   <p>",
"    In all of these settings, the potential for benefit must be discussed in the context of expected treatment-related toxicities including sterility in younger individuals, cardiomyopathy (particularly in patients with therapy-related breast sarcomas, who may have received prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based adjuvant chemotherapy), renal damage, second cancers, and overall impairment of quality of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H7#H7\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Sarcomas more commonly seen in adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, when chemotherapy is indicated based upon consideration of all patient-specific factors, a neoadjuvant rather than adjuvant approach is often preferred, to allow for an in vivo response assessment and the potential for improved surgical outcomes (see below). When adjuvant or neoadjuvant chemotherapy is chosen, we use the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , but in a patient with a treatment-related angiosarcoma who has received prior anthracycline-based chemotherapy, a taxane-containing regimen is an appropriate option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H18#H18\">",
"     \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Summary and recommendations'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210127\">",
"    <span class=\"h1\">",
"     NEOADJUVANT THERAPY FOR LARGE LOCALLY ADVANCED INITIALLY UNRESECTABLE LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the importance of negative surgical margins for local control and survival, neoadjuvant therapy may increase the likelihood of successful surgical resection for large high-grade breast sarcomas. There are no data from randomized trials or large retrospective reviews on preoperative RT or chemoradiotherapy for breast sarcomas; in the setting of extremity and chest wall sarcomas, the specific neoadjuvant approach (RT alone, concurrent chemoradiotherapy, or sequential chemotherapy followed by RT) depends upon institutional expertise and experience.",
"   </p>",
"   <p>",
"    For large, deep-seated tumors where the surgeon expects close or positive margins, preoperative treatment may be preferred over initial surgery in an attempt to improve resectability and the likelihood of achieving negative margins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Radiation therapy and chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy alone has been proposed as an effective strategy for neoadjuvant therapy of breast sarcomas, but there is a lack of prospective data to support this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, as noted above, concerns have been raised given that chemotherapy response rates in breast sarcomas are limited and not durable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy with local hyperthermia has also been proposed for the management of locally advanced, high-risk, and recurrent breast sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/39\">",
"     39",
"    </a>",
"    ]. A European randomized trial reported benefit from the addition of regional hyperthermia to neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone among patients with large high-grade tumors or initially unresectable disease involving the extremities or non-extremity sites (of which only 18 percent arose on the trunk). Whether benefit can be extrapolated to large, locally advanced breast sarcomas is uncertain. This approach, which is not widely used outside of Europe, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Chemotherapy with regional hyperthermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26983241\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about neoadjuvant therapy for patients with large, locally advanced or recurrent breast sarcomas should be made on a case by case basis, and these decisions are best made within a multidisciplinary group of sarcoma experts. In some cases (eg, locally unresectable or borderline resectable tumors), neoadjuvant RT may be preferred over chemotherapy given the risk of progression on chemotherapy. Alternatively, in the case of a radiation-associated sarcoma, additional RT may not be an option and thus chemotherapy (with regional hyperthermia, where available) or an initial surgical approach may be favored. When neoadjuvant chemotherapy is chosen, we use taxanes for angiosarcoma and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    for other histologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210134\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five-year disease-free survival rates for breast sarcomas range from 44 to 66 percent, and five-year overall survival rates are between 49 and 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7,20,22,24,37,40,41\">",
"     2,7,20,22,24,37,40,41",
"    </a>",
"    ]. As with soft tissue sarcomas arising elsewhere in the body, the prognosis for breast sarcomas is highly dependent upon histologic grade and tumor size; these factors determine disease stage (",
"    <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7,15,18,20,21,40,42\">",
"     2,7,15,18,20,21,40,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of grade and tumor size with outcome in primary (non-therapy-related) breast sarcomas can be illustrated by a series of 90 patients, in which the 10-year survival rates for grade 1, 2, and 3 tumors were 82, 62, and 36 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2\">",
"     2",
"    </a>",
"    ]. The corresponding 10-year survival rates for tumors &lt;5 cm, 5 to 10 cm, and &gt;10 cm were 76, 68, and 28 percent, respectively.",
"   </p>",
"   <p>",
"    The influence of histologic grade on outcomes for angiosarcomas of the breast is less clear. Although some series indicate a better prognosis for low-grade tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/21,30,43,44\">",
"     21,30,43,44",
"    </a>",
"    ], others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/25,45\">",
"     25,45",
"    </a>",
"    ]; histologic grading is generally not recommended for angiosarcomas. Given their poor clinical outcomes, they are all considered to represent high grade (grade",
"    <span class=\"nowrap\">",
"     3/3)",
"    </span>",
"    tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link&amp;anchor=H529562#H529562\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Histologic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive surgical margins increase the risk for local recurrence and death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/3,7,16,21,23,40\">",
"     3,7,16,21,23,40",
"    </a>",
"    ]. Adjuvant RT does not compensate for inadequate surgery, and re-excision to ensure clean margins is strongly encouraged in these cases. (See",
"    <a class=\"local\" href=\"#H12210099\">",
"     'Adjuvant RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Histologic subtype does not influence prognosis with the exception of angiosarcoma (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,7,20\">",
"     2,7,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation-induced sarcomas often present at an advanced clinical stage and are reported to have a worse clinical outcome than sporadic breast sarcomas. This is at least in part because the diagnosis is difficult to make in an irradiated breast, and because angiosarcomas, which are the predominant subtype, have a particularly poor prognosis (see below). However, in one study, the significantly lower disease-free survival rates in radiation-induced as compared with sporadic sarcomas were independent of histologic subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2299703\">",
"    <span class=\"h2\">",
"     Angiosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiosarcomas metastasize early, most often to the lung and liver. They also metastasize to bones, brain, skin, and the contralateral breast, which are unusual locations for other soft tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/30,47\">",
"     30,47",
"    </a>",
"    ]. In most (but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]) series, angiosarcomas have a worse prognosis than do other histologies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,15,22,26,37,42,47-52\">",
"     2,15,22,26,37,42,47-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the SArcoma and PHYllode Retrospective (SAPHYR) study, the three-year disease-free and overall survival rates for the 17 patients with primary angiosarcomas were 7 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, the three-year disease-free and overall survival rates for the 27 non-angiosarcoma primary breast sarcomas were 45 and 60 percent, respectively. These data are consistent with the relative risk of metastases for these two sarcoma subtypes.",
"   </p>",
"   <p>",
"    With more aggressive resection and increased use of multimodality therapy, outcomes may be slightly better, although the available data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/42,53\">",
"     42,53",
"    </a>",
"    ]. As an example, in a retrospective series of 55 women with breast angiosarcoma (23 radiation-associated, 32 primary), the two- and five-year overall survival rates were 64 and 38 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These better outcomes may be attributable to case mix. In many series, patients who develop angiosarcomas in radiation or lymphedema fields are more prone to local and distant recurrence and death from disease than are those who have primary angiosarcoma, even if they undergo a microscopically complete (R0) resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. As an example, in one series of 31 patients with a radiation-related breast angiosarcoma who underwent surgery, R0 resection was possible in 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/54\">",
"     54",
"    </a>",
"    ]. However, local recurrence occurred after a median of 6 months in 19 (83 percent) and regional or distant recurrences developed in 13 (57 percent).Only three patients remained alive after 2, 2.5, and 9 years, respectively, with no evidence of disease.",
"   </p>",
"   <p>",
"    However, this is not a uniform finding. In the retrospective series of 55 angiosarcomas described above, patients with radiation-naive angiosarcomas appeared to have a more favorable disease-free and overall survival in the first three years, but the overall Kaplan-Meier survival curves were not significantly different for the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10856756\">",
"    <span class=\"h1\">",
"     POSTTREATMENT CANCER SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since isolated limited metastatic tumor to the lung can be potentially resected for cure and is frequently asymptomatic, we recommend frequent follow-up, particularly in the first two years after treatment, since more than 80 percent of recurrences will be detected during this period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\", section on 'Pulmonary metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although posttreatment cancer surveillance guidelines have not been established through rigorous clinical investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/55\">",
"     55",
"    </a>",
"    ], we follow patients according to the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    consensus guidelines for soft tissue sarcoma of the extremity and trunk listed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination every three to six months for two to three years, then annually.",
"     </li>",
"     <li>",
"      &ldquo;Consider&rdquo; chest imaging every 6 to 12 months.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of local-regional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage II and III:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      History and physical examination and chest imaging every three to six months for two to three years, then every six months for the next two years, then annually.",
"     </li>",
"     <li>",
"      Periodic imaging of the primary site, based on estimated risk of local-regional recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, we follow these guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging of the primary site can be accomplished using MRI or CT of chest if a mastectomy has been performed. Breast MRI or ultrasound can be performed in patients who have had a lumpectomy. For those patients at higher risk of local recurrence, such as those with positive margins or those whose primary tumor site is not easily examined, we prefer MRI over CT scans. We scan the primary site at six month intervals for the first two years and then resume routine breast surveillance.",
"     </li>",
"     <li>",
"      When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. However, the benefit of judicious periodic imaging likely outweighs the risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .) For angiosarcomas, given their propensity to recur, earlier detection may allow for systemic therapeutic intervention, but such therapy is palliative in nature and there are no data (nor are there likely to be) that earlier diagnosis favorably affects outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210155\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT OR METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most recurrences are local, surgery may be potentially curative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Even locally recurrent angiosarcomas may be amenable to complete resection, especially if the tumor is 5 cm or less. In a series of 44 patients treated for locally recurrent angiosarcoma, the breast was the primary site of disease in 14 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/56\">",
"     56",
"    </a>",
"    ]. Most of the patients were treated with surgery and some also received adjuvant treatment. At a median follow-up of 36 months, nine developed a second local recurrence and 14 had distant metastatic disease. Systemic spread was more common in patients who did not have surgery or were incompletely resected (71 versus 13 percent in those who underwent a complete macroscopic resection). The estimated one-, two-, and five-year disease-specific survival rates were 80, 64, and 42 percent, respectively. Tumor size &gt;5 cm was the only independent predictor of adverse outcome on multivariate analysis.",
"   </p>",
"   <p>",
"    For patients who initially had breast conserving surgery, mastectomy should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/2\">",
"     2",
"    </a>",
"    ]. In all other cases of locoregionally advanced locally recurrent disease, treatment is similar to that for soft tissue sarcomas at other sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases, potentially curative metastasectomy may be feasible; this is most likely in patients with isolated limited pulmonary metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\", section on 'Pulmonary metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, most patients with metastatic breast sarcoma are not surgical candidates and instead are offered chemotherapy with palliative intent. Unfortunately, benefit from conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based chemotherapy is often short-lived, particularly in patients with angiosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27689/abstract/15,28,49,56-66\">",
"     15,28,49,56-66",
"    </a>",
"    ]. Patients with advanced angiosarcoma may benefit from taxanes, a class of agents that is of limited utility in other histologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H13#H13\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Taxanes and angiosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12210169\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast sarcomas are primary nonepithelial malignancies arising from the connective tissue within the breast. Sarcomas of the breast can arise de novo (primary) or as a result of radiation therapy or lymphedema of the arm or breast following treatment of another malignancy (therapy-related). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link&amp;anchor=H1#H1\">",
"       \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\", section on 'Introduction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As with soft tissue sarcomas arising in other areas of the body, a multidisciplinary approach at an experienced center involving surgical, radiation, and medical oncologists is preferred. (See",
"      <a class=\"local\" href=\"#H12210078\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery represents the only potentially curative modality for breast sarcomas. Mastectomy is often required for tumors that arise in previously irradiated tissue and for angiosarcomas. An adequate resection margin is the single most important determinant of long-term survival. (See",
"      <a class=\"local\" href=\"#H12210085\">",
"       'Surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend not performing axillary lymph node dissection in the setting of a clinically negative axilla (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The incidence of lymphatic spread is low for most soft tissue sarcomas and lymphadenectomy does not improve outcomes. (See",
"      <a class=\"local\" href=\"#H12210092\">",
"       'Management of regional nodes'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Preoperative RT may be considered for large deep tumors in a previously unirradiated field where the surgeon expects close or positive margins. However, if the surgeon feels that adequate margins are likely to be obtained, we prefer surgery initially, reserving the decision regarding RT until after review of the final pathology from the resection specimen.",
"     </li>",
"     <li>",
"      Adjuvant RT improves locoregional control, but the impact on survival is unclear. We suggest the addition of adjuvant radiation therapy (RT) to surgical resection for high-grade primary breast sarcomas that are &gt;5 cm and for patients with positive margins in whom reresection is not feasible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest adjuvant RT for patients with high-grade lesions &le;5 cm who have a radiation-therapy-na&iuml;ve angiosarcoma especially if margins are close (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), given the high locoregional recurrence rate. (See",
"      <a class=\"local\" href=\"#H19021753\">",
"       'Primary breast sarcomas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients (particularly young individuals) with completely resected low-grade sarcomas &gt;5 cm, the risk to benefit ratio of adjuvant RT should be weighed carefully given the association of breast RT with long-term complications.",
"      <br/>",
"      <br/>",
"      For patients with radiation-associated secondary breast sarcomas, the role of adjuvant RT is unclear, and the decision to pursue re-irradiation must be individualized. The amount of additional RT that may be given in a previously irradiated field is limited, and toxicities are greater. (See",
"      <a class=\"local\" href=\"#H12210113\">",
"       'Radiotherapy-related breast sarcomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy cannot be recommended routinely after resection of a breast sarcoma. In general, we suggest adjuvant chemotherapy for patients with high-risk primary (stage III disease with tumor size &gt;5 cm and high-grade, or node-positive) (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"       table 1",
"      </a>",
"      ) or recurrent breast sarcoma, and for patients with an angiosarcoma between 3 and 5 cm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12210120\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For other cases, the use of adjuvant chemotherapy must be addressed on a case by case basis, taking into consideration the patient's performance status, age, comorbid factors, disease location, tumor size, histologic subtype, and treatment-related toxicities. The potential for benefit must be discussed in the context of expected treatment-related toxicities including sterility in younger individuals, cardiomyopathy, renal damage, second cancers, and overall impairment of quality of life.",
"      <br/>",
"      <br/>",
"      For patients who decide to undergo adjuvant chemotherapy, as in other settings, we suggest using a regimen that contains both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=see_link&amp;anchor=H14#H14\">",
"       \"Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities\", section on 'Summary'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"       \"Treatment protocols for soft tissue and bone sarcoma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Taxanes are active against advanced angiosarcomas, and an adjuvant taxane-containing regimen is an appropriate alternative particularly for a treatment-related angiosarcoma in a patient who has previously received an anthracycline-containing adjuvant chemotherapy regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H13#H13\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Taxanes and angiosarcoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neoadjuvant rather than adjuvant therapy may be an appropriate approach in the setting of a large or recurrent initially unresectable or borderline resectable high-grade tumor. The optimal form of neoadjuvant therapy in such situations is not established, and decisions about neoadjuvant therapy should be individualized, and are best made within a multidisciplinary group of sarcoma experts. (See",
"      <a class=\"local\" href=\"#H12210127\">",
"       'Neoadjuvant therapy for large locally advanced initially unresectable lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment, for patients with stage II or III (",
"      <a class=\"graphic graphic_table graphicRef66617 \" href=\"UTD.htm?23/13/23773\">",
"       table 1",
"      </a>",
"      ) disease, we perform history and physical examination and chest imaging every three to six months for two to three years, then every six months for the next two years, then annually. Following treatment of stage I disease, we suggest a history and physical examination at three to six month intervals for the first two years, and yearly thereafter. Periodic imaging of the primary site is also indicated. For patients at higher risk of local recurrence such as those with positive margins or whose primary tumor site is not easily examined, MRI is preferred over CT scanning. (See",
"      <a class=\"local\" href=\"#H10856756\">",
"       'Posttreatment cancer surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most breast sarcoma recurrences are local and surgery may be potentially curative. (See",
"      <a class=\"local\" href=\"#H12210155\">",
"       'Treatment of recurrent or metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Palliative chemotherapy can offer some benefits in patients with metastatic breast sarcoma. In rare cases, potentially curative metastasectomy may be feasible; this is most likely in patients with isolated limited pulmonary metastases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link&amp;anchor=H2#H2\">",
"       \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\", section on 'Pulmonary metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/1\">",
"      Wiklund T, Huuhtanen R, Blomqvist C, et al. The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur J Cancer 1996; 32A:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/2\">",
"      Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/3\">",
"      Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. J Surg Oncol 2004; 87:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/4\">",
"      Shabahang M, Franceschi D, Sundaram M, et al. Surgical management of primary breast sarcoma. Am Surg 2002; 68:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/5\">",
"      North JH Jr, McPhee M, Arredondo M, Edge SB. Sarcoma of the breast: implications of the extent of local therapy. Am Surg 1998; 64:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/6\">",
"      Lum YW, Jacobs L. Primary breast sarcoma. Surg Clin North Am 2008; 88:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/7\">",
"      McGowan TS, Cummings BJ, O'Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys 2000; 46:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/8\">",
"      Moore MP, Kinne DW. Breast sarcoma. Surg Clin North Am 1996; 76:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/9\">",
"      Trent II JC 2nd, Benjamin RS, Valero V. Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol 2001; 2:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/10\">",
"      Chapelier AR, Bacha EA, de Montpreville VT, et al. Radical resection of radiation-induced sarcoma of the chest wall: report of 15 cases. Ann Thorac Surg 1997; 63:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/11\">",
"      Scow JS, Reynolds CA, Degnim AC, et al. Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol 2010; 101:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/12\">",
"      Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer 2003; 97:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/13\">",
"      Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat 2010; 122:619.",
"     </a>",
"    </li>",
"    <li>",
"     Rosen, PP. Sarcoma. In: Rosen's Breast Pathology, Rosen, PP (Eds), Lippincott Williams and Wilkins, Philadelphia 2001. p.813.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/15\">",
"      Sher T, Hennessy BT, Valero V, et al. Primary angiosarcomas of the breast. Cancer 2007; 110:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/16\">",
"      Barrow BJ, Janjan NA, Gutman H, et al. Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol 1999; 52:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/17\">",
"      Gullett NP, Delman K, Folpe AL, Johnstone PA. National surgical patterns of care: regional lymphadenectomy of breast sarcomas. Am J Clin Oncol 2007; 30:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/18\">",
"      Gutman H, Pollock RE, Ross MI, et al. Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery 1994; 116:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/19\">",
"      Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/20\">",
"      Terrier P, Terrier-Lacombe MJ, Mouriesse H, et al. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat 1989; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/21\">",
"      Bousquet G, Confavreux C, Magn&eacute; N, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol 2007; 85:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/22\">",
"      McGregor GI, Knowling MA, Este FA. Sarcoma and Cystosarcoma phyllodes tumors of the breast--a retrospective review of 58 cases. Am J Surg 1994; 167:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/23\">",
"      Kaklamanos IG, Birbas K, Syrigos KN, et al. Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature. Surg Today 2011; 41:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/24\">",
"      Fields RC, Aft RL, Gillanders WE, et al. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg 2008; 196:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/25\">",
"      Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 2008; 32:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/26\">",
"      Blanchard DK, Reynolds CA, Grant CS, Donohue JH. Primary nonphylloides breast sarcomas. Am J Surg 2003; 186:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/27\">",
"      Johnstone PA, Pierce LJ, Merino MJ, et al. Primary soft tissue sarcomas of the breast: local-regional control with post-operative radiotherapy. Int J Radiat Oncol Biol Phys 1993; 27:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/28\">",
"      Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/29\">",
"      Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. Cancer 1990; 66:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/30\">",
"      Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988; 62:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/31\">",
"      Sheth GR, Cranmer LD, Smith BD, et al. Radiation-induced sarcoma of the breast: a systematic review. Oncologist 2012; 17:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/32\">",
"      Erel E, Vlachou E, Athanasiadou M, et al. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast 2010; 19:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/33\">",
"      Feigenberg SJ, Mendenhall NP, Reith JD, et al. Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/34\">",
"      Palta M, Morris CG, Grobmyer SR, et al. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy. Cancer 2010; 116:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/35\">",
"      Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/36\">",
"      Lagrange JL, Ramaioli A, Chateau MC, et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the F&eacute;d&eacute;ration Nationale des Centres de Lutte Contre le Cancer. Radiology 2000; 216:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/37\">",
"      Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer 2006; 42:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/38\">",
"      Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v198.",
"     </a>",
"    </li>",
"    <li>",
"     Thalhammer, M, et al. Hyperthermia as a therapeutic option in recurrent breast sarcoma.Eur J Surg Oncol 2006; 32(S1):S64.Data presented at the 13th Congress of the European Society of Surgical oncology, Venice Italy, November 30-December 2, 2006. Abstract available online at file://www.sciencedirect.com.ezp-prod1.hul.harvard.edu/science?_ob=MImg&amp;_imagekey=B6WF4-4MM7RM7-7N-1&amp;_cdi=6784&amp;_user=209690&amp;_pii=S0748798306706503&amp;_origin=browse&amp;_zone=rslt_list_item&amp;_coverDate=11%2F30%2F2006&amp;_sk=999679999.8998&amp;wchp=dGLbVzW-zSkzS&amp;md5=9532dfbb86f060bb0bc3c495f9aceef2&amp;ie=/sdarticle.pd (Accessed on January 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/40\">",
"      Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004; 91:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/41\">",
"      Ciatto S, Bonardi R, Cataliotti L, Cardona G. Sarcomas of the breast: a multicenter series of 70 cases. Neoplasma 1992; 39:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/42\">",
"      Vorburger SA, Xing Y, Hunt KK, et al. Angiosarcoma of the breast. Cancer 2005; 104:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/43\">",
"      Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol 1981; 5:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/44\">",
"      Luini A, Gatti G, Diaz J, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat 2007; 105:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/45\">",
"      Shet T, Malaviya A, Nadkarni M, et al. Primary angiosarcoma of the breast: observations in Asian Indian women. J Surg Oncol 2006; 94:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/46\">",
"      Gladdy RA, Qin LX, Moraco N, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol 2010; 28:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/47\">",
"      Chen KT, Kirkegaard DD, Bocian JJ. Angiosarcoma of the breast. Cancer 1980; 46:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/48\">",
"      Strobbe LJ, Peterse HL, van Tinteren H, et al. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 1998; 47:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/49\">",
"      Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys 1999; 44:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/50\">",
"      Sordillo PP, Chapman R, Hajdu SI, et al. Lymphangiosarcoma. Cancer 1981; 48:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/51\">",
"      Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007; 14:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/52\">",
"      Christensen L, Schi&oslash;dt T, Blichert-Toft M, et al. Sarcomas of the breast: a clinico-pathological study of 67 patients with long term follow-up. Eur J Surg Oncol 1988; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/53\">",
"      Billings SD, McKenney JK, Folpe AL, et al. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol 2004; 28:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/54\">",
"      Seinen JM, Styring E, Verstappen V, et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol 2012; 19:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/55\">",
"      Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003; 30:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/56\">",
"      Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009; 16:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/57\">",
"      des Guetz G, Piperno-Neumann S, Chapelier A, et al. Postirradiation sarcoma: clinicopathologic features and results of chemotherapy (abstract). Proc Am Soc Clin Oncol 2002; 21:404a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/58\">",
"      Tomasini C, Grassi M, Pippione M. Cutaneous angiosarcoma arising in an irradiated breast. Case report and review of the literature. Dermatology 2004; 209:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/59\">",
"      Kuten A, Sapir D, Cohen Y, et al. Postirradiation soft tissue sarcoma occurring in breast cancer patients: report of seven cases and results of combination chemotherapy. J Surg Oncol 1985; 28:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/60\">",
"      Waldmann V. Liposomal doxorubicin in the treatment of metastasized angiosarcoma. Br J Dermatol 2003; 148:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/61\">",
"      Budd GT. Management of angiosarcoma. Curr Oncol Rep 2002; 4:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/62\">",
"      Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/63\">",
"      Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/64\">",
"      Baker LH, Frank J, Fine G, et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 1987; 5:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/65\">",
"      Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27689/abstract/66\">",
"      Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18:2081.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83132 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27689=[""].join("\n");
var outline_f27_2_27689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12210169\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19021643\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210078\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210085\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12210092\">",
"      Management of regional nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210099\">",
"      ADJUVANT RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19021753\">",
"      Primary breast sarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12210106\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12210113\">",
"      Radiotherapy-related breast sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210120\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26983248\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210127\">",
"      NEOADJUVANT THERAPY FOR LARGE LOCALLY ADVANCED INITIALLY UNRESECTABLE LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26983241\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210134\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2299703\">",
"      Angiosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10856756\">",
"      POSTTREATMENT CANCER SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210155\">",
"      TREATMENT OF RECURRENT OR METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12210169\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/83132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/83132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/13/23773\" title=\"table 1\">",
"      2010 TNM staging STS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14521?source=related_link\">",
"      Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=related_link\">",
"      Treatment protocols for soft tissue and bone sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27690="Stroke in the newborn";
var content_f27_2_27690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stroke in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Rebecca Ichord, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/2/27690/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/2/27690/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/2/27690/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal stroke may be defined as an acute neurologic syndrome with chronic sequelae due to cerebral injury of vascular origin occurring between 20 weeks gestation and 28 days postnatal life. These disorders include focal cerebral injury due to arterial ischemic stroke, cerebral venous thrombosis, and primary intracerebral hemorrhage. Perinatal stroke is a common cause of acute neonatal encephalopathy, and may manifest as seizures, altered mental status, and sensorimotor deficits. It is an important cause of chronic neurologic disability.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, diagnosis, prognosis, and management of perinatal stroke are reviewed here.",
"   </p>",
"   <p>",
"    Neonatal encephalopathies that resemble perinatal stroke can be seen in association with periventricular and intraventricular hemorrhage, diffuse cerebral injury following global cerebral hypoxic-ischemic insults, and periventricular leukomalacia that typically occurs in preterm infants. These disorders are reviewed briefly here and discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26677392\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal stroke encompasses cerebrovascular events that occur between 20 weeks of fetal life and 28 postnatal days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1\">",
"     1",
"    </a>",
"    ]. Modern definitions of perinatal stroke incorporate the time of identification of the condition and major clinical-anatomic stroke subtypes.",
"   </p>",
"   <p>",
"    Temporal classification is based on neuroimaging and distinguishes three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fetal, diagnosed before birth",
"     </li>",
"     <li>",
"      Neonatal, diagnosed from birth to 28 days postnatal life",
"     </li>",
"     <li>",
"      Presumed perinatal ischemic stroke (PPIS), diagnosed after 28 days of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major clinical-anatomic subtypes comprise the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arterial ischemic stroke, where the infarct conforms to occlusion of an arterial territory",
"     </li>",
"     <li>",
"      Hemorrhagic stroke, including parenchymal, subarachnoid or intraventricular hemorrhage",
"     </li>",
"     <li>",
"      Cerebral sinovenous thrombosis, which may or may not cause infarction and hemorrhagic infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arterial ischemic stroke, hemorrhagic stroke, and cerebral venous thrombosis account for 70, 20 and 10 percent of acute symptomatic perinatal stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Children in the presumed perinatal ischemic stroke group present during infancy with chronic focal neuromotor impairments due to perinatal vascular insults arising from either arterial or venous infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal stroke is not rare; the estimated incidence of ischemic perinatal stroke ranks second only to the incidence of ischemic stroke in the elderly, and exceeds the incidence in childhood by approximately 10-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1,2,5,7\">",
"     1,2,5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of perinatal stroke has been estimated from several reports that vary in definition, diagnosis, and ascertainment of cases. However, there are no population-based prospective studies of the incidence of perinatal stroke in the MRI era, and estimates relying on diagnostic code searches of administrative databases grossly underestimate the incidence. More accurate estimates may be obtained from expanded and verifiable search strategies designed to capture both acutely symptomatic neonates and infants with presumed perinatal ischemic stroke. Studies employing such methods suggest that the incidence of perinatal stroke in North America for arterial ischemic stroke and intracerebral hemorrhage combined is 35 per 100,000 live births annually, or 1 per 2800 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective population-based cohort study identified 60 children with perinatal arterial ischemic stroke born between 1997 and 2003 in Northern California [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/7\">",
"       7",
"      </a>",
"      ]. This yielded an estimated annual incidence of 29 per 100,000 live births, or 1 per 3500, for ischemic stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar study from Northern California identified 20 cases of perinatal acute symptomatic intracerebral hemorrhage, including 19 with intracerebral hemorrhage and one with subarachnoid hemorrhage (but excluding pure isolated intraventricular hemorrhage) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority (85 percent) were full-term newborns. The estimated annual incidence of perinatal hemorrhagic stroke was 6.2 per 100,000 live births, or 1 per 16,000.",
"   </p>",
"   <p>",
"    Although these results suggest that perinatal stroke occurs about once in 2800 births, this incidence is still likely to be an underestimate because it is based largely on retrospective cohort studies relying in part on administrative database search strategies, and does not include all cases of cerebral sinovenous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ARTERIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of perinatal arterial ischemic stroke is complex and multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thorough investigation of stroke risk factors in a consecutive cohort of perinatal arterial ischemic stroke may reveal one or more potential stroke risk factors in up to 75 percent of infants. However, true cause and effect for these factors in individual cases can rarely be proven unequivocally, and establishing a causal role for many risk factors awaits larger, more definitive, prospective or case-controlled studies. Advances in neuroimaging and progress in understanding fetal-maternal risk factors and placental disorders have led to a better understanding of the causes of perinatal stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,4,8\">",
"     2,4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral ischemic infarction may be due to arterial occlusion, hypoperfusion in a watershed territory, or venous outflow obstruction. In the absence of imaging confirmation of a clot or vessel occlusion, the precise vascular mechanism may be difficult to define with certainty. To date there are no published prospective cohort studies in which complete investigation of vascular systems (venous and both cervical and intracranial arteries) was carried out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of arterial ischemic stroke can be grouped into three types of pathophysiologic mechanisms (",
"    <a class=\"graphic graphic_figure graphicRef60300 \" href=\"UTD.htm?2/23/2425\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Emboli of cardiac, transcardiac or aortic arch origin",
"     </li>",
"     <li>",
"      Disorders of the cerebral arteries",
"     </li>",
"     <li>",
"      Thrombosis due to disturbed hemostasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders may originate from maternal, placental, or",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    conditions, or a combination. In a single center cohort of 94 cases of perinatal arterial ischemic stroke, a systematic and hierarchical classification system based upon clinical and neuroanatomic features was applied to categorize patients into the following major etiologic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Embolism, 33 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Meningitis/sepsis,",
"      </span>",
"      9 percent",
"     </li>",
"     <li>",
"      Trauma, 7 percent",
"     </li>",
"     <li>",
"      Primary thrombosis (proven and prothrombotic conditions), 4 percent",
"     </li>",
"     <li>",
"      Arteriopathy, 4 percent",
"     </li>",
"     <li>",
"      Other causes (multifactorial including blood loss, hypoxic-ischemic events, extracorporeal membrane oxygenation), 17 percent",
"     </li>",
"     <li>",
"      Unclassifiable, 26 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases of perinatal arterial ischemic stroke result from arterial infarction in the distribution of the middle cerebral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. &nbsp;The main branch, a distal cortical branch, or smaller lenticulostriate branches can be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,4,9-11\">",
"     2,4,9-11",
"    </a>",
"    ]. In a consecutive cohort study of 94 infants with 166 perinatal arterial ischemic strokes confirmed by MRI, the proportion of infarcts in the distribution of the middle cerebral, anterior cerebral and posterior cerebral arteries was 51, 19 and 18 percent respectively; cerebellar infarcts made up another 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although perinatal hypoxia-ischemia is sometimes implicated in the pathogenesis of arterial ischemic stroke, hypoxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia rarely are documented. Conversely, term newborns with well-defined neonatal encephalopathy can have arterial or venous ischemic stroke with or without diffuse watershed ischemic injury. As an example, a prospective cohort study of 124 term neonates with neonatal encephalopathy identified focal arterial or venous ischemic stroke in 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolism is considered a common cause of perinatal cerebral infarction. However, a clear embolic source is seldom identified. Newborns are thought to be at risk for emboli to cerebral vessels for several reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/3,4,8,13-16\">",
"     3,4,8,13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombosis of placental vessels normally occurs as pregnancy ends, and emboli may be released into the fetal circulation as the placenta separates at birth. In addition, placental pathology may lead to direct embolization into the fetal circulation or cause an inflammatory and prothrombotic state that promotes thrombus formation in the placenta and fetus [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Venous clots can cross through the patent foramen ovale and be directed to cerebral arterial vessels.",
"     </li>",
"     <li>",
"      Right-to-left shunts occur in congenital heart lesions, which permit emboli to enter the cerebral circulation.",
"     </li>",
"     <li>",
"      Emboli may result from thrombi that develop along indwelling umbilical vessel catheters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prothrombotic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prothrombotic disorders may contribute to perinatal stroke and influence outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/4,14,17-20\">",
"     4,14,17-20",
"    </a>",
"    ]. Coagulation disorders have been identified in as many as one-half of infants and children with stroke and may be a greater risk factor in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. Inherited prothrombotic disorders that are probable risk factors for perinatal arterial ischemic stroke include antiphospholipid",
"    <span class=\"nowrap\">",
"     antibodies/lupus",
"    </span>",
"    anticoagulant; factor V Leiden; congenital deficiency of protein C, protein S, or antithrombin; increased lipoprotein (a); prothrombin gene mutation; and the methylenetetrahydrofolate reductase T677T (MTHFR TT) genotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perhaps the strongest evidence supporting an association of prothrombotic conditions with perinatal stroke comes from a meta-analysis of 22 observational studies that included 1526 children and neonates with arterial ischemic stroke and 2700 control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/20\">",
"     20",
"    </a>",
"    ]. Summary odds ratios (OR) for arterial ischemic stroke were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or more genetic thrombophilias, OR 18.8 (95% CI 6.5-54.1)",
"     </li>",
"     <li>",
"      Protein C deficiency, OR 11.0 (95% CI 5.1-23.6)",
"     </li>",
"     <li>",
"      Antiphospholipid",
"      <span class=\"nowrap\">",
"       antibodies/lupus",
"      </span>",
"      anticoagulant, OR 7.0 (95% CI 3.7-13.1)",
"     </li>",
"     <li>",
"      Elevated lipoprotein(a), OR 6.5 (95% CI 4.5-9.6)",
"     </li>",
"     <li>",
"      Factor V Leiden mutation, OR 3.7 (95% CI 2.8-4.9)",
"     </li>",
"     <li>",
"      Antithrombin III deficiency, OR 3.3 (95% CI 0.7-15.5)",
"     </li>",
"     <li>",
"      Prothrombin gene mutation, OR 2.6 (95% CI 1.7-4.1)",
"     </li>",
"     <li>",
"      MTHFR TT genotype, OR 1.6 (95% CI 1.2-2.1)",
"     </li>",
"     <li>",
"      Protein S deficiency, OR 1.5 (95% CI 0.3-6.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Age group",
"    <span class=\"nowrap\">",
"     (perinatal/neonatal",
"    </span>",
"    versus older children) did not significantly affect the reported odds ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/20\">",
"     20",
"    </a>",
"    ]. Note that the association with arterial ischemic stroke was statistically significant for all of the above traits except antithrombin III deficiency and protein S deficiency. The strength of these findings is limited by the observational methodology of the included studies, the uncertain quality of the control subjects, and the potential for confounding from transient acquired abnormalities of some thrombophilic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prothrombotic risk factors were also investigated in a case-control study of 91 term newborns with symptomatic ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"     18",
"    </a>",
"    ]. Neonates with stroke were significantly more likely to have had at least one prothrombotic risk factor compared with controls (68 versus 24 percent).",
"   </p>",
"   <p>",
"    In another study, coagulation disorders were evaluated in 24 newborns with cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/24\">",
"     24",
"    </a>",
"    ]. Five infants were heterozygous for factor V Leiden and six had increased factor VIIIc concentration. Eight of 11 patients with hemiplegia or developmental delay had one or both disorders, compared with 1 of 13 patients with normal outcome. Hemorrhage may account for the worse outcome in infants with prothrombotic disorders. Additional hemorrhagic lesions occurred in all patients with factor V Leiden, compared to 30 percent of those without the mutation.",
"   </p>",
"   <p>",
"    Antiphospholipid antibodies in the neonate almost always result from placental transfer of maternal antibodies that are directed against anticoagulant proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link&amp;anchor=H13#H13\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\", section on 'Neonatal APS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386181\">",
"    <span class=\"h3\">",
"     Border zone infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Watershed or border zone regions exist along the boundaries of major arterial territories in the parasagittal cortical regions of the term infant. These regions are prone to ischemia under conditions of global brain hypoperfusion or oxygen deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/26\">",
"     26",
"    </a>",
"    ]. When cerebral oxygen delivery falls during perinatal hypoxic-ischemic events, a characteristic pattern of ischemic lesions develops in border zone regions. Such lesions may be asymmetric or focal despite the fact that the pathophysiology involves a systemic or global hypoperfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with parasagittal injury have neurologic signs consistent with the distribution of the lesion. Affected infants have hypotonia and weakness of the proximal extremities. Upper limbs, especially the shoulder girdle region, are affected more than lower. The diagnosis is confirmed by MRI ideally, or by ultrasonography or CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of maternal obstetric factors and intrapartum events is controversial and incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/3\">",
"     3",
"    </a>",
"    ]. However, case series and case-control studies suggest that there are a number of maternal risk factors for neonatal arterial ischemic stroke, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autoimmune and prothrombotic abnormalities such as antiphospholipid syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Placental thrombosis or abruption [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prolonged rupture of membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Twin-twin transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chorioamnionitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intrapartum maternal fever [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Smoking during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cocaine abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      History of infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In various case-control studies, neonatal factors associated with arterial ischemic stroke have included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early sepsis or meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18,31\">",
"       18,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypoxia-ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dehydration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypernatremia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polycythemia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Certain inherited metabolic disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low five-minute Apgar score [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among infants with acute perinatal arterial ischemic stroke, seizures are the presenting symptom in 48 to 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,9,36\">",
"     2,9,36",
"    </a>",
"    ]. Focal seizures are typically contralateral to the affected hemisphere in neonates with unilateral cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/9\">",
"     9",
"    </a>",
"    ]. Seizure onset typically occurs on the first day after birth. Among newborns with seizures, infarction is one of the most common causes along with neonatal encephalopathy, intracranial infections, and intracranial hemorrhage (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"UTD.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=see_link\">",
"     \"Etiology and prognosis of neonatal seizures\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a retrospective study of newborns with seizures who were diagnosed with arterial ischemic stroke (n = 27) or hypoxic-ischemic encephalopathy (n = 35), the presence of delayed seizure onset (&ge;12 hours after birth) and focal motor seizures were independent predictors of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because most strokes that are clinically apparent affect the middle cerebral artery, the arm and face are likely to be more affected than the leg. Many infants with unilateral lesions have a hemiparesis, although this may be difficult to detect except by the most experienced clinician. The hemiparesis may appear as asymmetry of spontaneous movements. However, hemiparesis caused by perinatal stroke is first detected in infancy (median six months in one series) in some patients after a normal neonatal course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/17,21,38\">",
"     17,21,38",
"    </a>",
"    ]. Infants with bilateral lesions typically have a mild quadriparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/9\">",
"     9",
"    </a>",
"    ]. Primitive reflexes, such as Moro and tonic neck reflexes, may be exaggerated.",
"   </p>",
"   <p>",
"    Sensory deficits may occur if the parietal and occipital lobes are affected. Ischemic stroke in the territory of the posterior cerebral artery frequently results in a visual field defect such as a homonymous hemianopia or quadrantanopia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/36\">",
"     36",
"    </a>",
"    ]. Diencephalic injury may result in disturbed temperature control and sleep-wake cycles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis of arterial ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of perinatal stroke includes defining the lesion with imaging techniques and investigating potential underlying causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ischemic stroke is confirmed by cranial MRI or CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55919 \" href=\"UTD.htm?18/34/18979\">",
"     image 1",
"    </a>",
"    ). These studies define the extent and vascular territory of the infarct, the number of lesions, and the presence or absence of hemorrhage.",
"   </p>",
"   <p>",
"    MRI is superior to CT, as it may detect small or early infarcts that are not apparent on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1\">",
"     1",
"    </a>",
"    ]. However, MRI sometimes cannot be obtained in the ill neonate because it requires more preparation and a longer scanning time than CT. Cranial ultrasonography, the primary imaging technique used to detect intraventricular hemorrhage and periventricular leukomalacia, is less useful for detecting ischemic stroke because of the peripheral location of most infarcts.",
"   </p>",
"   <p>",
"    Early infarction can be visualized with MRI using diffusion-weighted imaging (DWI) before the lesion can be seen with conventional MRI or CT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. This technique is based upon the decrease in the rate of diffusion of water molecules that occurs within minutes after an ischemic insult. The decreased rate of diffusion is detected as a bright signal on DWI that is thought to reflect cytotoxic edema or necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The temporal evolution of diffusion abnormalities seen on MRI is distinct in neonates compared with older children and adults. Diffusion-weighted MRI sequences may underestimate the full extent of infarct during the first 24 hours and after day five. T2 and FLAIR MRI sequences are more reliable than diffusion at day seven and later in term newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The site of the occluded vessel is inferred from the location and extent of the infarct in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large wedge-shaped infarcts involving the cortex in characteristic distributions result from occlusion of major cerebral arteries, predominantly the middle cerebral artery.",
"     </li>",
"     <li>",
"      Small subcortical infarcts in the white matter, basal ganglia, thalamus, and brainstem, ranging in size from several millimeters to several centimeters in diameter, are caused by occlusion of small arteries arising from the stem of the major cerebral arteries, such as the lenticulostriate branches from the proximal middle cerebral artery supplying the caudate and putamen.",
"     </li>",
"     <li>",
"      A single thrombosis in a large cerebral artery can result in multiple infarcts within the same vascular territory, depending upon the distribution of emboli.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Noninvasive neurovascular imaging, most often with magnetic resonance angiography (MRA), is widely used in modern stroke evaluation in children and adults. However, the utilization of MRA is less widespread in neonatal stroke. In a multicenter cohort study of 248 infants with acute symptomatic perinatal ischemic stroke, vascular imaging using MRA was obtained in 49 percent, compared with CT angiography and catheter angiography in 4 percent and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/43\">",
"     43",
"    </a>",
"    ]. Vascular abnormalities, including large vessel occlusions, dissection, and congenital vasculopathies, were seen in 22 percent of those imaged.",
"   </p>",
"   <p>",
"    Although little is known about neurovascular imaging findings in the evaluation of perinatal ischemic stroke, angiography can provide important information about stroke pathophysiology, as illustrated by the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRA can identify congenital vascular anomalies of the intracranial vessels that would predispose to the occurrence of a stroke during birth, such as PHACE, which refers to a neurocutaneous syndrome of posterior fossa brain malformations, hemangiomas, arterial anomalies, cardiac anomalies and coarctation of the aorta, and eye abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'PHACE syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly, MRA can identify carotid artery dissection and congenital anomalies of the aortic arch and cervical vessels that may cause perinatal stroke.",
"     </li>",
"     <li>",
"      Detection of a vascular occlusion (or lack thereof) may be diagnostic in terms of the stroke mechanism (eg, cardioembolism versus large artery occlusive disease versus other causes).",
"     </li>",
"     <li>",
"      MRA and magnetic resonance venography (MRV) together may clarify the territory of the infarct when its radiologic appearance is ambiguous regarding arterial versus venous origin. As an example, bilateral deep gray and periventricular white matter infarcts are much more suggestive of venous than arterial infarction, but this is difficult to prove without appropriate vascular imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many experts believe that vascular trauma and congenital vascular anomalies causing perinatal stroke are probably underdiagnosed, and will be missed if the evaluation fails to include cervical and intracranial vascular imaging. However, thrombotic occlusions of large cerebral arteries can move rapidly to distal branches and thus may not always be apparent on imaging performed many hours or days after the occlusion occurs, as is usually the case with perinatal stroke. In addition, occlusion of small vessels may be below the limit of detection.",
"   </p>",
"   <p>",
"    Cerebral artery flow velocity measured by transcranial Doppler sonography may be decreased in the involved vessel in newborns with cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, this technique is more useful in the evaluation of sinovenous thrombosis than ischemic stroke. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Cerebral sinovenous thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Conventional catheter angiography is rarely used to evaluate newborns with ischemic stroke, particularly since it has been supplanted by noninvasive imaging methods such as MRA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants who are acutely symptomatic with stroke present with seizures. In these cases, a complete evaluation should be performed to exclude other etiologies of seizures, including systemic infection. Studies should include a complete blood count with leukocyte differential, examination of the cerebrospinal fluid (CSF), and cultures of the blood and CSF. Serum concentrations of glucose, calcium, and electrolytes should be measured, and the urine should be screened for toxic substances. Studies to detect inborn errors of metabolism may be indicated in some circumstances (eg, persistent seizures). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with ischemic stroke should be evaluated for prothrombotic disorders. Because of the large volume of blood required to perform all studies, testing is sometimes performed in the parents, or is performed in the infant at the time of post-hospital follow up examination. The following factor studies should be obtained at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal blood should be tested for antinuclear antibodies, lupus anticoagulants, and anticardiolipin antibody. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"       \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Both parents should be tested for deficiencies of protein S and protein C. A family history of thrombosis or consanguinity renders this diagnosis more likely. Alternatively, parental testing may be postponed and narrowed down after results of studies on the infant are available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein S, protein C, and antithrombin III concentrations should be measured in the newborn at the time of acute presentation if evidence of other clots is present. Because normal values of these proteins are low in newborns, interpretation requires knowledge of neonatal norms for these values. Infants with low levels should be retested at three to four months of age, and if levels are persistently abnormal, such infants may benefit from consultation with a pediatric thrombosis expert. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic examination of the placenta should be performed to detect infarcts or clots.",
"     </li>",
"     <li>",
"      Prothrombin time and activated partial thromboplastin time should be measured at the initial presentation, especially if there is bleeding associated with the stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Homocysteine concentration can be measured in maternal serum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .) In the United States, newborn screening is available for homocystinuria in many States; this disorder is rare.",
"   </p>",
"   <p>",
"    Additional studies should be obtained when the infant is approximately three months of age. The infant should be tested for the factor V Leiden and prothrombin G20210A mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"     \"Prothrombin gene mutation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electroencephalogram (EEG) should be obtained in the newborn with seizures or other neurologic disturbance. The EEG may demonstrate a specific seizure focus. Changes in background activity may suggest more generalized brain involvement, and may be an early indication that hemiparesis will develop [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/48\">",
"     48",
"    </a>",
"    ]. Periodic lateralized epileptiform discharges (PLEDs) may be associated with structural cerebral lesions, including localized abnormalities such as cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnosis and treatment of neonatal seizures is often difficult but may be aided by video EEG monitoring. These topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with stroke should have an echocardiogram to detect structural heart disease with right-to-left shunt as a potential underlying etiology. The yield of this study is extremely low in the absence of a congenital anomaly. However, rare conditions that may lead to brain infarctions, such as atrial thrombosis, can be found [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term development is normal in approximately 19 to 33 percent of infants with perinatal ischemic infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/3,14,51,52\">",
"     3,14,51,52",
"    </a>",
"    ]. As an example, a study involving 46 children with perinatal cerebral infarction who were followed for 18 to 164 months (mean 42 months) found that neurodevelopmental outcome was normal in 15 (33 percent) and abnormal in 31 children (67 percent), of whom 23 had multiple disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/14\">",
"     14",
"    </a>",
"    ]. Cerebral palsy and cognitive impairment occurred in 22 and 19 children, respectively. A mechanism for recovery in some cases may be growth of undamaged brain at the margins of the infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/53\">",
"     53",
"    </a>",
"    ]. MRI signal abnormalities in descending motor pathways connected to the site of primary infarction, including restricted diffusion acutely and aberrant tractography at three months, may serve as sensitive and specific early predictors of motor impairment.",
"   </p>",
"   <p>",
"    Neurologic impairment associated with perinatal stroke depends upon the location and extent of the ischemic injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motor disability is common after perinatal ischemic stroke, with frank hemiparesis in approximately 25 to 30 percent and milder neuromotor dysfunction in another 30 percent of infants with unilateral infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/9,54\">",
"       9,54",
"      </a>",
"      ]. It develops in nearly all cases in which infarction involves the entire vascular territory of the middle cerebral artery. It is less likely to occur (&lt;10 percent) if a cortical branch or only the lenticulostriate vessels are affected.",
"     </li>",
"     <li>",
"      Diffusion-weighted MRI obtained between 3 and 10 days of age, and diffusion tensor imaging tractography at three months of age, can identify signal abnormalities representing probable Wallerian degeneration in the descending motor pathways (eg, corticospinal tract) projecting from the primary infarct (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55919 \" href=\"UTD.htm?18/34/18979\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]. When present, involvement of the corticospinal tract is predictive of later occurrence of motor impairment.",
"     </li>",
"     <li>",
"      Hemiparesis nearly always develops when there is some involvement of the hemisphere contralateral to the infarction, even if it is affected to a lesser extent, or if severe ischemia is bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Earlier studies found that cognitive impairment occurs in approximately 20 to 25 percent of infants with unilateral infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/9\">",
"       9",
"      </a>",
"      ]. Bilateral involvement or a large lesion increases the risk of poor outcome.",
"     </li>",
"     <li>",
"      Cognitive deficits may emerge with time, as suggested by findings from a longitudinal study of 26 children who presented with neonatal seizures and were diagnosed with unilateral perinatal infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/58\">",
"       58",
"      </a>",
"      ]. The children showed no differences from published norms on measures of intellectual ability when tested as preschoolers (mean age 4.8 years). However, mild but statistically significant declines in full scale IQ scores were present when they were retested at school age (mean age 8.9 years). The declines reflected impairment in nonverbal reasoning, working memory, and processing speed.",
"     </li>",
"     <li>",
"      Epilepsy is a common consequence of perinatal stroke, but little is known about its prevalence or predictors. The estimated prevalence of epilepsy ranges from 10 to 30 percent among children presenting with acute perinatal stroke, and from 40 to 67 percent among children presenting in delayed fashion with infantile hemiplegia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/52,59,60\">",
"       52,59,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perinatal stroke does not appear to impair social behavior in childhood. In one study, 39 survivors of perinatal unilateral cerebral infarction or intraparenchymal hemorrhage had no evidence of clinically significant behavioral or emotional problems, even when the frontal lobe was involved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cerebral palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal arterial infarction is the major known cause for cerebral palsy, accounting for approximately 30 percent of hemiplegic cerebral palsy cases among children born at term [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/1,62\">",
"     1,62",
"    </a>",
"    ]. The development of cerebral palsy after perinatal stroke appears to be associated with stroke size, stroke location, and with a delayed clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations are supported by a retrospective population based study that identified 36 infants with perinatal stroke who were observed for at least 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/52\">",
"     52",
"    </a>",
"    ]. Abnormal outcomes occurred in 29 patients (81 percent), and included cerebral palsy in 21 (58 percent), epilepsy in 14 (39 percent), language delay in 9 (25 percent), and behavioral abnormalities in 8 (22 percent). Cerebral palsy was associated with a delayed presentation (ie, the infant was considered neurologically normal before one month of age, but was later diagnosed with an old arterial stroke). In addition, the risk for cerebral palsy was associated with large stroke size and neuroimaging localization to Broca's area, Wernicke's area, internal capsule, or basal ganglia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence risk for cerebral or systemic thromboembolic events after arterial ischemic perinatal stroke appears to be low.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective case-controlled study that included 215 infants followed a median of 3.5 years, recurrent thromboembolism occurred in 3.3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study from California that identified 84 cases of perinatal arterial ischemic stroke, the five-year cumulative recurrence rate for any stroke was 1.2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CEREBRAL SINOVENOUS THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral sinovenous thrombosis (CSVT) can cause venous infarction, often associated with hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/13\">",
"     13",
"    </a>",
"    ]. Seizures and altered consciousness are common manifestations of CSVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic factors may predispose to CSVT (",
"    <a class=\"graphic graphic_figure graphicRef52442 \" href=\"UTD.htm?5/10/5283\">",
"     figure 2",
"    </a>",
"    ). Placental lesions may lead to an inflammatory and prothrombotic state that promotes thrombus formation in the placenta and fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/8\">",
"     8",
"    </a>",
"    ]. Thrombosis may be precipitated by damage to the cerebral sinus structures immediately beneath the sagittal and lateral sinus caused by the cranial molding that accompanies the birth process [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/17,65\">",
"     17,65",
"    </a>",
"    ]. After birth, changes in head position and external pressure can reduce blood flow in the jugular vein and superior sagittal sinus, potentiating thrombosis in susceptible individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Canadian Pediatric Ischemic Stroke Registry, a majority of the 69 newborns with CSVT had risk factors for thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"     67",
"    </a>",
"    ]. The most common predisposing factors were perinatal complications (eg, hypoxia at birth, premature rupture of the membranes, maternal infection), which were found in 51 percent. Dehydration and head and neck disorders were present in 30 and 16 percent of cases, respectively. Among 49 newborns tested, prothrombotic disorders were identified in 20 percent.",
"   </p>",
"   <p>",
"    In the series of 30 patients from San Francisco, all but one were born at or near term [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/68\">",
"     68",
"    </a>",
"    ]. Similar to the Canadian registry, perinatal complications were frequent. Prothrombotic disorders were identified in four of seven patients tested. Seven infants presented either before or after surgery for congenital heart disease. Nine were treated with extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension of the newborn, representing 5 percent of patients treated with ECMO during that period. The mechanism may be retrograde thrombosis of the venous system following occlusion of the right internal jugular vein by the ECMO catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most newborns with CSVT have neurologic signs, particularly seizures and alterations in consciousness.",
"   </p>",
"   <p>",
"    Among 69 newborns with CSVT in the Canadian registry, focal or generalized seizures occurred in 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"     67",
"    </a>",
"    ]. Diffuse neurologic signs, such as decreased level of consciousness and jitteriness, occurred in 58 percent of cases, and focal signs, including hemiparesis and cranial nerve palsies, were seen in 29 percent. Similar clinical presentations were reported among 84 prospectively enrolled neonates with isolated symptomatic CSVT in the International Pediatric Stroke Study (IPSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Canadian Pediatric Ischemic Stroke Registry, venous thrombosis was more likely to occur in a superficial than deep location (80 versus 39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"     67",
"    </a>",
"    ]. The superior sagittal and lateral sinuses were affected most often (62 and 39 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain edema and areas of hemorrhagic infarction, especially involving periventricular white matter, frequently accompany CSVT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/13\">",
"     13",
"    </a>",
"    ]. Infarction or hemorrhage may be present as isolated lesions or may be combined. In the IPSS, 67 newborns with CSVT had complete data regarding parenchymal lesions, and neuroimaging findings included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both ischemic infarction and hemorrhage in 39 percent",
"     </li>",
"     <li>",
"      Hemorrhagic infarction or other hemorrhage in 19 percent",
"     </li>",
"     <li>",
"      Isolated infarction in 7 percent",
"     </li>",
"     <li>",
"      No hemorrhage or infarct in 34 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All hemorrhages in the IPSS were observed before initiation of antithrombotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/69\">",
"     69",
"    </a>",
"    ]. Other studies have also reported high rates of hemorrhagic infarction with perinatal CSVT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Canadian Registry, 29 of 69 newborns (42 percent) with CSVT had parenchymal infarcts [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"       67",
"      </a>",
"      ]. Nearly all were hemorrhagic.",
"     </li>",
"     <li>",
"      In a retrospective multicenter European study of 52 neonates with CSVT proven by MRI or MR venography, the rate of parenchymal hemorrhagic infarction was 79 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The spectrum of anatomic lesions associated with CSVT in term newborns includes periventricular white matter infarction and intraventricular hemorrhage, lesions previously associated with premature birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Although limited by small numbers, one study reported that most preterm infants with CSVT presented with injury involving the entire periventricular white matter (5 of 6 cases), while most term infants with CSVT presented with focal punctate white matter lesions associated with restricted diffusion (15 of 20) and thalamic hemorrhage (11 of 20) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/73\">",
"     73",
"    </a>",
"    ]. In both groups, intraventricular hemorrhage was common (4 of 6 preterm and 16 of 20 term cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR or CT imaging confirms the presence and location of CSVT and associated infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66694 \" href=\"UTD.htm?36/26/37287\">",
"     image 2",
"    </a>",
"    ). Power Doppler ultrasonography can demonstrate reduced or absent venous flow in the affected sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/74\">",
"     74",
"    </a>",
"    ]. MRI, especially when used with venography (MRV), has greater sensitivity and specificity to detect thrombosis than CT or Doppler ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laboratory evaluation of CSVT is similar to that of cerebral infarction. Studies should be performed to detect systemic disorders and coagulation abnormalities. Infants who present with seizures require evaluation to exclude other causes. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Laboratory studies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Coagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most newborns (93 to 97 percent) with CSVT survive the acute period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. However, in a retrospective study from the Netherlands of 52 neonates with CSVT who had follow-up at a median age of 19 months, the mortality rate was 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurologic outcome in survivors is variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Canadian registry, neurologic deficit and seizures occurred in 61 and 20 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/17,67\">",
"       17,67",
"      </a>",
"      ]. Most neurologic deficits consisted of motor impairment.",
"     </li>",
"     <li>",
"      In an observational study from a tertiary center in Indianapolis, outcome data were available for 29 of 41 survivors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/75\">",
"       75",
"      </a>",
"      ]. Of these, only six (21 percent) had normal development. The remaining 23 (79 percent) had long-term impairments including cognitive impairment in 16 patients, motor impairment (cerebral palsy) in 18, and epilepsy in 11.",
"     </li>",
"     <li>",
"      In the study from the Netherlands, there were 42 survivors at follow-up (median age 19 months), and normal development was noted in 19 patients (45 percent), while moderate to severe neurologic impairments were present in 20 (48 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEMORRHAGIC STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhagic stroke refers to acute neurologic syndromes resulting from intracranial hemorrhage of nontraumatic origin. It has two main forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic conversion of ischemic infarction of arterial or venous origin",
"     </li>",
"     <li>",
"      Primary intraparenchymal hemorrhage from vascular anomalies (vascular malformations, and aneurysms) or from bleeding diatheses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Periventricular hemorrhagic infarction is particularly common in premature infants. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Periventricular hemorrhagic infarction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are limited data regarding the epidemiology, risk factors, and clinical features of hemorrhagic stroke in newborns. In a cohort of over 323,000 live births in northern California from 1993 to 2003, a retrospective review identified 20 cases of perinatal hemorrhagic stroke, including 19 with intracerebral hemorrhage and one with subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/5\">",
"     5",
"    </a>",
"    ]. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of perinatal hemorrhage stroke in this population was 6.2 in 100,000.",
"     </li>",
"     <li>",
"      Clinical features included encephalopathy in 20 patients (100 percent), seizures in 13 (65 percent), and focal weakness in one (5 percent). Of the 19 cases with intracerebral hemorrhage, the lesion was unifocal in 14 (74 percent) and unilateral in 15 (83 percent).",
"     </li>",
"     <li>",
"      Etiologies included thrombocytopenia in four patients (20 percent) and cavernous malformation in one (5 percent). No cause for the hemorrhage was found in 15 patients (75 percent).",
"      <br/>",
"      <br/>",
"      Each of the 20 cases was randomly matched with three controls by age and birth facility, and case control analysis revealed the following additional observations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"     <li>",
"      On univariate analysis, the predictors of perinatal hemorrhage were fetal distress, emergency cesarean delivery, prematurity, and postmaturity but not birth weight. Maternal characteristics did not differ between cases and controls.",
"     </li>",
"     <li>",
"      On multivariate analysis, independent predictors of perinatal hemorrhage were fetal distress and postmaturity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As these findings illustrate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/5\">",
"     5",
"    </a>",
"    ], no definitive cause can be determined for many cases of primary intraparenchymal hemorrhage, and this problem may persist even after extensive evaluation. For example, the location or size of a hemorrhage may be suggestive of an arteriovascular malformation or aneurysm, but the anomaly may not be demonstrated by imaging, perhaps because it is obliterated as a result of the hemorrhage.",
"   </p>",
"   <p>",
"    Additional risk factors for hemorrhagic stroke include extracorporeal membrane oxygenation (ECMO), coarctation of the aorta with or without hypertension, and venous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/13,76,77\">",
"     13,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Periventricular hemorrhagic infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periventricular hemorrhagic infarction is a severe form of brain injury that occurs in approximately 15 to 20 percent of premature infants with intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/78\">",
"     78",
"    </a>",
"    ]. The mechanism is thought to be obstruction of the medullary and terminal veins by the associated intraventricular hemorrhage, resulting in periventricular venous congestion, ischemia and venous hemorrhagic infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/79\">",
"     79",
"    </a>",
"    ]. The infarction is asymmetric, in contrast with the symmetric infarction that is typical of periventricular leukomalacia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of periventricular hemorrhagic infarction increases with decreasing gestational age and weight. In one retrospective series of 5774 infants with birth weight &le;2500 gm, the incidence of periventricular hemorrhagic infarction was 0.1, 2.2, and 10 percent for infants weighing 1500 to 2500 gm, 750 to 1500 gm, and &lt;750 gm, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/80\">",
"     80",
"    </a>",
"    ]. The mortality rate of infants with periventricular hemorrhagic infarction is 30 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/80-84\">",
"     80-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an arterial aneurysm is a rare cause of primary intraparenchymal hemorrhage in the perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/77,85\">",
"     77,85",
"    </a>",
"    ]. When it occurs, the intraparenchymal hematoma is usually large, and associated with subarachnoid, and often intraventricular, hemorrhage. The affected territory is middle cerebral artery, vertebrobasilar system, anterior cerebral artery, internal carotid, and circle of Willis near the junction of the posterior communicating and posterior cerebellar arteries in 40, 25, 15, 10, and 10 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/77\">",
"     77",
"    </a>",
"    ]. Rupture of an aneurysm causes an acute increase in intracranial pressure and severe neurologic deterioration. Seizures occur commonly and typically are focal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Arteriovenous malformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locations of arteriovenous malformations (AVMs) include the vein of Galen (the most common), cerebral hemispheres, thalamus and third ventricle, and choroid plexus. Most infants with vein of Galen malformations present with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary intraparenchymal hemorrhage is rarely proven to be due to rupture of an AVM in the newborn period. The outcome depends upon the location and extent of the hemorrhage, and by the extent of secondary injury caused by mass effect and hydrocephalus. The arterial embolization procedure used to eliminate flow through an AVM may be complicated by bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neonatal alloimmune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal alloimmune thrombocytopenia (NAIT) is a rare disorder in which fetal platelets contain an antigen inherited from the father that the mother lacks. The mother may form antibodies against the foreign (paternal) antigen; these antibodies cross the placenta and bind to the fetal platelets. Clearance of the antibody-coated platelets results in",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    thrombocytopenia. Intracranial hemorrhage, which may occur antenatally, is responsible for most of the morbidity and mortality of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12232?source=see_link&amp;anchor=H2#H2\">",
"     \"Prenatal management of neonatal alloimmune thrombocytopenia\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PERIVENTRICULAR LEUKOMALACIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periventricular leukomalacia is reviewed briefly here and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the preterm infant, the periventricular white matter is vulnerable to ischemic insult [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/87\">",
"     87",
"    </a>",
"    ]. However, PVL also may result from injury due to other causes, such as infection or cytokine exposure. Focal white matter injury resembling PVL is common among infants with complex congenital heart disease. The diagnosis of PVL is typically made by routine screening ultrasound examination, while MRI provides greater sensitivity and anatomical characterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link&amp;anchor=H15#H15\">",
"     \"Periventricular leukomalacia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PVL often has no overt clinical signs in affected infants, although some have weakness that is more prominent in the lower than upper extremities. This typically evolves to spastic diplegia later in infancy. Hemorrhagic PVL, unlike middle cerebral artery territory lesions, frequently involves the legs more than the arms and face, except in very extensive lesions. Hemorrhagic PVL is usually on the left side, or is worse on the left than the right side.",
"   </p>",
"   <p>",
"    The prognosis for infants with PVL depends upon the location and extent of the injury. Hemorrhagic PVL is associated with high mortality and neurologic sequelae in most survivors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=see_link&amp;anchor=H25#H25\">",
"     \"Periventricular leukomalacia\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of perinatal stroke is supportive. It should be directed at treatment of underlying conditions and preventing further injury. Adequate oxygenation and ventilation should be ensured. Dehydration and anemia should be treated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ]. Metabolic disturbances, such as acidosis, hypoglycemia, hypocalcemia, or electrolyte disorders, should be monitored and corrected. Antibiotic treatment is started until culture results are available if infection is suspected.",
"   </p>",
"   <p>",
"    Seizures should be treated with anticonvulsant medications. Because clinical identification of seizures is unreliable in neonates, prolonged video-EEG monitoring may be necessary to accurately characterize the extent, nature, and localization of clinical versus electrographic seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386299\">",
"    <span class=\"h2\">",
"     Arterial ischemic stroke management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of perinatal ischemic stroke with antiplatelet agents or anticoagulants is controversial. Except for the supportive care and treatment of seizures noted above, management in most cases consists of observation and monitoring. Because most thromboembolic strokes in infants do not recur or progress, this approach avoids the complications associated with anticoagulation.",
"   </p>",
"   <p>",
"    However, selected infants may benefit from treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , or low molecular weight heparin (LMWH).",
"   </p>",
"   <p>",
"    For neonates with a first arterial ischemic stroke, the 2012 American College of Chest Physicians (ACCP) guidelines suggest supportive care rather than anticoagulation or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in the absence of a documented ongoing cardioembolic source [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/89\">",
"     89",
"    </a>",
"    ]. For neonates with a first arterial ischemic stroke and a documented cardioembolic source, the ACCP guidelines suggest anticoagulation with unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH. For neonates with recurrent arterial ischemic stroke, the ACCP suggests the use of anticoagulant or aspirin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link\">",
"     \"Management of thrombosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines from the American Heart Association (AHA) Stroke Council published in 2008 state that anticoagulation with LMWH or unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    may be considered for neonates with severe thrombophilic disorders or multiple cerebral or systemic emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombolytic therapy is rarely if ever used to treat stroke in newborns, in contrast to older children or adults. The AHA guidelines recommend",
"    <strong>",
"     not",
"    </strong>",
"    using thrombolytic agents in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AHA guidelines state that it is reasonable to give folate and B vitamins to patients with a methylenetetrahydrofolate reductase (MTHFR) mutation in an effort to normalize homocysteine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In accord with national guidelines and available data, we suggest treatment with antithrombotic therapy using either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    , unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , or LMWH for neonates who have or may be at risk for recurrent arterial ischemic stroke due to documented systemic or cardiac risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cerebral sinovenous thrombosis management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of systemic anticoagulation for the treatment of acute perinatal cerebral sinovenous thrombosis (CSVT) remains controversial. This issue is reflected by inconsistency in the use of anticoagulation for this disorder. As an example, in the International Pediatric Stroke Study, approximately one-half of neonates with CSVT were treated with anticoagulation using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin (LMWH) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/69\">",
"     69",
"    </a>",
"    ]. Nevertheless, accumulating observational evidence supports the safety of anticoagulation for perinatal CSVT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-center prospective observational study found that clot propagation, often with new or progressive infarction, occurred in newborns with CSVT significantly more often in those who did not receive anticoagulation compared with those who did (10 of 35 [28 percent] versus 1 of 22 [5 percent]) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/90\">",
"       90",
"      </a>",
"      ]. Moreover, the use of anticoagulation was not associated with life-threatening hemorrhage.",
"     </li>",
"     <li>",
"      In a single-center cohort study in the Netherlands, 7 of 10 infants with thalamic hemorrhage due to CSVT received anticoagulation, and none had new hemorrhage referable to this therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized clinical trial of anticoagulation for neonatal CSVT is urgently needed.",
"   </p>",
"   <p>",
"    For neonates with CSVT without significant intracerebral hemorrhage, the American College of Chest Physicians (ACCP) guidelines suggest initial anticoagulation with unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH and subsequent anticoagulation with LMWH for a minimum of six weeks but no longer than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/89\">",
"     89",
"    </a>",
"    ]. One approach discussed by the ACCP is to assess for recanalization at six weeks and to stop anticoagulants if recanalization is complete or, if incomplete, to continue anticoagulation for an additional six weeks (total three months) and then stop. For neonates with CSVT who have significant hemorrhage, the ACCP suggests either anticoagulation or supportive care with radiologic monitoring of the thrombosis at five to seven days and anticoagulation if thrombus propagation is noted at that time.",
"   </p>",
"   <p>",
"    The American Heart Association guidelines state that anticoagulation with LMWH or unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    may be considered for neonates with clinical or radiologic evidence of propagating CSVT despite supportive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the available data, we suggest initial anticoagulation with unfractionated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    or LMWH for neonates with acute CSVT with or without associated intracranial hemorrhagic infarction or parenchymal hemorrhage. Anticoagulation should be continued after the acute period for at least six weeks using LMWH. Repeat imaging with MRI and MRV at the targeted endpoint of therapy (six weeks) may be useful in guiding duration of therapy. For neonates who have not achieved clinically significant recanalization, we suggest extending the duration of anticoagulation therapy for up to six months with the aim of attaining partial or full recanalization of thrombosed sinuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Intracerebral hemorrhage management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American Heart Association (AHA) recommend the following measures for neonates with intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Correction of markedly low platelet counts",
"     </li>",
"     <li>",
"      Replacement of deficient coagulation factors for neonates who have coagulation factor deficiency",
"     </li>",
"     <li>",
"      Vitamin K administration for neonates who have vitamin K-dependent coagulation disorders",
"     </li>",
"     <li>",
"      Ventricular drainage for those who develop hydrocephalus, followed by shunting if hydrocephalus persists",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AHA guidelines note that it is reasonable to evacuate an intraparenchymal brain hemorrhage to reduce elevated intracranial pressure, but it is not clear whether this intervention always improves outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H386360\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal stroke encompasses cerebrovascular events that occur between 20 weeks of fetal life and 28 postnatal days. Modern definitions of perinatal stroke incorporate the time of identification of the condition and major clinical-anatomic stroke subtypes. Temporal classification is based on neuroimaging and distinguishes three groups (see",
"      <a class=\"local\" href=\"#H26677392\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fetal, diagnosed before birth",
"     </li>",
"     <li>",
"      Neonatal, diagnosed from birth to 28 days postnatal life",
"     </li>",
"     <li>",
"      Presumed perinatal ischemic stroke (PPIS), diagnosed after 28 days of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major clinical-anatomic subtypes of perinatal stroke comprise the following (see",
"      <a class=\"local\" href=\"#H26677392\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial ischemic stroke, where the infarct conforms to occlusion of an arterial territory",
"     </li>",
"     <li>",
"      Hemorrhagic stroke, including parenchymal, subarachnoid or intraventricular hemorrhage",
"     </li>",
"     <li>",
"      Cerebral sinovenous thrombosis, which may or may not cause infarction and hemorrhagic infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal stroke is not rare; the estimated incidence of ischemic perinatal stroke ranks second only to the incidence of ischemic stroke in the elderly, and exceeds the incidence in childhood by approximately 10-fold. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of perinatal arterial ischemic stroke is complex and multifactorial. Most cases are probably due to thromboembolism from the fetal-placental circulation. Seizures are a common presenting symptom of perinatal arterial ischemic stroke. Many infants with unilateral lesions have a hemiparesis, although this may be difficult to detect. Infants with bilateral lesions typically have a mild quadriparesis. The diagnosis of ischemic stroke is confirmed by cranial CT or MRI. Of these, MRI best defines the extent and vascular territory of the infarct, the number of lesions, and the presence or absence of hemorrhage. The site of the occluded vessel is inferred from the location and extent of the infarct in most cases. Neurovascular imaging is useful for the detection of congenital vascular anomalies and vascular occlusion (or lack thereof). In addition, neurovascular imaging can clarify the territory of the infarct when its radiologic appearance is ambiguous regarding arterial versus venous origin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Arterial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral sinovenous thrombosis (CSVT) can cause venous infarction, often associated with hemorrhage. Seizures and altered consciousness are common manifestations of CSVT. MR or CT imaging confirms the presence and location of CSVT and associated infarction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemorrhage. MRI, especially when combined with magnetic resonance venography (MRV), has greater sensitivity and specificity to detect sinovenous thrombosis than CT or Doppler ultrasonography. Most newborns with CSVT survive the acute period. However, the neurologic outcome in survivors is variable. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cerebral sinovenous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemorrhagic stroke refers to acute neurologic syndromes resulting from intracranial hemorrhage of nontraumatic origin. Primary intraparenchymal hemorrhage can result from vascular anomalies (vascular malformations, and aneurysms) or from bleeding diatheses. In addition, hemorrhagic conversion can occur with ischemic infarction of arterial or venous origin. Periventricular hemorrhagic infarction is particularly common in premature infants. Clinical features of primary intraparenchymal hemorrhage typically include encephalopathy and seizures, and sometimes focal weakness. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Hemorrhagic stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of perinatal stroke is mainly supportive. Adequate oxygenation and ventilation should be ensured. Dehydration and anemia should be treated. Metabolic disturbances, such as acidosis, hypoglycemia, hypocalcemia, or electrolyte disorders, should be monitored and corrected. Antibiotic treatment is started until culture results are available if infection is suspected. Seizures should be treated with anticonvulsant medications (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most thromboembolic strokes in infants do not recur or progress. However, for neonates who have or may be at risk for recurrent arterial ischemic stroke due to documented systemic or cardiac risk factors for thromboembolic events, we suggest treatment with antithrombotic therapy using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      , unfractionated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      , or low molecular weight heparin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H386299\">",
"       'Arterial ischemic stroke management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates with acute CSVT, with or without significant secondary hemorrhage, we suggest anticoagulation therapy with unfractionated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Cerebral sinovenous thrombosis management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates with intracerebral hemorrhage, we suggest interventions including the correction of severe thrombocytopenia, replacement of deficient coagulation factors, vitamin K administration for those who have vitamin K-dependent coagulation disorders, and ventricular drainage for those who develop hydrocephalus, followed by shunting if hydrocephalus persists (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Intracerebral hemorrhage management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/1\">",
"      Raju TN, Nelson KB, Ferriero D, et al. Ischemic perinatal stroke: summary of a workshop sponsored by the National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke. Pediatrics 2007; 120:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/2\">",
"      Govaert P, Ramenghi L, Taal R, et al. Diagnosis of perinatal stroke I: definitions, differential diagnosis and registration. Acta Paediatr 2009; 98:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/3\">",
"      Nelson KB, Lynch JK. Stroke in newborn infants. Lancet Neurol 2004; 3:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/4\">",
"      Govaert P, Ramenghi L, Taal R, et al. Diagnosis of perinatal stroke II: mechanisms and clinical phenotypes. Acta Paediatr 2009; 98:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/5\">",
"      Armstrong-Wells J, Johnston SC, Wu YW, et al. Prevalence and predictors of perinatal hemorrhagic stroke: results from the kaiser pediatric stroke study. Pediatrics 2009; 123:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/6\">",
"      Kirton A, Deveber G, Pontigon AM, et al. Presumed perinatal ischemic stroke: vascular classification predicts outcomes. Ann Neurol 2008; 63:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/7\">",
"      Agrawal N, Johnston SC, Wu YW, et al. Imaging data reveal a higher pediatric stroke incidence than prior US estimates. Stroke 2009; 40:3415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/8\">",
"      Elbers J, Viero S, MacGregor D, et al. Placental pathology in neonatal stroke. Pediatrics 2011; 127:e722.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Hypoxic-ischemic encephalopathy: Clinical aspects. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.400.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/10\">",
"      Allan WC, Riviello JJ Jr. Perinatal cerebrovascular disease in the neonate. Parenchymal ischemic lesions in term and preterm infants. Pediatr Clin North Am 1992; 39:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/11\">",
"      de Vries LS, Groenendaal F, Eken P, et al. Infarcts in the vascular distribution of the middle cerebral artery in preterm and fullterm infants. Neuropediatrics 1997; 28:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/12\">",
"      Ramaswamy V, Miller SP, Barkovich AJ, et al. Perinatal stroke in term infants with neonatal encephalopathy. Neurology 2004; 62:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/13\">",
"      Miller V. Neonatal cerebral infarction. Semin Pediatr Neurol 2000; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/14\">",
"      Sreenan C, Bhargava R, Robertson CM. Cerebral infarction in the term newborn: clinical presentation and long-term outcome. J Pediatr 2000; 137:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/15\">",
"      Ruff RL, Shaw CM, Beckwith JB, Iozzo RV. Cerebral infarction complicating umbilical vein catheterization. Ann Neurol 1979; 6:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/16\">",
"      Pellicer A, Caba&ntilde;as F, Garc&iacute;a-Alix A, et al. Stroke in neonates with cardiac right-to-left shunt. Brain Dev 1992; 14:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/17\">",
"      Andrew ME, Monagle P, deVeber G, Chan AK. Thromboembolic disease and antithrombotic therapy in newborns. Hematology Am Soc Hematol Educ Program 2001; :358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/18\">",
"      G&uuml;nther G, Junker R, Str&auml;ter R, et al. Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. Stroke 2000; 31:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/19\">",
"      Simchen MJ, Goldstein G, Lubetsky A, et al. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 2009; 40:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/20\">",
"      Kenet G, L&uuml;tkhoff LK, Albisetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010; 121:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/21\">",
"      Golomb MR, MacGregor DL, Domi T, et al. Presumed pre- or perinatal arterial ischemic stroke: risk factors and outcomes. Ann Neurol 2001; 50:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/22\">",
"      Chalmers EA. Perinatal stroke--risk factors and management. Br J Haematol 2005; 130:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/23\">",
"      Trenor CC 3rd, Michelson AD. Thrombophilia and pediatric stroke. Circulation 2010; 121:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/24\">",
"      Mercuri E, Cowan F, Gupte G, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001; 107:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/25\">",
"      Lynch JK, Hirtz DG, DeVeber G, Nelson KB. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 2002; 109:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/26\">",
"      Volpe JJ, Pasternak JF. Parasagittal cerebral injury in neonatal hypoxic-ischemic encephalopathy: clinical and neuroradiologic features. J Pediatr 1977; 91:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/27\">",
"      Akanli LF, Trasi SS, Thuraisamy K, et al. Neonatal middle cerebral artery infarction: association with elevated maternal anticardiolipin antibodies. Am J Perinatol 1998; 15:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/28\">",
"      Lee J, Croen LA, Backstrand KH, et al. Maternal and infant characteristics associated with perinatal arterial stroke in the infant. JAMA 2005; 293:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/29\">",
"      Wu YW, Lynch JK, Nelson KB. Perinatal arterial stroke: understanding mechanisms and outcomes. Semin Neurol 2005; 25:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/30\">",
"      Cheong JL, Cowan FM. Neonatal arterial ischaemic stroke: obstetric issues. Semin Fetal Neonatal Med 2009; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/31\">",
"      Harteman JC, Groenendaal F, Kwee A, et al. Risk factors for perinatal arterial ischaemic stroke in full-term infants: a case-control study. Arch Dis Child Fetal Neonatal Ed 2012; 97:F411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/32\">",
"      Darmency-Stamboul V, Chantegret C, Ferdynus C, et al. Antenatal factors associated with perinatal arterial ischemic stroke. Stroke 2012; 43:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/33\">",
"      Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr 1986; 108:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/34\">",
"      Dominguez R, Aguirre Vila-Coro A, Slopis JM, Bohan TP. Brain and ocular abnormalities in infants with in utero exposure to cocaine and other street drugs. Am J Dis Child 1991; 145:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/35\">",
"      Heier LA, Carpanzano CR, Mast J, et al. Maternal cocaine abuse: the spectrum of radiologic abnormalities in the neonatal CNS. AJNR Am J Neuroradiol 1991; 12:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/36\">",
"      van der Aa NE, Dudink J, Benders MJ, et al. Neonatal posterior cerebral artery stroke: clinical presentation, MRI findings, and outcome. Dev Med Child Neurol 2013; 55:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/37\">",
"      Rafay MF, Cortez MA, de Veber GA, et al. Predictive value of clinical and EEG features in the diagnosis of stroke and hypoxic ischemic encephalopathy in neonates with seizures. Stroke 2009; 40:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/38\">",
"      Bouza H, Rutherford M, Acolet D, et al. Evolution of early hemiplegic signs in full-term infants with unilateral brain lesions in the neonatal period: a prospective study. Neuropediatrics 1994; 25:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/39\">",
"      Cowan FM, Pennock JM, Hanrahan JD, et al. Early detection of cerebral infarction and hypoxic ischemic encephalopathy in neonates using diffusion-weighted magnetic resonance imaging. Neuropediatrics 1994; 25:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/40\">",
"      Robertson RL, Ben-Sira L, Barnes PD, et al. MR line-scan diffusion-weighted imaging of term neonates with perinatal brain ischemia. AJNR Am J Neuroradiol 1999; 20:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/41\">",
"      Krishnamoorthy KS, Soman TB, Takeoka M, Schaefer PW. Diffusion-weighted imaging in neonatal cerebral infarction: clinical utility and follow-up. J Child Neurol 2000; 15:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/42\">",
"      McKinstry RC, Miller JH, Snyder AZ, et al. A prospective, longitudinal diffusion tensor imaging study of brain injury in newborns. Neurology 2002; 59:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/43\">",
"      Kirton A, Armstrong-Wells J, Chang T, et al. Symptomatic neonatal arterial ischemic stroke: the International Pediatric Stroke Study. Pediatrics 2011; 128:e1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/44\">",
"      Hess CP, Fullerton HJ, Metry DW, et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. AJNR Am J Neuroradiol 2010; 31:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/45\">",
"      Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/46\">",
"      Messer J, Haddad J, Casanova R. Transcranial Doppler evaluation of cerebral infarction in the neonate. Neuropediatrics 1991; 22:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/47\">",
"      Nishimaki S, Seki K, Yokota S. Cerebral blood flow velocity in two patients with neonatal cerebral infarction. Pediatr Neurol 2001; 24:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/48\">",
"      Mercuri E, Rutherford M, Cowan F, et al. Early prognostic indicators of outcome in infants with neonatal cerebral infarction: a clinical, electroencephalogram, and magnetic resonance imaging study. Pediatrics 1999; 103:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/49\">",
"      Rand&ograve; T, Ricci D, Mercuri E, et al. Periodic lateralized epileptiform discharges (PLEDs) as early indicator of stroke in full-term newborns. Neuropediatrics 2000; 31:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/50\">",
"      Zuasnabar A, Bejar R, Sherman F, Mannino F. An interesting case presentation: ultrasound diagnosis of primary atrial thrombosis associated with brain infarctions. J Perinatol 1991; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/51\">",
"      deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000; 15:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/52\">",
"      Lee J, Croen LA, Lindan C, et al. Predictors of outcome in perinatal arterial stroke: a population-based study. Ann Neurol 2005; 58:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/53\">",
"      Rutherford MA, Pennock JM, Cowan FM, et al. Does the brain regenerate after perinatal infarction? Eur J Paediatr Neurol 1997; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/54\">",
"      Mercuri E, Barnett A, Rutherford M, et al. Neonatal cerebral infarction and neuromotor outcome at school age. Pediatrics 2004; 113:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/55\">",
"      Husson B, Hertz-Pannier L, Renaud C, et al. Motor outcomes after neonatal arterial ischemic stroke related to early MRI data in a prospective study. Pediatrics 2010; 126:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/56\">",
"      Kirton A, Shroff M, Visvanathan T, deVeber G. Quantified corticospinal tract diffusion restriction predicts neonatal stroke outcome. Stroke 2007; 38:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/57\">",
"      van der Aa NE, Leemans A, Northington FJ, et al. Does diffusion tensor imaging-based tractography at 3 months of age contribute to the prediction of motor outcome after perinatal arterial ischemic stroke? Stroke 2011; 42:3410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/58\">",
"      Westmacott R, MacGregor D, Askalan R, deVeber G. Late emergence of cognitive deficits after unilateral neonatal stroke. Stroke 2009; 40:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/59\">",
"      Golomb MR, Garg BP, Carvalho KS, et al. Perinatal stroke and the risk of developing childhood epilepsy. J Pediatr 2007; 151:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/60\">",
"      Wusthoff CJ, Kessler SK, Vossough A, et al. Risk of later seizure after perinatal arterial ischemic stroke: a prospective cohort study. Pediatrics 2011; 127:e1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/61\">",
"      Trauner DA, Nass R, Ballantyne A. Behavioural profiles of children and adolescents after pre- or perinatal unilateral brain damage. Brain 2001; 124:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/62\">",
"      Wu YW, Lindan CE, Henning LH, et al. Neuroimaging abnormalities in infants with congenital hemiparesis. Pediatr Neurol 2006; 35:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/63\">",
"      Kurnik K, Kosch A, Str&auml;ter R, et al. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study. Stroke 2003; 34:2887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/64\">",
"      Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics 2007; 119:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/65\">",
"      Newton TH, Gooding CA. Compression of superior sagittal sinus by neonatal calvarial molding. Radiology 1975; 115:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/66\">",
"      Cowan F, Thoresen M. Changes in superior sagittal sinus blood velocities due to postural alterations and pressure on the head of the newborn infant. Pediatrics 1985; 75:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/67\">",
"      deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/68\">",
"      Wu YW, Miller SP, Chin K, et al. Multiple risk factors in neonatal sinovenous thrombosis. Neurology 2002; 59:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/69\">",
"      Jordan LC, Rafay MF, Smith SE, et al. Antithrombotic treatment in neonatal cerebral sinovenous thrombosis: results of the International Pediatric Stroke Study. J Pediatr 2010; 156:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/70\">",
"      Berfelo FJ, Kersbergen KJ, van Ommen CH, et al. Neonatal cerebral sinovenous thrombosis from symptom to outcome. Stroke 2010; 41:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/71\">",
"      Takanashi J, Barkovich AJ, Ferriero DM, et al. Widening spectrum of congenital hemiplegia: Periventricular venous infarction in term neonates. Neurology 2003; 61:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/72\">",
"      Wu YW, Hamrick SE, Miller SP, et al. Intraventricular hemorrhage in term neonates caused by sinovenous thrombosis. Ann Neurol 2003; 54:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/73\">",
"      Kersbergen KJ, Groenendaal F, Benders MJ, et al. The spectrum of associated brain lesions in cerebral sinovenous thrombosis: relation to gestational age and outcome. Arch Dis Child Fetal Neonatal Ed 2011; 96:F404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/74\">",
"      Bezinque SL, Slovis TL, Touchette AS, et al. Characterization of superior sagittal sinus blood flow velocity using color flow Doppler in neonates and infants. Pediatr Radiol 1995; 25:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/75\">",
"      Fitzgerald KC, Williams LS, Garg BP, et al. Cerebral sinovenous thrombosis in the neonate. Arch Neurol 2006; 63:405.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Hypoxic-ischemic encephalopathy: Neuropathology and pathogenesis. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.347.",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: Subdural, primary subarachnoid, intracerebellar, intraventricular (term infant) and miscellaneous. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/78\">",
"      Inder TE, Volpe JJ. Mechanisms of perinatal brain injury. Semin Neonatol 2000; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Germinal matrix-intraventricular hemorrhage of the premature infant. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/80\">",
"      Bassan H, Feldman HA, Limperopoulos C, et al. Periventricular hemorrhagic infarction: risk factors and neonatal outcome. Pediatr Neurol 2006; 35:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/81\">",
"      Guzzetta F, Shackelford GD, Volpe S, et al. Periventricular intraparenchymal echodensities in the premature newborn: critical determinant of neurologic outcome. Pediatrics 1986; 78:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/82\">",
"      Perlman JM, Rollins N, Burns D, Risser R. Relationship between periventricular intraparenchymal echodensities and germinal matrix-intraventricular hemorrhage in the very low birth weight neonate. Pediatrics 1993; 91:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/83\">",
"      de Vries LS, Roelants-van Rijn AM, Rademaker KJ, et al. Unilateral parenchymal haemorrhagic infarction in the preterm infant. Eur J Paediatr Neurol 2001; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/84\">",
"      Roze E, Kerstjens JM, Maathuis CG, et al. Risk factors for adverse outcome in preterm infants with periventricular hemorrhagic infarction. Pediatrics 2008; 122:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/85\">",
"      Grode ML, Saunders M, Carton CA. Subarachnoid hemorrhage secondary to ruptured aneurysms in infants. Report of two cases. J Neurosurg 1978; 49:898.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial mass lesions: Brain tumors and vein of Galen malformations. In: Neurology of the Newborn, 5th ed, Saunders Elsevier, Philadelphia 2008. p.989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/87\">",
"      Takashima S, Tanaka K. Development of cerebrovascular architecture and its relationship to periventricular leukomalacia. Arch Neurol 1978; 35:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/88\">",
"      Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/89\">",
"      Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/90\">",
"      Moharir MD, Shroff M, Stephens D, et al. Anticoagulants in pediatric cerebral sinovenous thrombosis: a safety and outcome study. Ann Neurol 2010; 67:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/2/27690/abstract/91\">",
"      Kersbergen KJ, de Vries LS, van Straaten HL, et al. Anticoagulation therapy and imaging in neonates with a unilateral thalamic hemorrhage due to cerebral sinovenous thrombosis. Stroke 2009; 40:2754.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6157 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27690=[""].join("\n");
var outline_f27_2_27690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H386360\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26677392\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ARTERIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prothrombotic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H386181\">",
"      - Border zone infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis of arterial ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - EEG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CEREBRAL SINOVENOUS THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEMORRHAGIC STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Periventricular hemorrhagic infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Arteriovenous malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PERIVENTRICULAR LEUKOMALACIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H386299\">",
"      Arterial ischemic stroke management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cerebral sinovenous thrombosis management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Intracerebral hemorrhage management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H386360\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6157|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/34/18979\" title=\"diagnostic image 1\">",
"      Stroke in newborn with seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/26/37287\" title=\"diagnostic image 2\">",
"      CSVT in a two-week old infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6157|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/23/2425\" title=\"figure 1\">",
"      Pathogenesis perinatal arterial ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/10/5283\" title=\"figure 2\">",
"      Perinatal stroke risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/34/7724\" title=\"table 1\">",
"      Etiologies of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6328?source=related_link\">",
"      Clinical features and electrodiagnosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41335?source=related_link\">",
"      Etiology and prognosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12232?source=related_link\">",
"      Prenatal management of neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_2_27691="Treatment Turner II";
var content_f27_2_27691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of Turner syndrome: Craniofacial malformation, abnormal carbohydrate metabolism, cardiovascular abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal period or at diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adulthood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Craniofacial malformation",
"       </td>",
"       <td>",
"        Otitis and high arched palate are common.",
"        <br/>",
"        Review results of newborn hearing screen.",
"       </td>",
"       <td>",
"        Otitis is common and should be treated aggressively.",
"        <br/>",
"        Orthodontic work may be necessary.",
"        <br/>",
"        Speech evaluation and/or therapy may be necessary.",
"       </td>",
"       <td>",
"        Continue to monitor hearing.",
"       </td>",
"       <td>",
"        Continue to monitor hearing.",
"        <br/>",
"        Andiogram every&nbsp;three to&nbsp;five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal carbohydrate metabolism",
"       </td>",
"       <td>",
"        &mdash;",
"       </td>",
"       <td>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"       </td>",
"       <td>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"        <br/>",
"        Insulin levels increase with growth hormone therapy.",
"       </td>",
"       <td>",
"        Annual fasting glucose and lipid profile.",
"        <br/>",
"        Glucose-tolerance test may be abnormal.",
"        <br/>",
"        Insulin resistance is common.",
"        <br/>",
"        Insulin levels decline after growth hormone therapy is stopped.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27691=[""].join("\n");
var outline_f27_2_27691=null;
var title_f27_2_27692="Healthier fast food meals";
var content_f27_2_27692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Healthier fast food meals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food item",
"       </td>",
"       <td class=\"subtitle1\">",
"        Energy, kcal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat, g",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fat, percent of energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #1: (Chick-Fil-A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grilled chicken sandwich (with mustard, lettuce, and tomatoes)",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fresh fruit cup (medium)",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yogurt cone",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chocolate milk",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         680",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         10",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         13",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Menu #2: (Wendy's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chili (small)",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baked potato (plain)",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mandarin oranges",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frozen yogurt dessert (small)",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         890",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wake Forest University Baptist Medical Center Drive thru Diet (available at www1.wfubmc.edu/Nurtition/Count+Your+Calories/dtd.htm). Additional data from:&nbsp;",
"     <a href=\"file://www.chickfila.com\" target=\"_blank\">",
"      www.chickfila.com",
"     </a>",
"     and",
"     <a href=\"file://www.wendys.com\" target=\"_blank\">",
"      www.wendys.com",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27692=[""].join("\n");
var outline_f27_2_27692=null;
var title_f27_2_27693="Pulse demand device and SaO2";
var content_f27_2_27693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Efficiency of pulse oxygen demand device versus continuous flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of oxygen saturation during oxygen delivery via continuous flow versus a demand pulsing device. The efficacy of this oxygen pulsing device is seven times that of continuous flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tiep BL, Nicotra MB, Carter R, et al. Low-concentration oxygen therapy via a demand oxygen delivery system. Chest 1985; 87:636.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27693=[""].join("\n");
var outline_f27_2_27693=null;
var title_f27_2_27694="Lung function smokers with COPD";
var content_f27_2_27694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Lung function decline over 5 years in smokers with COPD in the lung health study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    FEV",
"    <sub>",
"     1",
"    </sub>",
"    undergoes a one time change during the first year of follow up and then declines linearly. Patients who received ipratropium in addition to smoking intervention had a small increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    in the first year but then showed the same rate of decline as the others. This improvement in lung function with ipratropium was lost within a few weeks of stopping the medication at the end of the study (not shown).",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Anthonisen NR, Connett JE, Kiley JP, et al. JAMA 1994; 272:1497.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27694=[""].join("\n");
var outline_f27_2_27694=null;
var title_f27_2_27695="PCMZL solitary tumor on lower leg";
var content_f27_2_27695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous marginal zone lymphoma with solitary tumor on lower leg associated with Borrelia burgdorferi infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_2_27695=[""].join("\n");
var outline_f27_2_27695=null;
